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Summary
y  Inherited prion diseases are linked to mutations in the prion protein (PrP)
p  gene that are presumed to favor conversion of PrP into a neurotoxic isoform
(PrpSc) Several cellular models of inherited prion diseases have been 
Q developed in which mutant PrP costitutively expressed acquires PrP^^-like
properties but is not cytotoxic. However, the use of constitutive models does not 
exclude the potential toxicity of mutant PrP, as it can be speculated that only 
J  clones resistant to PrP toxicity are selected after clonal selection. To rule out
n  this possibility a tetracycline-inducible (Tet-on) model was developed in this
thesis, in which PrP expression is switched on after clonal selection.
D cDNAs encoding mouse wild-type PrP, as well as mouse PrP
homologues of the human D178N (D177N/M128 and D177NA/128) and nine- 
octapeptide (PG14) mutations under the control of the tetracycline-responsive 
element, were transfected in PC12 Tet-on cells. The Tet-on system was chosen 
based on the lack of pleiotropic or toxic effects and because it allows a tightly 
regulated expression of the protein of interest. To ensure unwanted background 
expression of PrP in the absence of inducer, cells were co-transfected with 
J  pTet-tTS, encoding the tet-controlled transcriptional silencer.
The D177N and PG14 mutants expressed in this system displayed 
biochemical properties reminiscent of PrP^^, including detergent insolubility and 
low protease resistance. Low levels of mutant PrPs were detected on the cell 
^ surface by confocal immunofluorescence analysis compared to wild-type PrP.
J
17
DThese mutant displayed reticular intracellular distribution, suggesting impaired 
J  delivery to the cell surface and retention in the endoplasmic reticulum (ER).
^  Evaluation of cellular viability revealed a decrement in cell survival after
96 h of mutant PrP expression, associated with an increased number of 
apoptotic cells. This effect was not fully consistent and was not exacerbated by 
Q neuronal differentiation with NGF or by treating cells with FI2O2 , tunicamycin, or
p. by removing serum. The results presented in this thesis also demonstrate that
expression of PrP does not protect PC 12 Tet-on cells from such stresses.
"I '
To explore the possibility that expression of mutant PrPs triggered toxic 
-1  response pathways in the ER, the mRNA level of ER stress markers was
measured. The results shown in this thesis indicate that, although the altered 
intracellular distribution of mutant PrPs suggested retention of the protein in the 
endoplasmic reticulum, ER stress responses were not detected.
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Chapter 1 : Introduction
1.1 General introduction
1.1.1 Prion diseases
Prion diseases, also called Transmissible Spongiform Encephalopathies 
(TSEs), are fatal neurodegenerative disorders that have attracted enormous 
attention because they have been proposed to exemplify a novel mechanism of 
biological information transfer based on the transmission on protein 
conformation, rather than on a nucleic acid sequence (Prusiner, 1982). This 
group of diseases includes Kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann- 
Straussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI) in 
humans (Table 1.1), as well as scrapie in sheep and goats. Bovine Spongiform 
Encephalopathy (BSE) in cattle, and encephalopathies in mink (Marsh and 
Hadlow, 1992), cats (Leggett et al., 1990), mule deer. Rocky Mountain e lk 
(Williams and Young, 1980; Williams and Young, 1982), and several exotic 
ungulates (Kirkwood and Cunningham, 1994; Taylor and Woodgate, 1997) 
(Table I.II).
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Table 1.1: Human prion diseases
Disease
Kuru (Fore people) 
Iatrogenic Creutzfeldt-Jakob
Variant Creutzfeldt-Jakob 
Sporadic Creutzfeldt-Jakob
Mechanism of pathogenesis
Infection through ritualistic cannibalism
Infection;
A) Peripheral transmission:
 Prion-contaminated human growth hormone
(hGH)
 Prion-contaminated gonadotrophin
B) Central transmission:
Prion-contaminated Dura mater 
Prion-contaminated Cornea 
Prion-contaminated Surgical instruments 
Prion-contaminated Cortical EEG electrodes
Infection from BSE -  contaminated food
Somatic mutation in the PrP gene?
Spontaneous convertion of PrP^ into PrP^^
Familial Creutzfeldt-Jakob . ^  Germline mutations in the PrP gene 
Gerstmann-Straussler-Scheinker Germline mutations in the PrP gene 
Syndrome
Fatal Familial Insomnia 
Sporadic Fatal Insomnia?
Germline mutations in the PrP gene 
Somatic mutation in the PrP gene? 
Spontaneous convertion of PrP^ into PrP^ "^ ?
20
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Table I II: Animal prion diseases
Disease %
Scrapie
Animal affected
Sheep, Goats
Bovine spongiform encephalopathy Cattle
Trasmisslble mink encephalopathy Mink 
(Marsh and Hadlow, 1992)
Chronic wasting disease 
(Williams and Young, 1980; 
Williams and Young, 1982)
Mule deer, white tailed dear 
Rocky Mountain elk
Feline spongiform encephalopathy Cats, pumas, tigers, lions,
(Kirkwood and Cunningham, 1994) cheetahs, ocelots
Exotic ungulate encephalopathy Nyala, oryx, greater kudu,
(Kirkwood and Cunningham, 1994; eland, gemsbok, American
Taylor and Woodgate, 1997) bison, Ankole cattle
21
Mechanism of pathogenesis
Infection in susceptible sheep
Infection with prion contaminated 
meat-bone meal
Infection with prions from sheeps 
or cattle
As sheep
Infection with prion contaminated 
meat-bone meal
Infection with prion contaminated 
meat-bone meal
DD
u
The Chemical nature of the infectious agent in TSEs has been the subject of 
intense scrutiny for nearly 40 years. Many lines of evidence indicate that an 
altered form of a cellular protein (named prion protein, PrP) plays a key role in 
the origin of these diseases. It accumulates in the brain upon conformational 
change, without modifications of the primary structure. According to the prion 
hypothesis (see section 1.2), this altered form (called PrP scrapie or PrP^^) 
would be able to self-propagate by impressing its abnormal conformation on 
normal cellular PrP (PrP^) molecules (Cohen et al., 1994). An alternative 
hypothesis states that there may be an undiscovered viral-like agent containing 
a nucleic acid genome that is responsible for transmission (Chesebro, 1997).
Three different manifestations of prion diseases are known: infectious, 
familial and sporadic. The infectious origin is dramatically illustrated by Kuru, a 
neurodegenerative illness of the Fore and related tribes of New Guinea that was 
found to be transmitted by ritual cannibalism (Gajdusek and Zigas, 1957). Other 
examples include iatrogenic cases of CJD due to dura mater grafts and 
therapeutic administration of cadaver-derived hormone (Brown et al., 1992) (for 
the description of human prion diseases see section 1.4), as well as BSE and 
its human counterpart “variant” CJD .
Bovine spongiform encephalopathy was first described in the United 
Kingdom (UK) (Jeffrey et al., 2001; Jeffrey and Wells, 1988; Wells et al., 1987) 
in 1986. In June a case of spongiform encephalopathy was discovered in a 
^  Nyala (a South African antelope which belongs to the family of Bovidae,
subfamily of Bovinae) which had been kept at Marwell Zoo (Jeffrey et al., 2001; 
Jeffrey and Wells, 1988) and in December Dr Gerald Wells reported the first 
case of spongiform encephalopathy in a cow (Wells et al., 1987). In the 
following years increasing numbers of cases were diagnosed in cows, reaching
0
D
D
n
D
D
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D
epidemic proportions and causing the death of now almost 180,000 animals. 
Other cases of bovine spongiform encephalopathy were also diagnosed in the 
UK in other captive Bovidae through 1986 and 1992 (Kirkwood et al., 1990). 
Epidemiological studies revealed that the use of meat and bone meal (MBM) as 
a high protein supplement feed might be the vehicle of infection (Wilesmith et 
al., 1988). MBM was produced from rendering the waste parts of mixed species 
P  including sheep and cattle that were not used for human consumption. It was
hypothesised that once the causative agent of BSE had been introduced into
nJ  the rendering process it would have been recycled to infect other cattle through
D
D
u
MBM. It was further postulated that BSE occurred in the UK first, rather than in 
any other country, because of the ratio of sheep to cattle tissue going into 
rendering in the UK. To eradicate the disease, in 1988 the government 
introduced the “Feed Ban”, which banned the feeding of ruminant proteins to 
ruminants. The effect was not immediately apparent because of long incubation 
period; however by 1992 the number of cases fell by about 40% a year on
"I average (Smith and Bradley, 2003). However, it turned out that this ban was
insufficient in totally preventing further cases of BSE and a stricter feed ban wasn
U introduced in August 1996. This new ban entirely prohibited cattle parts being
2  rendered into feed, including feed for chicken and pigs. Factors underlying this
1996 ban were that there were cross-contaminations in feed-factories thatn^
 produced both cattle and pig/chicken feed and farmers frequently did not
differentiate between cattle, pig and chicken feed. This such a measure was 
necessary because cattle protein, even if used legally in chicken and pig feed, 
inevitably ended up being fed to cattle as well. The few cases of BSE reported 
in animals born after 1 August 1996 are known as “BARB” (Born After the 
Reinforced feed Ban). To explain the persistency of the disease different
23
n
uD
D
hypothesis were made; 1) some animals might have been exposed to BSE 
through maternal transmission; 2) some animals might have been exposed to 
BSE through feed carried over before 1 August 1996; 3) there might be routes 
of transmission which have not yet been identified; 4) the disease may occur 
spontaneously.
^  Initially BSE was regarded as a problem confined to UK, but there were
n  soon indications that other countries to which cattle, cattle products and MBM
had been exported were also involved. The first BSE cases outside the UK 
]  were diagnosed in the Falkland Islands and Oman in 1989, in animals imported
from the UK. The first cases in cattle that were born and raised outside the UK 
were reported in the Republic of Ireland in 1989, in Switzerland in 1990 and in 
France in 1991. In 1997, the first cases were diagnosed in Belgium, the 
Netherlands and Luxemburg (Heim and Wilesmith, 2000). Other countries with 
native BSE cases are now Portugal, Spain, Liechtenstein and Japan. ImportednJ  and native cases have been diagnosed in Canada, Denmark, Germany and
1 Italy (Table I.Ill) (Smith and Bradley, 2003) (data from Office Internationale des
Epizooties, 01E).
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In 1996 the occurrence of a variant form of CJD (vCJD) was reported in 
UK, affecting young people and having consistent and unique 
clinicopathological pattern, including the presence of florid plaques extensively 
distributed in the cerebrum and cerebellum (Will et al., 1996). As of April 5, 
2004, a total of 156 (definite or probable) cases of vCJD had been reported 
J  worldwide: 146 in the UK, 6 in France, one each from Canada, Ireland, Italy and
United States. The observation that the majority of the patients (excluding the 
French and the Italian cases) had multiple-year exposures in the UK between 
1986 and 1996 raised concerns that BSE could have spread to humans, by 
dietary exposure. The infection of French and Italian patients must have come 
either from beef imported from the UK of from French BSE affected cattle.
Experimental evidence has provided compelling evidence of a link 
between BSE and vCJD. Brain material from bull BSE (cattle) and vCJD 
(human patients) produce the same profile of disease when inoculated in mice, 
based on the incubation time, the clinical symptoms, the type of lesions (Bruce 
et al., 1997; Hill et al., 1997a) and the glycoform pattern of protease-resistant 
PrP (Collinge et al., 1996); 2) neuropathologically, vCJD lesions are similar to 
lesions found in macaques inoculated with BSE (Lasmezas et al., 1996b).
Familial prion diseases, which include about 15% of the cases of CJD, all 
cases of GSS and almost all cases of FFI are inherited in an autosomal fashion 
and are linked to germline mutations in the PrP gene (Young et al., 1999). 
J  According to the prion hypothesis (see section 1.2) mutations destabilise the
conformation of the protein and favour spontaneous conversion to PrP^^ (Cohen 
et al., 1994). Sporadic prion diseases, which include most cases of CJD, have 
Q no obvious infectious or genetic aetiology and has a near uniform prevalence
P  worldwide. The origin of the disease can be explained by spontaneous
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conversion of wild-type PrP to the PrP^^ state without necessity for contact with 
“ * exogenous prions or alternatively by rare somatic mutations in the PrP gene. In
1  the viral theory, sporadic forms could be due to an ubiquitous infection and PrP
_  mutations might increase susceptibility to disease (Chesebro, 1997).
Familial and sporadic prion diseases, as well as infectious forms can be 
^  experimentally transmitted to laboratory animals, suggesting the ability of PrP^^
- j to propagate infection (Gajdusek et al., 1966; Gajdusek and Gibbs, 1971;
^ Gajdusek and Gibbs, 1972; Gajdusek et al., 1967; Gibbs et al., 1968).
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1.1.2 The cellular prion protein
The cellular prion protein (PrP^) is a 33-35 kDa glycoprotein, linked to the
I
outer leaflet of the cell membrane by a glycosyl-phoshatidylinositol (GPI) anchor 
J (Diener, 1987; Kretzschmar et al., 1986b; Stahl et al., 1987) . PrP^ is encoded
by a small single-copy housekeeping gene that in humans is located on 
chromosome 20 (Kretzschmar et al., 1986b). In man, the gene has only three
n
[J exons and the entire open reading frame (ORF) is in one exon. The 2.5 kb
transcript is expressed at high levels in the brain, spinal cord and at lower levels 
in other peripheral tissues, including lung, skeletal muscle, heart and lymphoid
n
J  tissues (Bendheim et al., 1992; Kretzschmar et al., 1986a). In the central
j j  nervous system (CNS), PrP is expressed in neurons, ependymal cells, choroid
plexus epithelium, endothelial cell, meninges and astrocytes (Brown et al.,n_) 1990). PrP mRNA is first detectable in the brains of mice beginning in early
embriogenesis, and its level increases as development proceeds (Manson et 
al., 1992).n
J  The primary structure of PrP'" is highly conserved across mammalian
species and contains several distinct domains, including an N-terminal signal
27
upeptide, a series of five proline- and glycine-rich octapeptide repeats, a central 
hydrophobic segment and a C-terminal hydrophobic region (Figure 1.1). 
Nuclear magnetic resonance analysis (NMR) of recombinant PrP^ from various 
species has revealed a C-terminal globular structure and an N-terminal flexible, 
unstructured region (Figure 1.2). The globular structure is composed of three a- 
helices (two of which are linked by a disulphide bridge) and two short anti­
parallel p-pleated segments (Riek et al., 1997).
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Figure 1.1: Post translational modifications of mouse PrP.
The translational product of 254 aminoacids is cleaved at the N-terminus and at 
the C-terminus. A GPI anchor is added to the serine 231 and N-glycosilation 
occurs at residues 182 and 198. A disulphide bridge is formed between cysteine 
residues 180 and 215. Repeats region, spanning residues 51-91, and MetA/al 
128, a common polymorphism on Caucasian population, are represented.
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Figure 1.2: Three-dimensional structure of moPrP (23-231).
NMR analysis of recombinant moPrP reveals an N-terminal random coil 
polypeptide (23-123) and a C-terminal globular structure. The globular structure 
is composed of three a-helices (residues 144-154, 175-193, 177-219), a short 
segment of helix-like structure residues (222-226) and two stranded antiparallel 
p-sheet (residues 128-131, 161-164).
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Like other membrane proteins, PrP is synthesized in the endoplasmic 
reticulum (ER) and transits the Golgi on its way to the cell surface. The murine 
PrP*  ^ protein is synthesised as a 254 amino acids polypeptide chain and is 
subject to several posttranslational modifications: the signal peptide of 22 
aminoacids is cleaved at the N-terminus, and the hydrophobic signal of 23 
amino acid is removed from the C-terminus on addition of the GPI anchor when 
in transit through the ER (Stahl et aL, 1987; Turk et al., 1988). Asparagine- 
linked glycosylation (N-glycosylation) occurs at residues 182 and 198 in a loop 
formed by the disulfide bond between cysteine residues at positions 180 and 
1  215 (Figure 1.1) (Caughey et al., 1989). The N-linked oligosaccharides added
initially in the ER are of the high mannose type and are sensitive to digestion by 
J endoglycosidase hi; these are subsequently modified in the Golgi to yield
1  complex type chains that contain sialic acid and are resistant to 
endoglycosidase H digestion (Safar et al., 1990; Stahl et al., 1992). At steady 
state, different forms of PrP can be detected by Western Blot, corresponding to
2  the fully glycosylated, mono-glycosylated and unglycosylated forms. In addition, 
PrP contains two independent functional nuclear localisation signals (NLS) in 
the N-terminal domain (Gu et al., 2003a). Nuclear forms have been described 
for PrP carrying the stop-mutations at codon 145 and 160 (Lorenz et al., 2002;
p. Zanusso et al., 1999).
Also in common with other GPI-anchor proteins PrP^ is transported to 
J  the cell surface where it is predominantly located in detergent resistant
p  microdomains, rich in sphingolipid and cholesterol, known as rafts or caveolae
(Gorodinsky and Harris, 1995; Peters et al., 2003; Vey et al., 1996). Saturated 
J  acyl chains covalently linked to the protein are sufficient for the raft association
of GPI-anchor proteins, where the acyl chains of the anchor interact with lipidsD
n
31
uD
D
D
D
D
of the rafts (Simons and Toomre, 2000). However, in the case of PrP, the N- 
terminus of PrP and not the GPI anchor, acts as a cellular raft targeting 
determinant, since raft association was abolished by the deletion of the N- 
terminal region (residues 23-90) (Baron and Caughey, 2003; Walmsley et al., 
2003) After its delivery to the cell surface, the protein constitutively cycles 
between the plasma membrane and an endocytic compartment, with a transit 
time o f -60 min (Shyng et al., 1993) (Figure 1.3A).
PrP^ undergoes different post-translational cleavages as part of its 
normal metabolism (Figure 1.3B). Both cleavages occur relatively slowly in 
comparison to the half life of the protein, so that at steady state several different 
cleavage products in addition to the intact protein can be detected. One 
cleavage occurs within the GPI-anchor (Borchelt et al., 1993; Harris et al., 1993; 
Parkin et al., 2004) and releases the polypeptide chain into the extracellular 
milieu. The cellular localization in which this cleavage occurs is unknown, 
although for other GPI-anchored proteins which undergo a similar cleavage it
r  has been speculated that a cell surface phospholipase is responsible (Low,
1989). The fact that the formation of this form of PrP is stimulated by the raft- 
J  disrupting agent filipin confirms the hypothesis that the cleavage occurs on the
cell membrane (Parkin et al., 2004). A second cleavage involves the action of a 
metalloprotease that acts very near to the GPI anchor and sheds PrP from the 
cell surface (Borchelt et al., 1993; Parkin et al., 2004). When PrP is internalised 
J  in the endocytic compartment some of the molecules are cleaved at position
111-112 (a-site) by metalloenzymes producing a C-terminal fragment named 
01 carrying the sugar chains and a complementary N-terminal fragment (N1) 
J  (Chen et al., 1995; Shyng et al., 1993; Vincent et al., 2000; Vincent et al., 2001).
nj Full length PrP and the C l fragment are re-exposed on cell membrane, while
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the N1 fragment is secreted into the extracellular milieu (Shyng et al., 1993; 
Vincent et al., 2000). Finally, in prion infected cells and brains, a longer C- 
terminal fragment starting from around residue 90 ((3-site), named C2 
accumulates (Caughey et al., 1989; Chen et al., 1995; Yadayalli et al., 2004). 
The accumulation of this form in scrapie infected cells is inhibited by calpain 
inhibitors, suggesting an active role of these proteases in the formation of C2. 
This fragment is also generated in small amounts in normal brain and in cell 
lines expressing endogenous PrP, from which it is also possible to recover the 
complementary N-terminal fragment, called N2 (Jimenez-Huete et al., 1998; 
Mange et al., 2004). Interestingly, the cleavage of PrP in the octapeptide region 
was observed after exposure to reactive oxygen species in the presence of 
divalent copper ions (Mange et al., 2004; McMahon et al., 2001). On the basis 
of these data it has been suggested that modulation of oxidative stress can be 
linked to the N-terminal cleavage of PrP (Mange et al., 2004). In this hypothesis, 
the C2 terminal fragment may be important for the function of PrP (through, for 
"] example, signal transduction pathways). Then the second cleavage, in the a-
site, would inactivate the biological active form (Mange et al., 2004).
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Figure 1.3: Processing of PrP^.
(A) Model for the endocytic targeting of PrP. After reaching the cell surface, PrP 
is internalized into an endocytic compartment from which most of the molecules
p. are recycled intact to the cell surface. A small percentage of the endocytosed
molecules are proteolitically cleaved, producing N-terminal and C-terminal 
fragments which are subsequently externalised. Some of the membrane- 
P  anchored PrP molecules are released into the extracellular medium by cleavage
J within or near the GPI anchor.
(B) Representation of moPrP and its fragments. N-glycosylation at residues 182 
-, and 196 and the GPI anchor, attached to the serine 231 are represented.
J  Octapeptide region (residues 51-91) is shown in yellow. PrP^ undergoes
different post-translational cleavages. Two different cleavages can occur within 
“ I or very near the GPI anchor after PrP has reached the cell surface, so that the
J  polypeptide chain is released in the extracellular milieu. The cleavage at the
position 111-112 (a-site) occurs in an endocytic compartment and determines 
the formation of two fragments: a N-terminal (N1) and a C-terminal (C l) which 
is glycosylated and GPI-anchored. The cleavage in the (3-site, located in the 
octapeptide region, produces a N-terminal fragment (N2) and a C-terminal 
glycosylated and GPI-anchored fragment (C2). N1 and N2 are released in the 
extracellular milieu, while C l and C2 can be attached to the cell surface or 
released.
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When PrP is synthesised in vitro (in transfected cells) or in mouse brain, 
it has been reported that some of the molecules may assume a transmembrane 
orientation (Hegde et al., 1998; Holscher et al., 2001; Kim et al., 2001). These 
species, designated "^ "^^ PrP and ^ "^^PrP, span the lipid bilayer once via a highly 
conserved hydrophobic region in the centre of the molecule, with either the N- 
terminus or C-terminus, respectively, on the extracytoplasmic side of the 
membrane. Because in^*"^PrP and ^ "^^PrP a different part of the protein is 
accessible to exogenous proteases, digestion of the two transmembrane forms 
yields two different fragments. One fragment, corresponding to ^^'^PrP, is 
COOH-terminal derived and glycosylated, and the other (from ^^"^PrP) is NHz- 
terminal derived and unglycosylated. ^‘"’PrP and ^ "^^ PrP are generated in small 
amounts (<10% of the total) as part of the normal biosynthesis of wild-type PrP 
in the endoplasmic reticulum (Figure 1.4). However, mutations within or near 
the transmembrane domain, including the A l 17V and P105L mutations linked tonU GSS, as well several artificial mutations not seen in patients, increased the
relative proportion of ^ "^^PrP to as much as 20-30% of the total (Hegde et al., 
1998; Hegde et al., 1999; Stewart and Harris, 2001). Current evidence indicates 
that the membrane topology of PrP is determined by competition at the 
translocon between two conflicting topological determinants in the polypeptide 
chain: the signal sequence that directs translocation of the N-terminus of the 
polypeptide chain to produce secreted PrP (^®^PrP) or ^ "^^PrP, and the central 
hydrophobic domain that directs translocation of the C-terminus across the
PI membrane to produce ^ "^^ PrP (Kim and Hegde, 2002; Kim et al., 2001; Stewart
and Harris, 2003).
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Figure 1.4: Schematic representation of ^^ "’PrP, ‘^ "^’PrP and secreted PrP.
During translation a small percentage of PrP does not enter the ER but 
assumes a transmembrane orientation. In ^ "^^PrP and '^ ‘"^PrP the N-terminus 
and the C-terminus are exposed to proteases added to the cytoplasmatic side, 
while secreted PrP is fully protected. After PK digestion, three different forms 
are detected by Western blotting: a N-terminal fragment of 14 kD, a C-terminal 
fragment of 18 kD, corresponding respectively to the protected '^ "^^ PrP and 
^ "^^PrP, and a band of 28 kD corresponding to secreted PrP.
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1,1.3 Function of PrP
The physiological function of the prion protein is unknown, although its 
localization on the cell surface would be consistent with roles in cell adhesion 
and recognition, ligand uptake or transmembrane signalling. Mice in which the 
PrP open reading frame of the gene has been disrupted display no gross 
development or anatomical defects (Bueler et al., 1992) but are reported in 
some studies to have electrophysiological and structural abnormalities in the 
hippocampus (Colling et al., 1996; Collinge et al., 1994; Curtis et al., 2003; 
Manson et al., 1994a) alteration in the circadian rhythm and changes in learning 
and memory (Nishida et al., 1997) and sleep pattern (Tobler et al., 1996). Other 
studies (Mabbott et al., 1997) revealed that proliferation of lymphocytes from 
PrP knock out mice by concanavalin A was significantly reduced to 50-80% that 
of wild-type PrP mice, suggesting a role for PrP in extra-neuronal tissues.
In contrast, Ngsk PrP°^° mice (Sakaguchi et al., 1996), in which the ORF
was deleted together with large portion of 5’ intron and the 3’ untranslated
region, suffered extensive Purkinje cell loss with progressive ataxia. This
phenotype was due to the ectopic expression of the PrP-like protein Doppel in
the brains of these mice (Li et al., 2000a; Li et al., 2000b; Moore et al., 1999).
Doppel is encoded by the P r n - d  locus, which is 16 kb downstream of the PrP
gene and is not normally expressed in the CNS. In Ngsk PrP°^° mice, as a
consequence of the ablation of the P r n - p  locus, the acceptor splice site of the
third P r n - p  exon is lost, causing exon skipping and formation of chimeric
transcripts that place P r n - d  under the control of the P r n - p  promoter. Doppel
toxicity was abolished by the presence of single wild-type P r n - p  allele
suggesting a functional interaction between the two genes (Mastrangelo and
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Westaway, 2001; Moore et al., 2001; Nishida et al., 1999; Rossi et al., 2001). In 
particular, the octapeptide repeats region was required to rescue the phenotype 
(Atarashi et al., 2003).
Although the normal, physiological role of PrP^ remains enigmatic, there 
is evidence that the protein binds copper and may also play a role in the 
J  trafficking of copper ions. Redox-active transition metal ions such as copper and
PI iron have a dual significance in relation to neurodegeneration (Sayre et al.,
1999). These metals are essential as cofactors for many enzymes, and their 
deficiency can lead to dysfunction in the CNS. Thus, the copper chelator 
cuprizone has long been recognized to cause a neuropathy in rodents that 
appears somewhat similar to scrapie (Carlton, 1969). On the other hand, 
elevated levels of these ions can also evoke disturbances characterized by
D
D
"} oxidative stress and free-radical production. The amino-terminal section of PrP
J
(spanning residues 51-71 of human PrP) contains a series of glycine and 
J histidine-containing peptides repeats, and the interaction of this region with Cu^ "^
1  has been studied in some detail (Brown et al., 1997a; Stockel et al., 1998).
Synthetic peptides from this region bind Cu^ "" with a Kd in the micromolar range, 
J thus suggesting that the interaction between copper and PrP is physiological.
Various studies have explored different aspects and consequences of the 
binding of Cu^ :^ 1) Cu^^ has been shown to facilitate the return of protease 
resistance and infectivity after dénaturation of PrP^^ with guanidine (McKenzie 
et al., 1998); moreover, studies in vitro indicate that copper favours the 
conversion of PrP^ to a protease-resistant form that is distinct from PrP^^ 
(Quaglio et al., 2001); 2) in transfected lines of N2a mouse neuroblastoma cells 
Q expressing mouse or chicken PrP, Cu^^ stimulates internalisation of PrP (Pauly
and Harris, 1998; Perera and Hooper, 2001); 3) the content of copper in
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membrane preparations from PrP null mice is about 20% of that in wild-type 
mice, and it has been argued that the neuronal Cu-Zn SOD (copper-zinc 
superoxide dismutase) is less active in PrP null mice and correspondingly 
higher in transgenic mice that over express PrP (Brown et al., 1997a; Brown et 
al., 1997b). However, other data indicate that PrP expression level does not 
influence the copper content of the brain, nor does it make any measurable 
contribution to dismutase activity (Waggoner et al., 2000). Moreover, when mice 
lacking the Sod 1 gene were crossed to PrP°^° mice or with mice expressing 
different level of PrP, no influence of the PrP dosage was detected on the SOD 
activity (Hutter et al., 2003).
A second perspective on the possible roles of PrP^ at the cell surface
has come from the study of PrP null mice expressing PrP molecules with
amino-proximal deletions (Shmerling et al., 1998). In mice expressing PrP
molecules in which aminoacids 32-80, 32-93 and 32-106 were deleted there
was no phenotype, but animals with longer deletions, from 32-121 or 32-134,
showed extensive death of neurons. Based on these observations, and given
the localisation of PrP as a GPI-anchored proteins in rafts, it was proposed that
PrP^ might elicit a cell survival signal upon binding to a putative receptor (or
ligand), and that deleted forms of PrP could bind to the receptor but fail to
supply this neurotrophic signal (Shmerling et al., 1998). Further to this, and in
support of a neuroprotective role for PrP, it has been shown that neuronal cell
cultures from PrP°^° mice are more susceptible to oxidative stress (Brown et al.,
1997b; White et al., 1999) and serum deprivation (Kuwahara et al., 1999).
Moreover, in  s i t u  hybridisation analysis of human brains with cerebral ischemia
or perinatal hypoxic ischemia revealed upregulation of PrP mRNA, suggesting a
role for PrP in the neuroprotective cellular response to hypoxic injury. These
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data have been confirmed in transgenic mice, being PrP°^° mice more 
susceptible to hypoxic injury than wild-type mice (McLennan et al., 2004). 
Réintroduction of a single PrP allele, as in hemizygous mice, was only partially 
protective, suggesting a quantitative effect.
These findings have prompted a search for PrP-interacting partners and 
several molecules have been found to interact with PrP, including laminin 
receptor precursor (Rieger et al., 1997), and plasminogen (Fischer et al., 2000). 
However, none of these interactors have yet revealed a functional pathway in 
which PrP would be involved in  v iv o .
Recently, PrP has been shown to be involved in different signal 
transduction pathways related to cell survival. First, it was shown that antibodies 
that cross-linked cell surface PrP stimulated the activation of Fyn tyrosine 
kinase (known to be associated with cellular proliferation and survival) in murine 
1C11 differentiated neuronal cells (Mouillet-Richard et al., 2000). Second, it has 
been demonstrated that PrP binds to Bcl-2 in the yeast two-hybrid system
(Kurschner and Morgan, 1995), that transfection of PrP or Bcl-2 rescued the
PrP null cells from apoptosis induced by serum deprivation (Kuwahara et al., 
1999) and that PrP protected human primary neurons from Bax-mediated cell 
death (Bounhar et al., 2001; Roucou et al., 2003).This neuroprotective role was 
abolished in PrP constructs lacking the octapeptide repeats or carrying the 
D178N mutation (Roucou et al., 2003). The neuroprotection of PrP required 
mature PrP but not the GPI anchor, indicating that cell surface signaling may be 
not the only protective pathways of PrP. Third, a PrP^ binding peptide has been 
shown to prevent apoptosis, by activating cAMP protein kinase A (PKA) and Erk 
J  pathways (Chiarini et al., 2002). The PrP binding protein was identified as the
n  stress-inducible protein 1 (STM) which is present in the cytoplasm and at the
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cell surface. Cell surface binding experiments showed that recombinant PrP*  ^
^  binds to STM and co-immunoprecipitation assay suggest that the two proteins
Q are associated in  v iv o . The authors proposed that the interaction could induce
neuroprotective signals that rescued cell from apoptosis (Zanata et al., 2002). 
Whereas the Fyn and STI1 related transduction functions appear to occur 
^  through the cell surface GPI-anchored protein, the anti-Bax function could be
mediated by cytosolic PrP or secreted PrP.
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1.1.4 TSE strain variation
It is well established that TSE agents, like conventional micro-organism, 
exhibit strain variation. Numerous distinct TSE strains have been identified in 
mice by serially passaging scrapie (Bruce, 1993; Bruce and Dickinson, 1985), 
BSE (Bruce et al., 1994; Fraser et al., 1992) or CJD (Bruce et al., 1997; 
Collinge et al., 1996) from a range of sheep, goat, cattle and human sources. 
The methods used for TSE strain discrimination have traditionally been based 
on simple observation of disease characteristics. The most useful have been 
the length of the incubation period between infection and the appearance of 
clinical symptoms and the type and distribution of pathological changes that are 
seen in the brain of infected animals (Bruce et al., 1991; Dickinson and Meikle, 
1971; Dickinson et al., 1968b; Fraser and Dickinson, 1973). TSEs strains have 
also found to differ in their clinical manifestation and their ease of transmission 
to new species. Prions exhibiting different biological properties were first 
recognized in goats with scrapie where different clinical phenotypes were 
manifested (Pattison and Millson, 1961). A link between PrP biochemical 
properties and strains was established with the finding that PrP^ *  ^ associated
with various murine scrapie strains differed in the relative proportion of PrP
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glycoforms (Kascsak et al., 1991). More recently when transmissible mink 
encephalopathy (TME) was transmitted to hamsters, two different strains (called 
“hyper” and “drowsy” because of the differences in clinical phenotype), were 
identified (Bessen and Marsh, 1992). Purification and analysis of PrP^^ from
"!
^  animals infected with hyper and drowsy agent revealed differences in
biochemical properties: in particular, PrP from drowsy-infected brains was more 
soluble in detergents and more sensitive to proteinase-k (PK) digestion; 
moreover, the site of protease cleavage was different. To explain these 
differences, the authors suggested the existence of different conformations of 
PrP. Later, it was demonstrated that these strain-specific properties could be 
transmitted to PrP^ in a cell free-system, providing evidence for self­
propagation of PrP^^ (Bessen et al., 1995). Finally, spectroscopy studies 
demonstrated that PrP^^ purified from hyper and drowsy did indeed show 
different conformation (Caughey et al., 1998). Different strains of TSE agent are 
associated with different glycoform ratios and different sizes of the PrP^^ 
domain that is resistant to digestion by proteinase-K (Collinge et al., 1996; 
Parchi et al., 1996). Precisely how these strain-specific glycoform ratios are 
maintained is currently an open question. They may be the consequence of 
preferential conversion of a particular PrP^ glycoform into PrP^^. In this 
instance, it would be the strain-specific PrP^^ that determines the final glycoformn
Li pattern (Somerville, 1999). Alternatively, if there are differences in the PK-
sensitivities of the different glycoforms of PrP^^, degradation of the newly
formed PrP^ *^  in endolysosomal compartments could account for the different
banding pattern seen in different strains (DeArmond et al., 1999). Alternatively,
J  the infected host may play a role in the molecular aspects of TSE strain
pathogenesis. Thus, differences in PrP^ glycosylation in different population of 
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neurons of the brain could target incoming infectivity to specific population of 
J neurons. This could be modulated by the possible binding of some ligand
1  playing a role in strain associated PrP-diversity. The complex interplay between
PrP^^ conformation, glycoform selection and ligand binding may cause PrP^^ 
strains to target and to be most efficiently propagated within subsets of cells 
J  that can provide the preferred glycoform and ligand. This cellular targeting, as
well as differences in susceptibility of target cells to the toxic effect of PrP^^ may 
then establish strain-dependent pattern of pathological lesion and the 
J  consequent phenotype of disease (Bruce et al., 1989). The existence of
different conformations of PrP and the hypothesis that each of them can target 
to different regions of the brain would therefore explain the large phenotypic 
variability described for human prion diseases (see section 1.4).
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1.2 The prion hypothesis
Scrapie has been known as a naturally occurring disease for over 250 years
n
J  in various parts of Europe (Parry, 1984). In 1936 Cuillé and Chelle
n  demonstrated the transmissibility of the disease by experimental inoculation, but
with a long incubation period. At that time, some type of virus was assumed ton
J  be the causative agent and Sigurdsson, because of the long incubation period.
coined the term “slow virus” (Sigurdsson, 1954). Later, it was observed that the 
scrapie agent had a very low molecular weight, was resistant to procedures that 
inactivated or modify nucleic acids but was sensitive to treatments that denature 
proteins (Alper et al., 1967; Pattison and Jones, 1967). This evidence 
suggested that the infectious agent could be a protein in nature, lacking a 
nucleic acid component but it was not clear how it could replicate itself. Griffith
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proposed three different mechanism to explain the self replication of proteins: 1) 
the “infective” protein could be a transcriptional activator of the gene (normally 
" j silenced) coding for the protein itself; 2) the “infective” protein could be a
conformationally different form of a cellular protein and was able to confer its 
conformation to the normal protein by physical interaction; 3) the “infective” 
protein could be able to stimulate the production of antibodies identical to the 
protein (Griffith, 1967).
Building on the second mechanism proposed by Griffith, Prusiner proposed 
the existence of a novel class of infectious agent that he named prions 
(jproteinaceous mfectious particle) (Prusiner, 1982). Attempts to purify the 
infectious agent from brains of hamsters infected with scrapie led to the 
discovery that the infectivity co-purrfied with a protein of 27-30 kDa, which was a 
protease-resistant fragment of a 33-35 kDa precursor protein. This proteinase 
resistant form of the protein, which was named PrP^^, for scrapie isoform of the 
prion protein, was found to be a conformationally altered isoform of a cellular 
protein, called PrP^, for cellular prion protein (Oesch et al., 1985). According to 
the prion hypothesis, PrP^ is converted into PrP^^ by a post-translational 
process that appears to involve a conformational change, with transition of a- 
1  helices into p-sheets (Figure 1.5) (Caughey et al., 1991b). Stochastic
fluctuations in the structure of PrP^ would generate a partially unfolded 
monomer (PrP*) that is an intermediate in the formation of PrP^°. PrP* can 
revert to PrP^, be degraded or form PrP^^ Normally the concentration of PrP* 
would be low and PrP^^ would be formed in insignificant amount (Cohen et al.,
1994). In the case of infectious prion diseases, exogenous prions containing
■n
J PrP^^ would act as a template to promote the conversion of PrP* into PrP^^
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(Cohen et al., 1994). In the case of inherited prion diseases, PrP mutations
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would destabilize PrP and promote its conversion into PrP* (Cohen et al., 
^  1994). Indeed, the majority of point mutations that segregate with inherited
^  diseases fall within or near the four putative a-helices (Hsiao et al., 1989).
Finally, the sporadic forms may result from the rare occasions in which there is 
sufficient accumulation of PrP* to produce PrP^^ (Cohen et al., 1994). Based on 
experimental and computational results it has now been suggested that the
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fundamental unit of PrP^^ structure is a trimer of parallel left-handed p-helices; 
moreover, trimers could assemble by hydrogen bonds determining protein 
aggregation (Govaerts et al., 2004; Wille et al., 2002) (Figure 1.5).
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Figure 1.5: Modelling of PrP^ *^  formation.
(A) A model of the monomer of mouse PrP^^: the main conformational change 
occurs between residues 89 and 170 while the two C-terminal a-helices of PrP*" 
are retained. (B) Trimeric model of PrP^^ built by superimposing three 
monomeric models (C) A model for PrP^^ fiber constructed by assembling five 
trimeric disc.
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PrP^^ differs from PrP^ in several physicochemical properties: it is partially 
resistant to PK digestion and forms aggregates, determining its insolubility in 
non-denaturing detergents. The tendency to aggregate also determines the 
formation of fibrillar structures called prion rods that show the typical fluorescent 
birefringence of amyloid when stained with Congo Red (Prusiner et al., 1983). 
Probably because of the resistance to protease, PrP^^ accumulates in the 
p  brains of affected animals and humans, where it is thought to propagate itself by
impressing its abnormal conformation on PrP^, generating additional molecules 
of PrP^".
Two mechanisms have been proposed for PrP^^ formation (Figure 1.6). The 
heterodimer model posits that PrP^^ exists in a stable monomeric state that can 
J bind PrP^ forming an heterodimer, and catalyses a conformational change in
n PrP^ to form an homodimer of PrP^^ (Bolton and Bendheim, 1988; Griffith,
1967). The two PrP^^ molecules than separate to give two PrP^^ monomers. 
J The fundamental underlying postulates of this model are that PrP^^ is more
"j stable thermodynamically than PrP^, conversion of PrP^ to PrP^^ is rare unless
catalysed by pre-existing PrP^^ and that the PrP^^ homodimer tends to
—T
J dissociate. In the nucleated polymerisation model (Gajdusek, 1988; Jarrett and
"j Lansbury, 1993), oligomerization of PrP is necessary to stabilize PrP^^
sufficiently to allow its accumulation to biologically relevant levels. Spontaneous 
“ * formation of seeds of PrP^^ is rare because of the weakness of monovalent
r  interactions between PrP^ molecules and the oligomer. However, once formed,
Ü
oligomeric or polymeric seeds are stabilized by multivalent interactions. In 
^  familial and sporadic human TSEs, formation of an initial template (or seed)
might be a spontaneous and stochastic event that can be potentiated by
P specific mutations (Caughey et al., 1995; Jarrett and Lansbury, 1993). In TSEs
J 48
u
D
1
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of infectious origin transmission might be explained by acquisition of preformed
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Figure 1.6: Mechanistic models for formation of PrP^  ^from PrP^
(Aguzzi and Polymenidou, 2004)
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J  Support for the concept that PrP^ is converted to PrP^^ in the presence of
pre-existing PrP^^ has been derived from “conversion assay” in cell-free 
models. In these experiment [^^Sjmethionine-labeled PrP^ was converted into 
proteinase-K resistant ^^S-PrP in the presence of purified PrP^^ (Kocisko et al., 
q  1994). This converting activity was dependent on the initial concentration of
PrP^^ and was associated only with aggregates (Caughey et al., 1995). The 
cell-free conversion of PrP^ to PrP^^ was also demonstrated i n  s i t u ,  by 
incubating purified [^^SJmethionine-iabeled PrP^ with brain slices of TSE- 
infected animals. In particular, proteinase-K resistant ^^S-PrP was found exactly 
at the sites of endogenous PrP^^ deposits (Bessen et al., 1997). The cell-free 
conversion reaction studies validate the prion hypothesis, indicate that PrP 
conversion activity is associated with PrP^^ aggregates and therefore support 
the nucleation-dependent protein polymerization hypothesis.
A strong prediction of the prion hypothesis is that expression of PrP by the 
host is necessary for the propagation of the infectious agent and the 
development of the disease. In accordance with this prediction, it has been 
convincingly shown that P rn -p ^ '^  mice, in which the prion protein gene has been 
inactivated through homologous recombination, are resistant to prion infection 
and do not sustain replication of the infectious agent (Bueler et al., 1993; 
Caughey et al., 1995). Prn-p°^° mice remained completely healthy even when 
transgenic embryonic neuronal tissue overexpressing PrP was transplanted into 
their brain and infected with scrapie prions (Brandner et al., 1996a). The graft 
accumulated high level of PrP^^ and infectivity that migrated into the host brain, 
but only the graft developed the typical histopathological changes of scrapie, 
with no replication of PrP^^ in the null tissue. Recently it has been demonstrated
n
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(Mallucci et al., 2003) that depleting endogenous neuronal PrP^ in conditional 
PrP knockout mice with established neuroinvasive prion infection reversed early 
spongiform change and prevented neuronal loss and progression to clinical 
disease. This occurred despite the accumulation of extra-neuronal PrP^^ to 
levels seen in terminally ill wild-type mice. These last results, together with the
ny  neurografts experiments, clearly demonstrate that the continuous PrP
D
0
D
expression in neurons is necessary for the onset and progression of the 
disease.
nLJ There is also compelling evidence that the primary sequence of PrP
n  encoded by the host is a major determinant of the species-specificity, incubation
time, and neuropathological characteristics of prion transmission (Bessen et al., 
J 1995; Bessen and Marsh, 1992). For example transgenic mice harboring
hamster PrP were susceptible to hamster prions while non transgenic (Tg) mice 
did not (Scott et al., 1989). Tg mice expressing both mouse and hamster PrP 
could be infected with prions from both species but exhibited typical 
neuropathological changes characteristics of the species inoculated (Prusiner et 
al., 1990). These and other lines of evidence prove that PrP plays a key role in 
the disease process, and it has become increasingly difficult to explain all the 
existing data by a viral theory of pathogenesis. What some have considered to 
be a significant argument against the prion hypothesis, the existence of prion 
strains that produce different incubation times and neuropathological profiles in 
J  a single host, can now be explained by evidence that each strain may represent
. a distinct, self propagating conformation of PrP^^ (see section 1.1.4 ).
The recent finding that recombinant mouse PrP(89-231) polymerised into 
amyloid fibrils produces neurological dysfunction when injected intracerebrally 
r-j into transgenic mice expressing PrP(89-231) and that the disease is
D
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transmissible to non-transgenic mice in serial passages, constitute the most 
^  compelling demonstration of the validity of the prion hypothesis (Legname et al.,
1 2004).
J 1.3 Yeast and fungal prions
0 The prion hypothesis has now been extended to explain phenomena 
involving other proteins. Using genetic criteria, the non-Mendelian yeast 
q  elements [URE3] and [PST] were identified as prions of the Ure2 and Sup35
proteins, respectively (Wickner, 1994) (Figure 1.7). (Note: the convention here 
J is that capital letters signify dominancy, brackets signify noncromosomal
inheritance). [URE3] results in a deregulation of nitrogen catabolite repression 
and is derived from an aggregated state of the Ure2 protein. Vest cells 
presented with a rich nitrogen source, such as ammonia, shut off production of 
enzymes necessary for the utilization of poor nitrogen sources. A poor nitrogen 
source, such as proline, does not shut off utilization of other poor sources. This 
phenomenon is called “nitrogen catabolite” (Cooper et al., 1992). When 
ammonia is supplied as a nitrogen source, ureidosuccinate (USA) is not 
normally taken up, while it is taken up when a poor nitrogen source like proline 
is supplied. Mutants able to take up USA in the presence of ammonia defined 
the chromosomal urel and ure2 genes and the nonchromosomal genetic 
element [URE3] (Lacroute, 1971) (Figure 1.7A). [PST] enhances the 
suppression of nonsense codons and is derived from the “prion state” of Sup35 
protein. Sup35 is a subunit of the termination factor that recognizes the 
termination codon and cleaves the completed peptide from the final tRNA, 
thereby terminating translation. Mutations in the SUP35 gene or conversion of
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Sup35 protein to a prion impairs the normal termination process (Figure 1.7B) 
(Cox, 1965).
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Figure 1.7: Phenotype of yeast prions [URE3] and [PSI+].
(A) In a rich nitrogen source USA is not taken up by yeast cells. However, when 
Ure2p protein acquires the prion state or when the corresponding gene is 
ablated, USA is taken up by the cells (Wickner et al., 2001).
(B) In [psi ] cells (top), Sup35 is soluble and binds to Sup45. The Sup35/Sup45 
complex promotes translation termination at nonsense codons. In [PST] cells, 
Sup35 forms aggregates and can not complex to Sup45. Consequently, 
ribosomes are able to read through nonsense codons (Serio and Lindquist, 
2001).
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Among the earliest and strongest genetic indications that [URE3] and 
J [PSF] were “prion” forms was the finding that their d e  n o v o  appearance was
1 efficiently induced by overexpression of the URE2 and SUP35 genes,
respectively. These results were interpreted as providing evidence for the prionnLJ model since an excess of the protein should increase the probability that the
"J prion form of the protein would appear and start a self-amplifying chain reaction,
establishing the prion state. In further support of the “protein only” hypothesis, 
the d e  n o v o  induction of the [URE3] and [PSP] prions was directly shown to be 
1  caused by an excess of the protein. This finding established that the proteins
alone were sufficient to cause the appearance of [URE3] or [PST] (Wickner, 
1994).
Unlike PrP^^ however, yeast prions are not pathogenic. Rather, they 
produce changes in the phenotype that mimic conventional loss-of-funotion 
mutations. The patterns of their inheritance, however, are very different. The 
loss-of-function phenotypes caused by yeast prions are dominant, rather then 
recessive. Moreover, they are inherited in a non-Mendelian fashion. When a 
haploid [URE3] or [PSP] strain (producing the prion form) is mated to haploid 
[ure3] or [psP] (producing the non-prion form), the resulting diploid has a 
suppression phenotype, that is respectively, [URE3] or [PSP]. On sporulation, 
none of the progeny are [ure3‘] or [psP], as expected for a nuclear determinant. 
Instead, [URE3] or [PSP] are transmitted to all progeny (Cox, 1965; Lacroute, 
1971).
Ure2 and Sup35 are normally soluble proteins, but they form protease K- 
resistant aggregates upon conversion to the prion state in  v iv o  (Masison and 
Wickner, 1995; Patino et al., 1996). Aggregates isolated from extracts of [PSP] 
or [URE3^] cells seed the rapid conversion of the purified corresponding
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proteins into amyloid fibers (Paushkin et al., 1997). The induction of the prion 
J State could also be obtained when only a portion of the proteins, called the prion
domain, was overexpressed (Masison and Wickner, 1995). This domain, 
responsible for the prion behaviour, shows the following characteristics: 1) it is 
extremely rich in the polar residues glutamine and asparagines (DePace et al., 
1998); 2) it has no definite secondary structure (Thual et al., 1999); 3) it is 
required for prion propagation, as shown by studies with partially deleted 
proteins (Masison and Wickner, 1995); 4) it can exist as soluble species or 
1  ordered self-perpetuating aggregates (Taylor et al., 1999).
The [Het-s] prion from the filamentous fungus P o d o s p o r a  has also been 
proposed as a prion-like protein. It is believed to mediate the barrage reaction of 
incompatibility after cell fusion, by promoting programmed cell death when 
incompatible cells attempt to fuse (Coustou et al., 1997). Recently, it has been 
suggested that a neuronal member of the CPEB family (cytoplasmic 
polyadenylation element binding protein), which regulates mRNA translation in
D
0
D
n  the sea-slug A p ly s ia ,  also possesses prion-like properties (Si et al., 2003a; Si et
J
al., 2003b). Like the [Het-s] prion, it is the dominant, self-perpetuating prion-like 
]  form of CPEB that has the greatest capacity to stimulate translation,
n  These findings demonstrate that the conformational change is a common
J
mechanism for other proteins. However, while abnormal conformations of PrP
nJ  are associated to pathogenicity, prions in yeast and fungi determine a change in
D the phenotype. The recent finding that other neuronal proteins besides PrP (Si 
et al., 2003a; Si et al., 2003b) might be able to propagate their conformation 
indicates that this molecular transformation could serve important physiological 
1  functions also in the central nervous system of mammalians.
]
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1.4 Human prion diseases
One of the many challenging features of the prion diseases is the 
prominent heterogeneity. While the pathology of other diseases of the central 
nervous system, such Alzheimer’s disease, Huntington’s corea and Parkinson’s 
disease are rather homogeneous, prion diseases include a wide spectrum of 
histopathological phenotypes (Gambetti et al., 2003a). The heterogeneity 
reflects several factors. Firstly, prion diseases are unique among the diseases 
n  described above, because some forms have clearly been shown to be
infectious. Second, depending on the origin of the exogenous infectious prion, 
the form of the disease acquired by infection may display phenotypes that are 
quite different. This is the case of iatrogenic CJD and vCJD that display different 
pathological features (Brown et al., 2000). Third, there are a large number of 
mutations that are associated with quite different disease phenotypes (Ghetti et 
al., 1995; Parchi et al., 1999). Fourth and finally, the sporadic forms of CJD 
themselves have an unusual degree of phenotypic heterogeneity (Parchi et al.,
1996) (Table I.IV).
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Table I.IV: Clinical and hystopathological differences in human prion diseases
Sporadic CJD 
(Gambetti et a!., 
2003a)
45-75 years Dementia, myoclonus, variable 
cerebellar dysfunction
Spongiosis,
astrogliosis
iatrogenic CJD 
(Brown et al., 1992)
1.5-30 years Dementia, myoclonus, variable 
cerebellar dysfunction
Spongiosis,
astrogliosis
vCJD
(Will, 2003)
14-70 years 
(average=28)
Behavioural and psychiatric 
disturbances, cerebellar ataxia
Florid amyloid plaques
Familial CJD 
(Gambetti et al., 
2003a)
20-85 years Dementia, myoclonus, variable 
cerebellar dysfunction
Spongiosis,
astrogliosis
GSS
(Ghetti et al., 1995)
20-60 years Cerebellar dysfunction, pyramidal 
motor dysfunction, intellectual 
deterioration
Amyloid plaques
FFI
(Gambetti et al., 1995)
25-61 Insomnia, motor dysfunction Thalamic involvement
Kuru
(Goldfarb, 2002)
30 years 
(average)
Cerebellar ataxia, pyramidal motor 
dysfunction
Amyloid plaques
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Recent understanding of the molecular mechanisms that play a central 
role in the pathogenesis of prion diseases has provided insight into the 
J  modalities of the phenotypic heterogeneity of these diseases. Codon 129 of the
PrP gene is the site of a common methionine(M)/valine(V) polymorphism. In the 
^  Caucasian population, 36% of individuals are homozygous MM, 52% are
heterozygous MV and 12% are homozygous W  (Collinge et al., 1991). It was 
observed that the phenotype of prion diseases, whether sporadic, familial and 
acquired, was often different depending on the genotype at codon 129. This
n
J  codon plays a two-fold role in modulating the disease outcome. On the mutant
i-j allele, it determines the basic features of the disease phenotype, as illustrated
by mutation at codon D178N (mutation in the genome resulting in the aspartate
nJ  residue at position 178 being replaced by asparagine), which can be linked to
q  CJD or FFI based on the residue specified at codon 129 of the mutant allele. In
particular, D178N/129Val is always associated with a familial form of CJD, while 
D178N/129Met is associated with FFI. On the normal allele, codon 129 may 
n  modulate the severity of the phenotype (Collinge et al., 1991; Palmer et al.,
1991). To explain phenotypic variability, it has been hypothesised that distinct 
P R N P  variants may result in PrP isoforms having different properties and 
topographic distribution that determine the phenotypic expression of disease. In 
this regard, it has been found that PrP extracted from FFI and CJD brains differ 
in their degree of glycosylation and size of protease-resistant core (Monari et 
al., 1994).
As mentioned above (section 1.1.1), four diseases affect humans: Kuru,
Creutzfeldt-Jacob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome
J  (GSS) and fatal familial insomnia (FFI) (Table 1.1 and I.IV). About 85% of human
prion disease occurs sporadically as CJD at an approximate rate of 1 case for
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million of population per year that is uniform around whole world (Collinge, 
J 1997).
J  Kuru is geographically restricted to the Opaka area of the highlands of
Papua-New Guinea (Gajdusek and Zigas, 1957). Over 2700 cases of Kuru have
^  been documented since 1957 in a total population of 36,000 people. The
possibility of transmission through endocannibalism was raised by 
p. anthropological enquiry (Gajdusek, 1977) and the decline in the epidemic
following the cessation of this ritual in the tribes is consistent with the 
J  mechanism of transmission (Goldfarb, 2002; Will, 2003). Women and children
PI consumed diseased relatives as a mark of respect, leading to the spread of the
infection. Clinically, cases of Kuru presented with a pure cerebellar syndrome 
and the total illness duration ranged from 6-36 months (Gajdusek and Zigas, 
"j 1957; Zigas and Gajdusek, 1957). Genetic studies indicate that homozygosity at
codon 129 (particurarly for methionine) was associated with an earlier age of 
J onset and a shorter duration of illness than was heterozygosity, but other
n  clinical characteristics were similar for all genotypes (Cervenakova et al., 1998).
CJD occurs primarily as a sporadic disorder and rare cases have 
J resulted from iatrogenic transmission. The two most frequent causes of
" j  iatrogenic CJD have arisen following implantation of dura mater grafts and
treatment with growth hormone or gonadotropin prepared from human pituitary 
-  glands from individuals incubating the disease. The transmission of CJD by
cadaveric dura mater grafts was first recognized in 1987 and there have now 
been at least 136 cases world-wide (Will, 2003). About 30,000 children had 
been treated with pituitary-derived growth hormone (hGH) by 1985, when the 
occurrence of three CJD in two hGH recipients provided strong evidence of 
transmission via hGH. hGH production required the pooling of many thousands
D
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of glands and it is presumed that contamination of the hormone preparation 
occurred when pituitary glands derived from patients who had died from CJD or 
J  incubating the disease were included in the production process (Will, 2003).
Less frequent occurences of iatrogenic CJD have resulted from corneal 
transplantation, contaminated electroencephalographic (EEG) electrode 
implantation and surgical operations using contaminated instruments (Brown et 
al., 1992).
Approximately 15% of cases of CJD are inherited in a dominant fashion 
and linked to insertional or point mutation in the P R N P  gene. Insertional 
mutations consist of 1, 2, 4, 5, 6, 7, 8 and 9 octapeptide repeat insertions 
between codons 51 and 91 of PrP. Several point mutations determine a CJD 
phenotype, the most common of which are the substitu tion
J
D
D
1  aspartate>asparagine at codon 178 (coupled with valine at codon 129),
J
glutamic acid>lysine at codon 200, valine>isoleucine at codon 210. Other casesnU of familial CJD are associated with rare mutations, i.e. the substitution
”  valine>isoleucine at codon 180, threonine>alanine at codon 183 and
methionine>arginine at codon 232 (Gambetti et al., 2003b) (Figure 1.8). The
term CreutzfeIdt-Jakob was introduced in 1922 following the reports of two
German physicians, Hans Gerais Creutzfeldt and Alfons Maria Jakob of six
cases with a novel neurodegenerative disease (Creuzfeldt, 1920 ; Jakob, 1921).
From the beginning CJD became controversial as questions were soon raised
J concerning the homogeneity of the cases reported by the two physicians. The
heterogeneity was further underlined by the number of subtypes identified by
different authors. The most common subtype is recognized clinically by the
occurrence of progressive dementia associated with myoclonus, pyramidal,
 ^ extrapyramidal and cerebellar signs. The neuropathological hallmarks of the
62
udisease are neuronal loss, astrogliosis and spongiform changes. Lesions were 
observed to affect variably either the entire cerebral cortex or only certain layers 
selectively, and variability extents to basal ganglia and cerebellum (Gambetti et 
al., 2003a; Ironside, 1996).
In variant CJD (vCJD) the early clinical course is dominated by 
psychiatric symptoms, although a minority have neurological symptoms. After 
about 6 months, there are neurological signs, including ataxia, cognitive 
impairment and involuntary movements, which may be dystonie, choriform or 
J  myoclonic. Neuropathological analysis shows florid plaques extensively
q  distributed in the cerebrum and cerebellum (Will, 2003)
GSS is a genetic form of prion disease that segregates with the following
D
nJ  point mutations in P R N P  gene (Ghetti et al,, 1995): 1) proline>ieucine at codon
D
D
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D
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102, 2) proline>leucine. at codon 105, 3) alanine>valine at codon 117, 4) 
tyrosine>stop at codon 145, 5) phenylalanine>serine at codon 198, 6) 
arginine>glutamine at codon 217 (Figure 1.8). Although insert mutations are 
commonly found in CJD, to date GSS appears linked only to an eight 
octapeptide repeat expansion (Goldfarb et al., 1992). Clinical presentations of 
GSS are ataxia, extrapyramidal syndrome, spastic paraparesis and dementia. 
The pathological hallmark of the disease is the deposition of PrP amyloid in the 
central nervous system (Ghetti et al., 1995).
FFI is predominantly linked to the substitution aspartate>asparagine at
" 1  codon 178 (Medori et al., 1992) with a methionine at codon 129 although
recently a sporadic form of the disease has also been recognized (Montagna et 
al., 2003) (Figure 1.8). The disease is characterized clinically by untreatable 
insomnia, endocrine abnorm alities and motor dysfunction. The 
neuropathological signature is a selective atrophy of the anterior ventral and
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mediodorsal thalamic nuclei in which more than 50% of the neurons are lost. 
This loss is associated with reactive astrogliosis (Manetto et al., 1992).
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Figure 1.8: Structural features and pathogenic mutations of prion protein.
Pathogenic mutations associated with human prion diseases are shown below 
the PRNP coding sequence. These consist of expansions of the octarepeat 
region (shown in dark) and point mutations causing aminoacids substitutions. 
Polymophisms occurring in the human population are shown above the PRNP 
coding sequence. The three a-helices (H1, H2 and H3) and the two short 13- 
sheets (yellow arrows) identified by NMR are represented. Protease resistant 
core of PrP^^ is shown in gray (Telling, 2000).
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1.5 Experimental approaches to prion diseases
1.5.1 Cell-free models
The conversion of PrP^ to neuropathological forms is central to the 
pathogenesis of TSEs. Although the mechanism of conversion from PrP^ to 
PrpSc full neuropathological implications of PrP^^ deposition in  v iv o  remains
J
uncertain, studies of PrP conversion in cell-free models have provided important 
J  insights into the circumstances in which PrP can adopt a PrP^^-like protease
n  resistant state upon interaction with PrP^^. Thus, when incubated with PrP^^ the
PrP^ tends to bind to PrP^^ and then slowly convert to a protease resistant 
J  state. This reaction has been shown to occur under a variety of conditions. The
"I simplest contained mixture of purified p^SJmethionine-labeled PrP^ and purified
J
PrpSc (Kocisko et al., 1994). The conversion reaction could be stimulated by
n
LJ detergent, chaperone proteins (DebBurman et al., 1997; Kocisko et al., 1994;
Raymond et al., 1997), sulphate glycans and elevated temperature (Wong et 
al., 2001). Converting activity was associated with PrP^ *  ^polymers but not with 
^  soluble, monomeric PrP (Caughey et al., 1995). Kinetic analyses provided
J  evidence that the conversion process could be separated into two stages, first
the binding of PrP^ to PrP^^and then a slower conversion of the bound PrP^ to 
PrP^^ (Bessen et al., 1997; Horiuchi and Caughey, 1999). Direct contact 
J  between PrP^ and PrP^^ was found to be necessay, as studies of the
conversion reaction between GPI-anchored, membrane bound PrP isoforms 
revealed that conversion was not efficient when PrP^ and PrP^^ were attached 
to separate membrane vesicles. Conversion of PrP^ was only detected when 
vesicle were fused or PrP^ was detached from its GPI anchor and ceased to be
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membrane bound (Baron et al., 2002). The conversion reaction has also been 
performed in scrapie infected brain slices (Bessen et al., 1997) and cellular 
~[ extracts (Saborio et al., 1999).
In most of the above studies, the yield of PrP^^ conversion was low; for
1
this reason, in order to amplify PrP^^ substantially i n  v i t r o ,  the “protein 
^  misfolding cyclic amplification” was developed (PMCA) (Saborio et al., 2001). In
this system, detergent extracts of TSE-infected animals were mixed with vast 
excesses of similar extracts of PrP^-containing normal brain tissue and 
1  subjected to repeated cycles of sonication and incubation. More than 30-fold
increases in the amount of PrP resistant to PK digestion over that provided in 
the infected brain were reported. This result suggested that this procedure 
might be exploited to enhance the detection of PrP^° in TSE diagnostic tests. In 
- j  addition, because the reported yield was much higher than the yields observed
previously between purified proteins, it was suggested that unidentified auxiliary
nJ  factors provided in the crude normal brain homogenate might be important in
n  the PrP^-PrP^^ conversion (Saborio et al., 2001). One of these factors has been
identified as an RNA species, since addition of mammalian mRNA stimulatednJ  amplification and treatment with RNAse diminished the yield of the reaction
(Deleault et al., 2003). To date, protease resistant PrP produced in vitro has 
lacked detectable infectivity (Bieschke et al., 2004; Hill et al., 1999),nJ  demonstrating a distinction between protease resistance and infectivity.
D
D
The cell-free conversion model has also been used to study the 
mechanisms related to the existence of strains (as described in Section 1.1.4) 
and to the species barrier. A species barrier in the TSEs is defined as the 
^  resistance to TSE disease by one host species after infection with the TSE
agent of another species (this argument will be discussed in more detail in
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uSection 1.5.3.1). The fact that PrP^^ binds PrP*  ^ (DebBurman et al., 1997; 
Horiuchi and Caughey, 1999) suggests that the PrP aminoacid sequence may
—I
J  be involved in the conversion process. Many “heterologous” conversion
reactions have been performed using PrP^ of one species (or sequence) and 
PrP^^ of another. Profound sequence specificity was observed (Bossers et al., 
Q 1997; Kocisko et al., 1995; Raymond et al., 1997); in fact, in comparing
PI reactions driven by a given PrP^^, 5 to 50-fold stronger conversion efficiencies
can occur with PrP^ molecules from highly susceptible animals versus clearly 
resistant species/genotypes. It seems that the log of the relative intracerebral 
"I transmission titre might be roughly proportional to the relative cell-free
conversion efficiency (Raymond et al., 2000).
Cell-free conversion assays have also been used to gauge the relative 
susceptibilities of various hosts to TSE agents from different source species. 
For instance, little is known about the transmissibility of chronic wasting disease 
of deer to non-cervid species (Miller et al., 2000). In cell-free conversion 
reactions, PrP^^ purified from sick cervids readily induced the conversion of 
cervid PrP^to the protease-resistent state (Raymond et al., 2000). In contrast, 
cervid PrP^^-induced conversion of human, bovine and ovine PrP^ was 14-100 
fold, 5-12 fold and 2-3 fold less efficient, respectively, than the most convertible 
cervid PrP^ (Raymond et al., 2000).
Studies of the species specificity of conversion reaction have revealed 
that, in some interspecies combinations, the binding of PrP*  ^ to heterologous 
PrP^^ can occur more efficiently than the subsequent conversion to PrP^^ 
(Horiuchi et al., 2000). Thus, the species specificity of PrP^^ formation may be 
determined more by the conversion step than the initial binding step.
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1.5.2 Cellular models
During the past two decades, considerable efforts have been made to 
establish culture models of genetic and infectious forms of prion diseases and 
especially cellular cultures supporting prion replication. These models present 
obvious advantages including: 1) the ability to analyse, at the molecular and 
cellular levels, the biological properties of PrP^ and PrP^^; 2) the possibility of 
determining the nature of the infectious agent and the factors determining its 
propagation; 3) the screening of drugs with potential therapeutic values; 4) the 
determination of biological markers of the infection with potential diagnostic and 
physiological interest.
1.5.2.1 Scrapie infected cells
The approach most frequently used to propagate prions ex v iv o  has been 
to incubate cell cultures in medium containing infectious fractions and to monitor
J  for the replication of PrP^ *^  (Butler et al., 1988; Race et al., 1988; Race et al.,
1987; Taraboulos et al., 1990b). Following the inoculation of the culture with
1
“ I whole brain homogenates of infected animals, or with purified PrP^ " ,^ cells are
J  generally washed extensively and serially passaged several times. The infected
cultures continuously produce authentic PrP^^ that can induce prion disease in
laboratory animals (Race et al., 1987).
Several techniques currently exist to detect the presence of PrP^^ in
infected cells. The most common is proteinase-K resistance assay of cell
lysates, followed by SDS-PAGE separation and Western blot analysis using
anti-PrP antibodies. Protease resistance is manifested by production of an N-
terminally truncated core of 27 to 30 kDa. Moreover, using antibodies that
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selectively recognize PrP^^, it is possible to detect this form in an ELISA
(enzyme-linked immunosorbent assay) assay. This technique is based on the 
previous finding that some antibodies raised against PrP^^ do not recognize 
PrP^ (Korth et al., 1997; Paramithiotis et al., 2003). The explanation for this is 
that PrP^ and PrP^^ differ in conformation and the epitope recognized by an 
antibody specific for PrP^^ can be masked in PrP^ and v ic e  v e r s a .  Recently 
other techniques have been established, such as cell blot (Bosque and 
Prusiner, 2000) and slot blot (Winklhofer et al., 2001). In the cell blot, cells are 
grown on a coverslip and subsequently transferred on a nitrocellulose 
membrane; in slot blots, cell lysates are filtered through a nitrocellulose 
membrane. In both cases PrP^^ is revealed, after PK digestion, with anti-PrP 
antibodies.
Only some neuronally-derived cell lines appear to be susceptible to
infection with scrapie prions in vitro. These have included N2a mouse
neuroblastoma cells (Butler et al., 1988; Race et al., 1987), P C I2 rat
pheochromocytoma cells (Rubenstein et al., 1984) and T-antigen-immortalized
hypothalamic neurons (GT1) (Schatzl et al., 1997). Several authors have tried
J  to derive infected cultures directly from infected animals but only one group has
J  succeeded, producing the SMB cell line (Clarke and Haig, 1970a; Clarke and
Haig, 1970b). In some cases scrapie infected N2a display no obvious cytolytic
changes (Butler et al., 1988) but in some other cases alterations were reported,
such as increased chatecolamine and decreased free serotonin and
noradrenalin levels (Markovits et al., 1983), or alterations in the bradykinin-
mediated responses and in membrane fluidity (Kristensson et al., 1993; Wong
et al., 1996). In PC I2 cells differentiated with nerve growth factor (NGF), the
infection was accompanied by decreases in the activity of enzymes involved in
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uthe cholinergic neurotransmitter pathway (Rubenstein et al., 1991). Finally, a 
recent study demonstrated that prion infection impaired the cellular response to 
oxidative stress in GT1 cells (Milhavet et al., 2000). Unfortunately, it is not clear 
jq whether the changes described were necessary due to infection by the scrapie
agent rather than to clonal differences or other factors present in the inoculum.
nJ  Recently it has been demonstrated that brain-derived primary cells maintained
q  in cultures can enter an infected state after exposure to scrapie agent (Cronier
et al., 2004). In these experiments both neurons and astrocytes sustained prion 
propagation, leading to progressive neuronal loss.
Prion-infected cultures represent a useful model to understand the 
cellular and molecular events leading to the formation of PrP^^ Traditional 
immunofluorescence methods detected PrP^ on the cell surface of cultured 
cells (Stahl et al., 1987). However, when applied to scrapie-infected cells these 
methods failed to yield an additional, scrapie specific signal. The discovery that 
dénaturation of PrP^^ greatly enhanced its immunoreactivity (Serban et al..
D
0
D 1990) led to the development of a protocol for the detection of PrP^^ 
(Taraboulos et al., 1990b). A speckled cytoplasmatic PrP-specific signal was 
then detected in scrapie infected cells that colocalized with a ligand of wheat 
germ agglutinin, a marker for trans-Golgi network and lysosomes (Taraboulos et 
al., 1990b). More precisely, immunoelectron microscopy techniques showed 
deposition of PrP^^ deposition in secondary lysosomes (McKinley et al., 1991).
1 Pulse chase experiments determined that PrP^ was the precursor of PrP^^ and
p. that PrP^^ acquired protease resistance as a result of a slow post-translational
process (Borchelt et al., 1990; Caughey and Raymond, 1991). Acquisition of 
this abnormal property was not impaired by the inhibition of glycosylation 
tq (Taraboulos et al., 1990a) and occurred after exposure of PrP on the cell
71
n
usurface (Borchelt et al., 1992). In particular, PrP^^ was inhibited by treatment of 
cells at 18°C, a temperature that impairs the endosomal pathway (Borchelt et 
al., 1992). In order to gain insights into the exact sites involved in the genesis of 
PrP^^ the effect of mutant forms of the Rab family was examined (Beranger et 
al., 2002). The traffic of proteins between organelles occurs through vesicular 
intermediates that selectively convey proteins from one compartment to 
another. In this contest the Rab family plays a role in ensuring accurate 
targeting or docking of transport vesicles with their acceptor membranes 
J  (Gonzalez and Scheller, 1999). When a dominant-negative of Rab4, which is
1  normally involved in protein recycling from endosomes to the plasma membrane
(McCaffrey et al., 2001), or a constitutively activated RabGa, which normally 
J stimulates retrograde transport from Golgi to the ER (Martinez et al., 1994) were
^  overexpressed in scrapie-infected N2a cells, a marked conversion of PrP^ to
the pathogenic form PrP^^ was detected (Beranger et al., 2002). These results 
J  showed that retrotransport of PrP^ toward the ER increased the production of
J  PrP^^ and suggest that this organelle plays an important role in the conversion
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1.5.2.2 Transfected cells
Models of familial diseases have been developed by constructing stably 
transfected cell lines that express PrP molecules carrying mutations associated 
with human genetic forms, such as the point mutations P102L, D178N, E200K,
n  Q217R or the insertional mutation of 9 octapeptide (Chiesa and Harris, 2000;
Daude et al., 1997; Lehmann and Harris, 1996a; Singh et al., 1997). These 
forms of PrP displayed biochemical properties reminiscent of PrP^^, such as
detergent-insolubility (manifested by sedimentation at 186,000 x g from
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Triton/deoxycholate lysates) and protease resistance, (production of an N- 
"I terminally truncated core of 27 to 30 kDa after treatment with low doses of PK).
Moreover, as part of the conversion to PrP^^ state, mutant proteins became 
_  physically inaccessible to PIPLC (phosphatidylinositol phospholipase-C)
release. However, these mutant molecules were distinguishable from PrP^ *  ^
1  extracted from the brains of prion disease patients by their relatively low
PI protease resistance and the lack of infectivity. In fact, while PrP^^ purified by
infected brains is resistant to high concentration of PK, mutant PrP expressed 
by cells is resistant only to mild concentration of the enzymes (50-100 p.g/ml 
versus 0.5-2 pg/ml) and is not able to produce disease when injected into 
laboratory animals (Dr David Harris, personal communication). The mild 
resistance to PK would account for the difficulty in recovering the 27-30 kDa 
fragment after digestion of mutant PrPs, thus justifying the lack of PK resistance 
found in some cell models (Petersen et al., 1996).
In transfected cells, as in scrapie-infected models, conversion of PrP^ to 
PrP^^ has been found to be a post-translational event (Borchelt et al., 1990; 
Daude et al., 1997). Intermediate biochemical steps in the conversion process 
have been identified by measuring the kinetics with which three PrP^^-related 
properties (PIPLC resistance, detergent insolubility and protease resistance) 
develop in pulse chase labelling experiments. It was found that mutant PrP 
becomes resistant to PIPLC treatment early after synthesis, in the endoplasmic
0
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J  reticulum, probably reflecting a conformational change. The second step in the
P, conversion process is acquisition of detergent insolubility followed by acquisition
of protease resistance. These last two steps develop in a post-Golgi
J  compartment, either upon arrival at the plasma membrane or along an
q  endocytic pathway (Daude et al., 1997).
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The localisation of mutant PrP was studied by light and electron 
microscopic techniques. Despite equivalent expression levels by Western 
blotting, all cells expressing mutant PrP showed much weaker surface staining 
^  than those expressing wild-type PrP (Capellari et al., 2000; Gu et al., 2003b;
Ivanova et al., 2001; Jin et al., 2000; Negro et al., 2001; Zanusso et al., 1999). 
To visualize intracellular PrP, fixed cells were permeabilized with Triton-X 100 
PI prior to application of primary and secondary antibodies. In cells expressing
wild-type PrP, staining was restricted to the perinuclear Golgi, a localisation that
nj  probably reflects slow transit in this compartment on the way to cell surface. In
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contrast, many cells expressing mutant PrP showed a much more widespread 
pattern of staining that colocalized with ER markers. These results suggest that 
several different pathogenic mutations share the property of impairing delivery 
of PrP molecules to the plasma membrane and cause their partial accumulation 
within the ER (Capellari et al., 2000; Gu et al., 2003b; Ivanova et al., 2001; Jin 
et al., 2000; Negro et al., 2001; Petersen et al., 1996; Zanusso et al., 1999).
1.5.3 Animal models
Animals from different species have represented essential models to 
study infectious and genetic prion diseases. Experiments conducted in sheep
^  and primates in 1960’s allowed demonstration of the transmissibility of scrapie,
Kuru and CJD (Cuille and Chelle, 1939; Gajdusek et al., 1966; Gajdusek and
Gibbs, 1971; Gajdusek et al., 1967) and to study the different route of infection 
(Dickinson et al., 1974; Duffy et al., 1974; Kimberlin and Walker, 1978). 
Moreover, infection of sheep and mice allowed investigation of the PrP genetic 
variability that determines the susceptibility of sheep to develop scrapie
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(Dickinson and Meikie, 1971; Dickinson et al., 1968a; Dickinson et al., 1968b; 
Hunter et al., 1997a; Hunter et al., 1997b).
Transgenetic technology has provided the means to generate lines of 
mice in which PrP gene is ablated or in which the mice express a modified or 
mutated form of the protein. These models allow studies not only of the effect of 
J  gene manipulation on mice phenotype but also allow the demonstration that PrP
expression is necessary to develop disease after prion infection and the 
delineation of the regions of PrP that are dispensable for susceptibility to 
infection.
Finally, models of infectious and genetic prion diseases constitute an 
useful tool for testing therapeutic approaches in  v iv o .
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1.5.3.1 Conventional mice and other animals
In animal models of prion diseases, the most rapid and most efficient 
method for inducing spongiform encephalopathy in the laboratory is the 
U  intracerebral inoculation of brain homogenate. In addition, prion diseases can
■n be transmitted by feeding (Anderson et al., 1996), by intraperitoneal injection
(Kimberlin and Walker, 1978) as well as by intraocular infection (Scott et al.,
nj  1993a) and corneal grafts (Duffy et a!., 1974). Over many years, the results of
D oral challenge have suggested that immune cells might be of importance in the 
peripheral pathogenesis of prion disease. An early rise in prion infectivity can benJ  observed in the distal ileum of infected animals (Wells et al., 1994), where
n  Peyer’s patches acquire strong immunopositivity for the prion protein.
Immunohistochemical stains with antibodies to the prion protein typically reveal
a robut signal in primary B-cell follicles and germinal centres, in a wide variety
of secondary lymphoid organs including appendix and tonsils (Hill et al., 1997b).
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Ail the above evidence suggest that Peyer’s patches may represent a portal of 
entry for orally administered prions, at least in scrapie, CWD and vCJD. Normal 
prion protein is expressed at moderate levels in circulating lymphocytes 
(Cashman et al., 1990). Innate or acquired deficiency of lymphocytes impaired 
peripheral prion pathogenesis, whereas no aspects of pathogenesis are 
affected by the presence or absence of lymphocytes upon direct transmission of
^  prion to the CNS (Lasmezas et al., 1996a). In particular, the presence of B-cells
(but not expression of prion protein by these cells) is indispensable for 
1  pathogenesis (Aguzzi, 1997; Klein et al., 1997).
An interesting discrepancy that remains to be addressed concerns the 
actual nature of the cells that replicate and accumulate prions in lymphoid
organs. Lymphocytes may be important for trafficking prions within lymphoid
J  organs, but they do not appear to represent the major hideout for the infectious
agent. Follicular dendritic cells (FDC) are a prime candidate prion reservoir,
n
J  since they express large amounts of PrP and PrP accumulation tends to co-
localize with FDCs in light and electron microscopical analysis (Jeffrey et al., 
2000b). Moreover, it has been shown that FDC depletion impairs PrP^^
accumulation in the spleen after peripheral inoculation (Montrasio et al., 2000).
Experiments performed since the early 1960s have demonstrated that 
transmission of prion disease from one species to another is considerably less 
efficient than within species, and hence the term “species barrier" was coined 
J  by Pattison in 1965 (Pattison, 1965). The effect of the species barrier is to
lengthen the mean incubation period and to reduce the fraction of inoculated 
animals succumbing to clinical disease. To explain these phenomena it was 
argued that the incubation period could be so long as to exceed the natural life­
span (Dickinson et al., 1975). When, following transmission across a species
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barrier, brain homogenates from the recipient is passaged through the same 
species, the incubation period shortens and become much more consistent (Hill 
et al., 2000; Kimberlin and Walker, 1978; Zlotnik, 1965). First attempts to cross 
the species barrier were conducted with rats inoculated with sheep scrapie or 
mouse scrapie (Chandler and Fisher, 1963). None of the rats infected with 
sheep scrapie developed any sign of disease, even if analysis of brain showed
"I vacuolation and degeneration. Conversely, one animal infected with mouse
infectious material showed symptoms and lesions suggestive of experimental
scrapie. In the second passage, all rats inoculated with the infected rat brain
n  developed the disease, demonstrating the transmissibility of mouse scrapie to
rats (Chandler and Fisher, 1963). Other crucial findings came from experiments
with wild-type mice inoculated intracerebrally with high doses of 263K or Sc237 
hamster prions. Even if the animals did not develop clinical disease 1-2 years 
after inoculation, the brains contained high levels of prions that, when 
inoculated into further mice and hamsters, caused clinical prion disease. The 
Q PrpSc fgypçj in the brains of the inoculated mice was derived from mouse and
not hamster PrP^, suggesting replication of mouse PrP^^ (Hill et al., 2000; 
Kimberlin and Walker, 1978). These results suggest that, because of the 
J  differences in the primary sequence between PrP^ and PrP^^, the conversion
rate is very slow and the accumulation of PrP^^ does not reach toxic levels 
during the lifespan of the animals. Supporting these data, when “heterologous” 
J  cell-free conversion reactions have been performed using PrP^^ of one species
and PrP^ of another, striking sequence specificity was observed, which 
correlated with known susceptibilities of hosts to cross-species infection 
(reviewed in section 1.5.1).
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Although a strong species barrier has frequently been observed when 
prions are transferred to one mammalian species to another, BSE prions have 
been transmitted to a variety of other species, where, in some cases, a 
relatively low barrier to clinical disease was observed. Transmission 
experiments of BSE and vCJD to mice lead to the demonstration that vCJD is 
derived from BSE. In fact, incubation periods and lesion profiles of mice infected 
with vCJD sources were closely similar to those of mice infected with BSE 
(Bruce et al., 1997).
Conventional mice have been extensively used to study the role of the 
host in transmission of prion diseases, by inoculating animals that differed by 
genetic background. Early experiments with inbred mice identified the S in e  
(acronym for scrapie incubation time) gene as< important in host susceptibility to 
scrapie (Dickinson and Meikie, 1971; Dickinson et al., 1968a; Dickinson et al., 
1968b) and subsequently S in e  was found to be the gene encoding PrP (Hunter 
et al., 1987; Moore et al., 1998). in mice, only two alleles of the PrP gene have
n  been identified (designated a and b), encoding proteins that differ by two
aminoacids at codon 108 and 189 (Westaway et al., 1987). Mice with short 
incubation time possess codons 108 and 189 that encode leucine and 
threonine. Conversely, mice with long incubation time possess codons at these 
positions that encode phenylalanine and valine. It has been shown that each 
strain of TSE agent interacted with the PrP gene in a complex way, with each
1  strain producing a characteristic and highly reproducible pattern of incubation
period in the three possible PrP mouse genotypes, i.e. the two homozygotes 
and the heterozygote (Bruce and Fraser, 1991; Dickinson and Meikie, 1971).
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1.5.3.2 Transgenic mice
The possibility of ablating endogenous genes or introducing foreign 
genes into the germ line of mammalians has allowed the creation of further 
animal models of prion disease. As described in Section 1.1.3, transgenic 
technology has been used extensively to study the function of the prion protein 
and its influence on disease propagation, through gene ablation.
J Transgenetics has been also used to investigate scrapie incubation times
in mice with different wild-type PrP gene copy number and therefore different 
PrP expression levels. This research has identified the importance of gene 
J  dosage in shortening the incubation time of prion protein diseases (Westaway
n  et al., 1991) and led to the discovery that a number of lines of transgenic mice,
LJ '
bearing high copy number of a wild-type PrP transgene, develop a late onset 
^  neurological disorder characterized by spongiform changes in the CNS
J  (Westaway et al., 1994). These observations imply that overexpression of wild-
type PrP is sufficient to induce a neurological syndrome similar to prion disease. 
In contrast, mice ablated of the PrP gene are instead resistant to prion infection, 
implying the absolute requirement of PrP expression to confer susceptibility to 
prions (Bueler et al., 1993; Manson et al., 1994b)
Mutations in the PrP coding region have also been engineered into mice 
in order to mimic familial forms of human prion diseases. The first mutation 
studied was the proline>leucine substitution at codon 102, linked to GSS. 
Tg(PIOIL) mice, expressing high level of the mouse homologue of the P102L, 
developed a spontaneous neurological disease (Hsiao et al., 1990). Symptoms 
included ataxia, spongiform degeneration, gliosis but little PrP plaque formation 
in the brain. PrP^^ was low or undetectable and brain extracts from
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spontaneously sick mice did not transmit neurodegeneration to wild-type mice. 
Conversely, animals expressing a lower level of the mutant protein (Tg196 
mice) did not develop spontaneous disease but were reported to develop a 
neurological syndrome when inoculated with Tg(P101L) brain expressing high 
level of PrP (Hsiao et al., 1994; Tremblay et al., 2004). These animal models
nJ  were obtained by traditional transgenic methods, where the insertion is based
on nuclear injection into a one-cell embryo of a DNA segment containing the 
GRP. Of interest, the DNA segment usually concatenates prior to integration, 
J resulting in random insertion of multiple gene copies into one or few sites of the
n genome, with the result that each transgenic line is unique. Depending on the
site of insertion, expression of the transgene can be silenced or modulated by 
J  neighbouring regulatory elements (Hatada et al., 1999).
1  An alternative approach was to create the point mutations PI 01L in mice
through a 2-stage homologous recombination in embryonic stem (ES) cells so
J that only endogenous level of PrP would be made under control of PrP
j" promoter (Manson et al., 1999). This line did not shown clinical signs of
neurodegenerative disease for up to 899 days of age but showed altered
incubation times to disease in response to GSS prion when compared to wild-
J  type mice.
The difference in the expression level explains the apparent
discrepancies of the results obtained in all the Tg(PIOIL) mice described
^  above. It is conceivable that if Tg(PIOIL) mice expressing low level of the
P, mutant PrP lived longer they might develop spontaneous disease. Such a view
is supported by the fact that humans with known pathogenic mutations do not
develop disease until late in life. For the same reason overexpression of mutant
PrP may accelerate the process of spontaneous conversion of PrP carrying
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pathogenic mutation, which will manifest as disease in the lifetime of mice. 
^  Moreover, this hypothesis explain why inoculation of Tg(P101L) mice
^  expressing a low level of PrP with the brain from spontaneously ill Tg(P101L)
p. caused the appearance of the disease phenotype.
The expression level of the mutant transgene modulated disease in the 
case of Tg(PG14) mice. These mice expressed mouse PrP molecules 
— containing an insertion of 9 additional octapeptide repeats that is associated
with a familial prion disorder in humans. Two Tg(PG14) independent lines 
expressing the mutant PrP at the physiological PrP level developed a 
n spontaneous neurological illness characterized by ataxia, cerebellar granule
cells loss and accumulation of an aggregated and protease-resistant form of 
J mutant PrP (Chiesa et al., 1998). The time of onset and the course of the
n disease were related to the expression level: mice expressing 1 fold the
physiological PrP level developed developed the disease after -230, while mice
n
J expressing 2 fold the physiological level developed the disease after -60  days.
1 Conversely, Tg(PG14) mice expressing 0.15 fold did not develop spontaneous
disease (Chiesa et al., 2000; Chiesa et al., 1998). The mutant PrP form
J  accumulating in spontaneously ill mice was mildly PK-resistant and, although it
was clearly pathogenic, it did not appear to be infectious. This and other
observations (see section 1.6) led to the hypothesis that pathogenicity and
infectivity are distinct properties of the prion protein (Chiesa et al., 2003).
As mentioned above (see section 1.1.2), the prion protein can be
synthesized in several topological forms. The role of these different forms was
explored with transgenic mice expressing mutations (related to human
diseases, such as A117V or artificial mutations, like KH->II , ASTE, AV3 and
G123P) that had been shown in  v i t r o  to alter the relative ratios of the topological
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forms (Hegde et al., 1998). Transgenic mice carrying the A l 17V, KH->II or AV3 
mutations showed a marked increase in the form and developed clinical
signs of neurological disease, including ataxia and paresis. The brains of the 
sick mice were found to contain ^ "^^ PrP and not PrP^^. Conversely, Tg(ASTE) 
and Tg(G123P) synthesized only PrP that transited normally through the ER 
(Se^PrP) and did not shown any signs of illness (Hegde et al., 1998). Thus, this 
specific transmembrane form of PrP can confer neurodegeneration in mice with 
features typical of prion disease.
1.6 Pathogenicity of prion protein
According to the prion hypothesis, PrP^^ is the infectious form of PrP but
J
there is no evidence that PrP^^ itself corresponds to the pathogenic form thatnJ  ultimately kills neurons i n  v iv o .  Since depletion of PrP does not induce
1  pathology typical for prion diseases (Bueler et al., 1992), it is likely that PrP
gains some toxic function upon its conversion to PrP^^ or some other abnormal 
-J forms of PrP. The most compelling evidence that is the primary toxic
entity in prion diseases is the temporal and anatomical correlation that is often 
observed between accumulation of this isoform and the appearance of 
^  neuropathology and clinical symptoms (DeArmond et al., 1987; Jendroska et
J  al., 1991; Williams et al., 1997). In fact, PrP^^ as detected by
immunocytochemistry or Western blotting, usually appears prior to development 
of neuropathological changes. As the amount of PrP^^ increases during the 
1  course of illness, the pathology becomes more severe. Neurografts have been
used to address the question of whether the presumed toxic effect of PrP®  ^ is 
related to its generation within neurons or its accumulation in the extracellular
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space (Brandner et al., 1996a; Brandner et al., 1996b). In these experiments.D
J  brains of P rn -p ^ '^  mice; when mice were inoculated intracerebrally with scrapie.
embryonic neurons from PrP^ expressing mice were transplanted into the
PrP^^ was generated only in the neuronal graft. Strikingly, substantial amount of 
PrpSc spread from the graft site into the adjacent host tissue, but did not caused 
pathological changes. Recently it has been demonstrated (Mallucci et al., 2003) 
that depleting endogenous neuronal PrP^ in conditional PrP knockout mice with 
established neuroinvasive prion infection reversed early spongiform change and 
J prevented neuronal loss and progression to clinical disease. This occurred
despite the accumulation of extra neuronal PrP^^ to levels seen in terminally ill 
wild-type mice. One interpretation of these results is that PrP^^ deposited 
extracellularly is not deleterious to neurons. Alternatively, extracellular PrP^^ is 
toxic only once it exceeds a threshold level, but only to cells expressing PrP.
Although accumulation of PrP^^ is often temporally and spatially 
associated with the development of pathology, several situations have now 
been described where this correlation is weak, or where neurodegeneration 
occurs in the presence of low or undetectable levels of PrP^^. A first example in 
which correlation between PrP^^ and occurrence of pathology is weak relates to 
scrapie transmission to mice expressing high level of PrP. Tga20 mice that 
express approximately 10 times more PrP than normal mice displayed a 
dramatically shortened incubation period when challenged with scrapie prions
1 (Fischer et al., 1996). However, the rate of accumulation of PrP^^ in the brains
 I
of Tga20 mice did not correlate with the shortened incubation time and course
of the illness. In terminally ill animals, the amount of PrP^^ detectable by
Western blotting was only about 50% of the amount found in infected, wild-type
mice but the prion infectivity titer was equivalent (Fischer et al., 1996). Another
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example involves transmission of GSS prions to mice in which both copies of 
the endogenous PrP gene have been replaced with once harbouring the GSS
1  associated P.101L mutation (this Tg(P101L) model has been described in
section 1.5.3.2). In this case, the mice became clinically sick and developed 
^  vacuolar degeneration, but very low levels of PrP^^ were present by Western
Blotting, and immunocytochemistry (Manson et al., 1999). Finally, C57BL/6 mice 
infected with the BSE agent exhibited neurological symptoms and neuronal 
death, but the majority of them had no detectable level of conventional PrP^^. 
Q Despite the absence of PrP^^, the cerebral tissue of these mice could transmit
P  the disease when inoculated in a second series of mice (Lasmezas et al.,
1997).
Inherited forms of prion disease confirm that the presence of PrP^^ is 
dispensable for the occurrence of the disease. For example, patients with GSS 
caused by the A117V mutation lack detectable PrP^^ (Piccardo et al., 2001; 
Tagliavini et al., 2001). Another kind of pathologic PrP that is cleaved by PK at 
both the N-and the C-termini, has been found in the brains of A117V patients to 
yield a 7 kDa fragment, considerably smaller that the 27-30 kDa PrP derived 
from PrP^^ Truncated forms are seen even without PK digestion and are the
n  major component of the amyloid plaques seen in GSS patients carrying different
mutations (Petersen et al., 1996). These results indicate that at least some 
mutations may cause disease by altering the conformation of the PrP molecule
^  in a way that is distinct from that induced by interaction with PrP^^. Analogous to
familial prion diseases of humans, the spontaneous illness developed by 
several kinds of PrP transgenic mice have provided support for the possibility 
that neurodegeneration can occur in the absence of PrP^^. Thus Tg(PIOIL) 
mice show typical clinical features of murine scrapie but without accumulation of
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PrpS^ in the brain (Hsiao et al., 1990). Similarly, Tg(PG14) expressing a prion 
protein with a nine octapeptide insertion develop a spontaneous neurological 
disorder characterized by the accumulation in the brain of a weakly PK-resistant 
form of mutant PrP (Chiesa et al., 1998).
^  The evidence that neuropathology can develop in the apparent absence
of PrP^^ and that PrP^^ can accumulate without causing clinical symptoms,
p. argues that PrP^^ might itself not be neurotoxic, and that molecules other than
PrpSc could be responsible for prion-induced neurodegeneration. In principle,
n
J  such neurotoxic species could be intermediates in the prion replication process
-| that may or may not be infectious. The existence of a PrP^-PrP^^ conversion
intermediate, designed PrP*, has been hypothesized based on theoretical 
considerations (Cohen et al., 1994). Another possibility is that pathology is 
triggered by an altered oligomeric form of PrP, that is distinct from PrP^ * .^ While 
Tg(PG14) mice express a PrP form that is weakly protease resistant and non
nJ  infectious, inoculation of these mice with prions of the RML strain induced
n  accumulation of a form of PG14 PrP that was infectious and highly protease
 _
resistant (Chiesa et al., 2003). These PrP forms, designed respectively 
PG i4 spon and PG14^‘^ ‘’ , where shown to differ profoundly in their oligomeric 
state with PG14 aggregates being much larger and more resistant to 
dissociation (Chiesa et al., 2003).
Several pieces of evidence have shown that the altered conformational
^  state of PrP and its aggregation are necessary to trigger toxicity in  v i t r o .  PrP
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purified from infected brain has been shown to trigger apoptosis in N2a cells
(Hetz et al., 2003). However, disruption of p-sheet structure completely
abolished the toxicity of the protein (Hetz et al., 2003). Another support to the
connection between neurotoxicity and structure/aggregation came from the use
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of synthetic peptides, homologous to different fragments of prion protein. 
PrP(106-126) has been reported to be toxic to hippocampal and cerebellar 
granule neurons, neuroblastoma and PC12 cells (Fioriti et al., 2004; Forloni et 
al., 1993; Hope et al., 1996). Toxicity was associated to the p-sheet content and 
to the aggregation state of the peptide (Hope et al., 1996; Jobling et al., 1999; 
Rymer and Good, 2000).
Recent studies have indicated that the transmembrane form of PrP 
ctmprp play g Koy pathogenic role in some prion diseases. As described in 
sections 1.1.2 and 1.5.3.2 this form is generated in small amounts as part of 
normal biosynthesis of PrP (Hegde et al., 1998). However, mutations within or 
near the transmembrane domain, including A117V linked to GSS as well 
several “artificial” mutations, increased the relative proportion of ^^^PrP (Hegde 
et al., 1998; Hegde et al., 1999; Stewart et al., 2001; Stewart and Harris, 2001). 
Several lines of in  v iv o  data also suggest that ^ "^^PrP plays an important role in 
the pathogenesis of some prion diseases. First, transgenic mice carrying one of 
the ^^"^PrP-favouring mutations developed a scrapie-like neurological disease, 
characterized by ataxia and paresis without accumulation of PrP^^
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nU Neuropathological examinations of brains showed vacuolar degeneration of the
J  grey matter neuropil and astrocytic gliosis (Hegde et al., 1998). The disease
was not an effect of the high copy number of the transgene, being the highest 
copy number present in Tg(WT) mice that remained healthy. Second brain 
^  tissue from patients with the A ll7 V  mutation, where there is a reported lack of
conventional PrP^^ (Piccardo et al., 2001; Tagliavini et al., 2001), was found to 
contain detectable ^ "^^PrP (Hegde et al., 1998). Third, when transgenic mice 
"J expressing wild-type hamster PrP were inoculated with mouse prions, the
n  amount of ^*^PrP as well as PrP^^ were found to increase during the course of
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illness (Hegde et al., 1999). Thus, could be increased either by
mutations in the PrP molecule or via formation of PrP^^, leading to 
neurodegeneration. Although it is clear that ^^^PrP favouring mutations cause a 
neurodegenerative phenotype when expressed in Tg mice (Hegde et al., 1998), 
the data about the accumulation of *^ ‘^PrP in scrapie infected animals is not 
J clear (Hegde et al., 1999). The published experiment involved the use of a PrP
^  reporter construct to monitor ^ "^^PrP levels, and the maximal increase in ^ "^^PrP
was only 3-fold, much smaller than the increase in PrP^^ Other data indicate 
1  that scrapie infection of N2a cells and mouse brain does not alter the amount of
ctmprp, thus excluding that ^ "^^ PrP is the proximate cause of neurodegeneration 
in infectious prion diseases (Stewart and Harris, 2003).
Recently, it has been shown that forced cytoplasmic expression of PrP in 
transgenic mice by microinjecting a mouse PrP construct ablated of the signal 
peptide, leads to severe and rapid onset of neurodegeneration (Ma et al., 2002). 
The toxicity of cytoplasmic PrP (cyPrP) appeared to be selective to neurons as 
other tissues expressing cyPrP (such as heart) did not show pathology. In 
addition, cell-type specific toxicity was recapitulated in culture, where only 
neuronal-derived cell lines were susceptible to cyPrP-mediated apoptosis (Ma 
et al., 2002).
Like other membrane proteins, PrP enters the ER concurrent with itsn
LJ synthesis by membrane-bound ribosomes and for this reason nascent PrP
1  cannot normally access the cytoplasm. During or shortly after its entry into the
ER, PrP undergoes folding and maturations events (see section 1.1.2). it is 
plausible that some proportion of nascent PrP would fail to mature properly, 
J  making it a target for ER quality-control systems (Ellgaard and Helenius, 2003).
These are common pathways in which misfolded proteins are recognized and
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triaged for ER-associated degradation (ERAD), a process that involves 
retrograde translocation of substrates into the cytoplasm (possibly through the 
Sec61 translocon) where they are ubiquitylated and destroyed by .proteasome 
(Tsai et al., 2002). Evidence to support this concept for PrP has recently been 
provided by studies in which proteasomal degradation is inhibited (Ma and 
Lindquist, 2001; Ma and Lindquist, 2002; Wang et al., 2004; Yedidia et al., 
2001; Zanusso et al., 1999) or PrP misfolding is increased (Cohen and 
Taraboulos, 2003). Under these conditions a predominantly non-glycosylated 
1  form of PrP is observed to accumulate in the cytoplasm: this abnormal form has
PrP^^-like properties, i.e. detergent insolubility and PK-resistance. Most 
intriguing was the capability of these molecules to self-propagate after the 
removal of the proteasome inhibitors. In fact, while neuronal cell death could be 
an indirect effect of proteasome inhibitors rather than the effect of cytotoxic form 
of PrP, the acquisition of abnormal biochemical properties and the capability of 
self-propagating constitute an important evidence that PrP^ molecules can 
occasionally undergo conformational change to PrP^^. These abnormal forms 
(that are normally degraded) were able to propagate their conformation (Ma and 
Lindquist, 2002), thus validating the prion hypothesis.
As cyPrP has been shown to be neurotoxic, it is conceivable that the 
access of PrP to the cytoplasm and its retention in the cytoplasm is the 
neurodegenerative trigger. Two further recent findings support this idea: 1) a 
mutated form of PrP (D177N), the mouse homologue of the D178N mutation 
linked to familial prion disease in humans, was shown to access the cytoplasm 
to a greater degree than did the wild-type PrP (Ma and Lindquist, 2001), and 2) 
mutations in a central hydrophobic region of PrP, that lead to increased 
generation of transmembrane forms of PrP, caused neurodegeneration in
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transgenic mice (Hegde et al., 1998). Thus, some heritable mutations might, via 
multiple mechanisms, converge to a final pathway involving access of at least 
1 one portion of PrP to the cytoplasm (Ma and Lindquist, 2001; Ma et al., 2002;
Yedidia et al., 2001; Zanusso et al., 1999). If mutant PrP retrotran s locates in the 
u  cytoplasm, the predicted size of PrP that accumulates should be of the fully
^  processed molecule, i.e. 27 kD for the unglycosylated form. It has been
demonstrated that in CHO and PC I2 cells a small fraction of PrP molecules, 
both wild-type and mutant (the point mutation D177N, and the insertional 
1 mutation PG14 ) were subjected to proteasomal degradation in transfected cells
p. by a pathway that did not involve retrotranslocation from the ER lumen (Drisaldi
et al., 2003). Indeed, proteasome inhibitors in transfected cells expressing wild 
type (WT) or mutant PrP caused the selective accumulation of a form of PrP 
that was approximately 2 kDa larger than the mature unglycosylated species; 
this larger PrP molecule probably represented PrP molecules that resided on 
the cytoplasmic face of the ER membrane and that had never been translocated
D
D
D
n  into the ER lumen for further processing. The failure to translocate was probably
U
due to a slight inefficiency in PrP signal, as replacing it with a more efficient 
J signal sequence increased the translocation (Rane et al., 2004). These PrP
n species reacted with an antibody that was specific for PrP molecules bearing an
—
intact signal peptide (Drisaldi et al., 2003), indicating that these PrP proteins 
had not been exposed to signal peptidase, which resides in the lumen of the ER 
(Zwizinski and Wickner, 1980). In addition, these forms lacked N-linked glycans 
and a GPI anchor, shown by the fact that their migration was not shifted by 
treatment with glycosidases or PIPLC (Drisaldi et al., 2003). These features
D
D
J  were therefore consistent with a lack of processing by oligosaccharyl
transferase and GPI transamidase, both of which reside in the ER lumen
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(Geetha-Habib et al., 1988; Udenfriend and Kodukula, 1995). In addition,
^  topology analysis using a protease protection assay demonstrated directly that
the protein was located entirely on the cytoplasmic side of the ER membrane
_  (Drisaldi et al., 2003). Finally, immunolocalization studies indicated that it
accumulated in an ER pattern after proteasome inhibitor treatment (Drisaldi et
al., 2003). Collectively, these results indicated that a small fraction of PrP
-] chains failed to be translocated into the ER lumen during their synthesis, but
remained closely associated with the cytoplasmic face of the ER membrane
where they were rapidly degraded by the proteasome. However, because all
n  these results were obtained in transfected cells overexpressing PrP it is not
possible to exclude the possibility that this mechanism is non-physiological.
J Indeed, untranslocated PrP does not accumulate in cultured primary cerebellar
"i granule cells treated with proteasome inhibitors, implying that untranslocated
PrP is unlikely to be an obligate by-product of PrP biosynthesis in neurons
J (Drisaldi et al., 2003). In contrast, accumulation of a single PrP isoform, lacking
Q signal peptide, in the cytosol of some neuroblastoma cell lines (N2a, BE(2)-M17
and SK-N-SH) and in primary neurons was detected after co-treatment with
brefeldin A (which blocks the transport of secreted proteins beyond the
endoplasmic reticulum (Misumi et al., 1986) and the proteasome inhibitor
epoxomicin (Roucou et al., 2003). However, while this form was toxic in N2a
cells and showed the abnormal biochemical properties described for PrP^^,
neither toxicity or alteration of biochemical properties was shown in primary
neurons or BE(2)-M17 and SK-N-SH cells (Roucou et al., 2003). The
physiological retrotranslocation of PrP is indeed still controversal, as another
[ j  group recently reported the accumulation of a 27 kD form of the protein,
depleted of the signal peptide, after proteasome inhibition in several cell lines
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expressing high level of endogenous PrP and in primary cortical neurons (Wang 
J  et al., 2004).
Taken together, all the results described demonstrate that a cytosolic PrP 
can accumulate in different cellular models in non-physiological conditions: 1) 
because of impaired degradation of abortively translocated, signal peptide- 
bearing molecules synthesized from the CMV promoter (Drisaldi et al., 2003) or 
J  2) favouring the accumulation of protein in the ER by brefeldin A treatment
(Roucou et al., 2003) or simply by inhibiting proteasome (Wang et al., 2004). In 
^  none of the described case, however, did cytosolic PrP forms show a clear and
Q reproducible cytotoxicity, thus making it unlikely that neurodegeneration in prion
disease may ensue from abnormal accumulation of toxic PrP species in the
nJ  cytoplasm.
D A number of inherited human diseases are attributable to defects in 
export of a mutant protein from the ER. In some cases, such as cystic fibrosis 
and hereditary hemochromatosis (Aridor and Balch, 1999), the mutant protein is
1  retrotranslocated from the ER and degraded by the proteasome, resulting in
failure of the protein to reach its normal cellular destination. In other disorders,
nJ  such as hereditary emphysema (PiZ variant) and congenital hypothyroidism, the
T retained protein accumulates in the ER without being degraded. In these cases,
the disease phenotype is due to a toxic effect of the accumulated protein, which 
-J stimulates one or more ER stress response pathways (Aridor and Balch, 1999).
J  It was hypothesized (Drisaldi et al., 2003) that some inherited prion disorders,
such as those due to PG14 and D177N mutations, are members of this second 
category of ER retention diseases. Accordingly, imunofluorescence studies 
showed that less mutant PrP is present on cell surface compared to WT. 
p. Although transit of D177N and PG14 mutant PrP molecules out of the ER is not
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uD completely blocked, their export rate is reduced sufficiently to cause anaccumulation of the protein in the ER at steady state (Ivanova et al., 2001).
Thus these ER-accumulated proteins could induce an ER-stress response (also 
P, called the unfolded protein response, DPR), which included a signalling
component known to trigger molecules, such as CHOP-GADD153, promoting 
Q cell-death (Kaufman, 1999). Supporting this hypothesis, up regulation of ER
stress genes such as genes encoding for glucose-regulated protein GRP58, 
GRP78 and GRP94 has been demonstrated in N2a cells challenged with 
purified PrP^^ in the brain of infected animals and of sporadic and variant CJD 
(Hetz et al., 2003).
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1.7 The unfolded proteins response (UPR)
All eucaryotic cells have an extensive membranous labyrinth network of 
n  branching tubules and flattened sacs called the endoplasmic reticulum (ER). A
large fraction of all cellular proteins are translocated into the ER where folding, 
J  oligomerisation and other post-translational modifications occur prior to
"I transport to the extracellular surface or to cellular organelles, such as the Golgi
compartment or lysosomes. Many proteins that acts as molecular chaperones 
or folding catalysts reside in the ER and form a matrix on which newly 
synthesised proteins attain their final conformation (Ellgaard and Helenius, 
2003). This interaction ensures that only properly folded and assembled 
proteins exit the ER compartment, a process known as “quality control” (Hurtley 
et al., 1989). Molecular chaperones were originally defined as families of 
proteins that assist in the self-assembly of other chains (Ellis et al., 1989). 
Several chaperones are known to be members of the family of heat shock
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proteins (HSPs). Heat shock is only one of several different types of stress thatn^
 can cause protein dénaturation and the HSP60, HSP70 and HSP90 classes of
proteins, so named for their approximate molecular weight, are known to play 
crucial compensatory roles that allow cell survival (Craig et al., 1994).
To maintain the efficiency of quality-control mechanisms in diverse 
conditions, living cells have evolved regulatory circuits that monitor the levels of 
available chaperons. This is true for both the cytosol and the ER, and 
compartment-specific responses clearly exist that selectively restore optimal 
levels of the desired folding factors. Accumulation of aberrant proteins in the 
cytosol triggers the heat-shock response, resulting in the novo synthesis of 
HSP70 and other cytosolic chaperons (Morimoto, 1998). But if aberrant proteins 
accumulate in the ER, cells activate a different response. The ER is sensitive to 
alterations in homeostasis: upon a variety of different stimuli, signals are 
transduced from the ER to the cytoplasm and the nucleus. The immediate 
response occurs at the translational apparatus, whereas changes in gene 
expression promote long-term adaptation or apoptotic cell death (Kaufman, 
1999). These stimuli include calcium depletion from the ER lumen, inhibition of 
asparagine (N)-linked glycosylation or of disulphide bond formation, expression 
of mutant proteins or protein subunits and also overexpression of wild-type 
proteins. When protein misfolding occurs and unfolded proteins accumulate and 
aggregate in the ER, the cell activates adaptive signalling pathways that are 
programmed to enhance the folding capabilities in this compartment. This signal
J
response was termed the unfolded protein response (UPR) (Kaufman, 1999). 
The UPR is essential for survival of all eukaryotic cells under conditions of 
J  stress and is also implicated in the pathogenesis of a number of disease such
as hereditary enphysema and cystic fibrosis (Aridor and Balch, 1999). The UPR
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culminates in the induction of the ER stress-response genes, including those
that encode several glucose-regulated proteins (GRP), such as GRP78 and
GRP94, calreticulin, growth arrest and DNA damage gene 153 (GADDI53),
protein disulfide isomerase (PDI), and x-box-binding-protein (XBP1) (Kaufman,
1999; Lee et al., 2002). GRP78 was identified as an ER-localized protein that
bound to the heavy-chain immunoglobulins and inhibited their secretion in the
absence of the light chain in pre-B lymphocytes (Haas and WabI, 1983). For this
reason it was named immunoglobulin binding protein (BiP). Indipendently BiP
was identified as a member of a protein family that is expressed at high levels
upon exposure to glucose (for this reason called glucose-regulated protein,
GRPs) and was named GRP78 (Shiu et al., 1977). More recently, it has been
shown that BiP is identical to GRP78 (Munro and Pelhamf, 1986). BiP is a
member of the HSP70 family and displays weak ATPase activity that is
stimulated by peptides that contain hydrophobic amino acids, it interacts
transiently with exposed hydrophobic patches on protein folding intermediates
and it is thought to prevent their aggregation (Kassenbrock et al., 1988; Kim and
Arvan, 1998). GRP94, also known as endoplasmin, is a member of the HSP90
family and is also a calcium binding protein (Kim and Arvan, 1998). This protein
associates with nascent polypeptides that have exposed unfolded patches and
has a weak ATPase activity. Like BiP, it is found to interact with misfolded
proteins for prolonged periods after synthesis (Kim and Arvan, 1998).
Calreticulin is a lectin (a protein which binds carbohydrates) and is homologous
to another ER resident protein named calnexin. They both interact with
monoglicosylated, trimmed intermediates of the N-linked core glycans on newly
synthesised glycoproteins, thereby preventing their transit through the secretory
pathway. Calreticulin is also the major calcium-binding and storage protein in
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the ER (Kim and Arvan, 1998). GADD153, also known as CHOP 10 (C/EBP 
J homologous protein 10) was originally identified as a gene induced on DNA
damage and growth arrest (Kim and Arvan, 1998). However, subsequent 
studies have demonstrated a strong correlation between development of ER 
stress and induction of CHOP (Wang et al., 1996). CHOP is a small nuclear 
protein that can heterodimerize with C/EBP family members and activate 
downstream target genes which negatively regulate cell growth or induce
j
apoptosis (Barone et al., 1994; Ron and Habener, 1992). CHOP 10 is regulated
^  not only at transcriptional level but also at a post-translational level: on
phosphorylation of serine residues by p38 MAP kinase, its transcriptional
activity increases (Wang and Ron, 1996). Protein disulfide isomerase (PDI)
catalyses oxidative folding and increases the rate at which proteins attain their
final folded conformation (Lambert and Freedman, 1985). XBP1 is a basic
leucine-zipper (b-zip) transcription factor originally identified as a protein binding
to the cis-acting x-box present in the promoter regions of human major
"I histocompatibility complex class II genes (Liou et al., 1990). XBP1 mRNA is
spliced in response to ER stress to produce a highly active transcription factor
J  that enhances transcription of genes implicated in glycoprotein degradation
(Yoshida et al., 2003).
The activation of UPR has been extensively studied in yeast cells. In
S a c c h a r o m y c e s  c e r e v is ia e ,  the proximal sensor of the UPR is the protein
kinase and endoribonuclease Irelp, the translation product of inositol-requiring
1 gene (IRE1). Ire lp is a transmembrane type I protein, the N-terminal half of
which is located in the ER lumen; the protein kinase and endoribonuclease are
located in the cytoplasmic side. Protein accumulation in the ER promotes Irelp
dimerization, autophosphorylation and activation of its ribonuclease activity
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(RNAse) (Shamu and Walter, 1996). The only substrate known is HAC1 mRNA 
(homologous to ATF/CREB T) encoding the b-ZIP transcriptional factor Haclp 
that binds to the UPR target genes. Irelp cleaves HAC1 mRNA at two sites to 
remove a 252 nucleotide intron (Sidrauski and Walter, 1997). Hacpi is 
synthesized only after I re Ip-mediated splicing occurs because the HAC1 intron 
has a strong ability to block translation.
Two related homologues of yeast IRElp, referred to as IREa and IREip, 
have been identified in both the human and murine genome (Tirasophon et al..
nJ  1998; Wang et al., 1998). Both are type I transmembrane proteins in the ER,
-1  with their cytoplasmic regions carrying protein kinase and endoribonuclease
domains. Purified IREIa and IREip can cleave HAC1 precursor mRNA at the 
J  same sites as yeast Irelp (Tirasophon et al., 1998). In mammalian cells, XBP1
has been identified as a substrate for endoribonuclease activity of IR EIa and 
IREip (Yoshida et al., 2001) (Figure 1.9).
In higher eukaryotic cells, the other pathway for gene activation upon 
accumulation of unfolded protein in the ER involves the activation of the 
activating transcription factor 6 (ATF6) (Haze et al., 1999). ATF6 is 
^  constitutively expressed in the ER as a 90 kDa type II transmembrane protein.
J  The N-terminal half, facing the cytoplasm, contains a b-zip motif. Upon
p. activation of the UPR, ATF6 is proteolyzed within the transmembrane domains
by site-1 and site-2 (SP1 and SP2) protease to release a 50 kDa cytosolic
nJ  fragment (p50ATF6). p50ATF6 migrates to the nucleus and activates
-n transcription of ER chaperones and enzymes mainly implicated in protein
quality control and folding (Figure 1.9). BiP and XBP1 are genes that are 
induced by overexpression of ATF6 (Yoshida et al., 1998).
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Therefore, IRE1 and the ATF6 signaling pathways merge through
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LJ regulation of XBP1 activity to induce downstream gene expression. Whereas
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ATF6 increases XBP1 mRNA, IRE1 removes the 26-nucleotide intron that 
increases XBP1 transactivation potential (Lee et al., 2002).
The third ER sensor is the protein kinase Perk (Liu et al., 2000; Shi et al.,
1998). After trans-autophosphorylation Perk phosphorylates its only known 
substrate, the a  subunit of eukaryotic translation initiation factor 2 (elF2 a), to 
limit polypeptide chain initiation. This phenomenon is called translation 
attenuation and protects cells under conditions where proteins cannot fold 
properly. This pathway also activates ATF4, causing increased expression of 
genes involved in aminoacid import and redox regulation, and the 
CHOP/GADDI53 involved in apoptosis (Harding et al., 2003) (Figure 1.9).
UPR not only plays an important role in protecting cells from adverse 
physiological conditions, but recent studies suggest that activation of at least a 
part of the UPR is involved in normal physiological processes like differentiation 
of B cells into plasma cells (Gass et al., 2002) and the secretion of insulin by p 
islet cells of the pancreas in response to changes in blood glucose levels 
(Harding et al., 2001).
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Figure 1.9: Schematic representation of UPR.
When misfolded proteins accumulate in the ER, three ER localised membrane 
proteins are activated, Perk, Ire1 and ATF6. Activation seems to be mediated 
by the release of BiP from the ER transmembrane proteins. Upon activation. 
Perk phosphorylates elF2a, causing translational inhibition. Subsequently, 
ATF4 is up-regulated increasing the transcription of genes involved in 
aminoacid import, redox regulation and apoptosis (like CHOP). Upon 
accumulation of unfolded proteins ATF6 leaves the ER to enter the Golgi 
apparatus where it is cleaved to release a 50 kDa fragment (by 81P and S2P 
proteases) that enter the nucleus. P50-ATF6 increases the transcription of ER 
chaperons. Simultaneously UPR induces activation of ribonuclease activity of 
IRE1. Translation of spliced XBP1 generates a potent transcriptional activator 
that increases transcription of genes implicated in glycoprotein degradation.
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1.8 Development of inducible cellular models of familial prion diseases
As mentioned in section 1.5.3.2, neurotoxicity of mutant PrP has been 
demonstrated in  v iv o  by generating transgenic mice lines that express altered 
forms of PrP linked to familial prion diseases (Chiesa et al., 1998; Hsiao et al., 
n  1990). Conversely, mutant PrP expressed in transfected cells acquired scrapie-
like properties but has not shown toxicity in any cellular type, including neuronal 
lines (Chiesa and Harris, 2000; Petersen et al., 1996; Priola and Chesebro, 
1998; Singh et al., 1997; Zanusso et al., 1999). Several hypotheses can be 
proposed to explain these results. First, mutant protein could not be sufficiently 
“scrapie-like”, or neuronal degeneration could require interaction with other cell 
types, such as microglia or astrocytes. Secondly, a toxic effect could require 
chronic exposure of cells over many months, much longer than can be achieved 
in culture. Finally, since PrP expression in the described models was 
constitutive, it was possible that only clones resistant to the toxicity of PrP 
expression had been selected after transfection. In fact, cells can evoke 
different type of responses to accommodate expression of a the toxic protein 
(Sherman and Goldberg, 2001).
To exclude this possibility, i.e. toxicity of the transfected protein during 
clonal selection, an inducible model can be established. In this case, 
J  transcription is activated after clonal selection by adding a specific inducer.
Inducible systems are also particularly useful as they allow direct comparisons 
of the effect of protein expression on the same cellular background to be made, 
J  avoiding clonal variability. It is therefore possible to study the potential
cytopathic effect of protein expression and the molecular mechanism leading to
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cell death, manifested by differences in genes expression, differences in protein 
activation, etc.
" j A number of inducible promoters have been described in eukaryotic cells
that are responsive to heavy metal ions (McNeall et al., 1989), heat shock
(Bienz and Pelham, 1986) or hormones (Renkawitz et al., 1982; Rousseau, 
1984). However, these systems have generally suffered from leakiness of the 
inactive state or from pleiotropic effects caused by the inducing agent itself. An 
example of the pleiotropic effect, i.e. the tendency to affect the expression of 
Q  multiple gene other than the target, is represented by the use of steroid
hormones as an inducer, known to regulate the expression of several genes. To 
avoid pleiotropic effects regulatory systems that do not rely on endogenous 
2  control elements have been developed; the ecdysone inducible system, based
on the D r o s o p h i la  m e la n o g a s t e r  m o l t in g  hormone (No et al., 1996), and the Tet- 
system, based on the tetracycline repressor of E . c o l i  are those most commonly 
used.
J 1.9 Tet-on and let-off gene expression systems
D
1.9.1 How the Tet-sy8tern works
In E. C o li , the Tet repressor protein (TetR) negatively regulates the 
genes of the tetracycline-resistance operon on the TnlO transposon. The TetR 
blocks transcription of these genes by binding to the tet operator sequences 
(tetO) in the absence of tetracycline (Tc). TetR and tetO provide the basis of the 
Tet-off and Tet-on for mammalian experimental systems (Gossen and Bujard,
1  1992; Gossen et al., 1995).
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The first component of the Tet-system is the regulatory protein based on 
TetR. In the Tet-off System, this protein is a fusion product of aminoacids 1-207 
Q of TetR and the C-terminal 127 aminoacids of the Herpes Simplex Virus protein
VP16. The VP16 domain converts the TetR from a transcriptional repressor to a 
transcriptional activator. The hybrid protein is known as the tetracycline- 
controlled-transactivator (tTA). The second component is the response plasmid, 
which expresses the gene of interest under control of the tetracycline-response 
element, or TRE. The TRE consists of seven direct repeats of a 42-bp 
sequence containing the tetO, and is located just upstream of the minimal 
cytomegalovirus (CMV) promoter. Binding of the regulatory protein to the 
promoter allows transcription; when tetracycline is added to the medium it 
prevents the binding and causes a 10-fold decrease of the transcription within 8 
h (Figure 1.1 OA, taken from the Tet-on & Tet-off gene expression system 
manual, Clontech).
The Tet-on system is similar to the Tet-off system, but the regulatory 
protein is based on a “reverse” Tet repressor, rtTA (reverse tTA), created by 
four amino acid changes in TetR. Addition of the effector doxycycline (Dox, an 
analogue of tetracycline) results in binding of rtTA to tetO, which allows gene 
activation up to 1000-fold (Figure 1.1 OB taken from the Tet-on & Tet-off gene 
expression system manual, Clontech).
The Tet-off and Tet-on system have several advantages over other 
Q regulated gene expression systems (Gossen and Bujard, 1992; Gossen et al.,
1995):
1. There is extremely tight on/off regulation. Background or leaky
^  expression in the absence of induction is extremely low (Harkin
et al., 1999; Li et al., 1998) (Figure 1.100).
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2. TetR or rTetR act specifically on their target sequences, 
avoiding any pleiotropic effect (Harkin et al., 1999).
3. The response to the inducer is high and fast: induction can be 
detected within 30 minutes and reaches up to 10,000 fold 
induction levels (Yin et al., 1996) (Figure 1.10C).
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Figure 1.10: The BD™ Tet-Off and Tet-On Systems.
(A) BD™ Tet-Off System. The Tet-controlled transactivator (tTA) is a fusion of 
the wild-type Tet repressor protein (tetR) to the VP16 activation domain (AD) of 
herpes simplex virus.
(B) BD™ Tet-On System. Four amino acid changes to TetR alter its binding 
characteristics and create the reverse TetR (rTetR), which binds the TRE in the 
presence of doxycycline.
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J To ensure the absence of unregulated gene expression in the Tet-on
1  system, it is possible to introduce another element, the pTet-tTS, which
encodes a transcriptional silencer (tTS) that blocks transcription of genes under 
J control of the TRE in the absence of Dox (Figure 1.11) (Freundlieb et al., 1999).
The addition of tTS reduces background expression in mammalian cell lines 
(Forster et al., 1999; Freundlieb et al., 1999; Rossi et al., 1998) and in 
transgenic animals (Perez et al., 2002; Zhu et al., 2001) even if it sometimes 
Q affects the maximal expression level (Knott et al., 2002)
. Different plasmids harboring the TRE element are available: in pBI-G the
promoter is bi-directional and the inducer regulates expression of the gene of 
interest along with p-galactosidase (Figure 1.12A). Because this plasmid does 
not encode for any selective agent resistance the plasmid pTK-Hyg must be co­
transfected (Figure 1.12B).
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Figure 1.11: The role of pTet-tTS plasmid.
(A) Map of pTet-tïS, which expresses tTS inhibitor.
(B) Dose response curve demonstrating controlled expression in a cell line co­
expressing tTS and rtTA. Cells, constitutively expressing rtTA, were transiently 
transfected with a plasmid expressing tTS and a control vector expressing 
luciferase downstream of the TRE. Cells were cultured in the indicated levels of 
Dox. After 24 hr, cells were harvested and assayed for luciferase activity. SD = 
silencing domain. AD = activation domain. Data provided courtesy of S. 
Freundlieb, e t  a i ,  Zentrum für Molekulare Biologie (ZMBH), Heidelberg.
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Figure 1.12: Schematic representation of pBI-G and pTK-Hyg plasmids.
(A) Map of pBI-G, harboring the TRE element.
(B) Map of pTK-Hyg, which confers resistance to hygromycin.
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1.9.2 Applications of the tet-system
Tet inducible systems have been successfully used in cellular and animal 
models of other neurodegenerative diseases, such as Parkinson’s disease (PD)
nJ and Huntington’s disease (HD).
PD is a progressive neurodegenerative disorders caused by the loss of 
dopaminergic neurons in the substantia nigra (Nussbaum and Polymeropoulos,
1997). Although mutations in a-synuclein have been identified in autosomal 
dominant PD, the mechanism by which neuronal cell death occurs remains 
unknown. To study the involvement of a-synuclein in dopaminergic neuronal 
cell death, PCI 2 cell lines have been established in which wild-type or mutant 
protein can be derepressed by removing doxycycline (Lee et al., 2003; Tanaka 
et al., 2001). These studies showed that expression of mutant a-synuclein upon 
removal of doxycycline decreased proteasome activity and increased the 
^  sensitivity of cells to mitochondria-dependent apoptosis.
HD is a neurodegenerative disorder caused by the abnormal expansion 
of a polyglutamine tract in the huntingtin protein (Bates, 2003). In order to study
nJ the cellular response to mutant huntingtin, 293 Tet-off and PC I2 Tet-off cells
expressing wild-type or a mutated form of the protein have been established. 
Huntingtin aggregation led to distinct perinuclear inclusion bodies and resulted
nJ  in redistribution of several cellular factors, such as stress proteins and
components of the proteasome system to the inclusion bodies. Inclusion body 
formation also resulted in cell toxicity and ultrastructural changes such 
disruption of the nuclear envelope and cytoplasmic vacuolation (Igarashi et al., 
2003; Waelter et al., 2001). A conditional mouse model of HD has also been 
generated using the tet-responsive system. Mice expressing a mutated
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huntingtin developed a progressive motor dysfunction, that was associated withn
U severe neuronal inclusions. Blockage of expression in symptomatic mice by
^  Dox administration led to disappearance of inclusions and to amelioration of the
phenotype. The use of the conditional model therefore demonstrated that the 
continuous influx of the mutant protein is required for pathology in HD 
(Yamamoto et al., 2000).
J 1.9.3 Use of the Tet system in cellular and animal models for the
investigation of prion diseasesD
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The Tet-on and the Tet-off systems for expression of PrP have been
studied in N2a cells (WindI et al., 1999). However, the Tet-off system showed
leakage with maximal PrP expression achieved irrespective of whether Dox was
present in the medium. In contrast, quantitative analysis of the N2a-rtTA cells
revealed an expression level that was four times higher in the induced state
than in the uninduced condition and slightly higher in comparison to the
1  expression level of PrP under control of a constitutive CMV promoter. In the
absence of inducer, the expression level was indistinguishable from the
endogenous PrP expression of N2a cells. Expression was directly related to
Dox concentration and reversed within 96 h of Dox depletion (Windl et al.,
1999). These N2a-rtTA cells were also used to demonstrate that murine PrP in
which all the alanine residues of the sequence AGAAAAGA (spanning
aminoacids 109-112) were replaced by glycine residues acquired PK resistance
(Wegner et al., 2002).
PrP was also expressed in RK13 Tet-on cells that do not express PrP
(Rachidi et al., 2003). In this model, a link between PrP^, copper binding and
resistance to oxidative stress was reported (Rachidi et al., 2003). Expression of
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PrP in fact, was related to an increased concentration of copper in cell 
membrane and determined an increased survival after oxidative stress.
A Tet-off system was also used to control expression level of wild-type 
PrP in transgenic mice (Tremblay et al., 1998). Doxycycline administrated to 
adult Tg mice acutely repressed the expression of PrP but did not produce any 
J  recognizable adverse effects in mice. This result indicated that high levels of
P  PrP were not essential for short-term neuronal survival and its expression could
be repressed over 20-fold without effects. Upon PrP repression, mice 
1 challenged with RML prions remained free of any signs of CNS dysfunction for
-j more than 380 days. Histological analysis showed a low level of PrP^^, probably
due to the leakage of the promoter. In contrast, mice that had not been treated 
with Dox developed a progressive ataxia starting 50 days after inoculation with 
prions. These experiments provided supporting evidence that low levels of 
PrP^^ do not produce clinical or neuropathological effects (Tremblay et al.,
1998).
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1.10 Work of this thesis
As discussed in Sections 1.6 and 1.8, many investigations have sought 
to identify the molecular basis of mutant PrP toxicity. However, none of the i n  
v i t r o  models of familial prion diseases developed to date demonstrated a clear- 
cut cytopathic effect of mutant PrP expression. Moreover, the pathogenic 
molecular mechanisms by which mutant PrP causes neuronal cell and 
dysfunction remain uncertain.
In an attempt to reproduce neuronal degeneration in  v i t r o  and to gain 
insights into the molecular mechanisms leading to cell death, an inducible
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umodel of familial prion diseases was developed by expressing the mouse 
J  homologue of the D178N mutation in two forms (D177N (Met128) and D177N
^  (VaI 128) in PC12 Tet-on cells. The same insertional mutation, PG14, which has
been previously characterised in PC 12 cells (Chiesa and Harris, 2000) and Tg 
mice (Chiesa et al., 1998) was also expressed. Further, because an 
involvement of the UPR in prion diseases has recently been reported (Hetz et 
al., 2003), this model was used to evaluate differences in the expression level of 
UPR gene in the induce state v e r s u s  the un-induced state. The P C I2 cell line 
was chosen to directly evaluate the potential cytopathic effect of mutant PrP 
-I expression in cells that have acquired a neuronal phenotype, by activating
transcription after differentiation with nerve growth factor (NGF). A Tet-on
n
‘ system was preferred, rather than a Tet-off, because of the absence of leakage
of expression when combined with the tTS repressor (Forster et al., 1999; 
Freundlieb et al., 1999; Rossi et al., 1998).
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Chapter 2: Materials and Methods
2.1 Cloning of wild-type and mutant PrP cDNAs into the 
Bidirectional Tet vector
Construction of cDNAs encoding wild-type (M128, WT) or PG14 PrP 
carrying an epitope tag for the monoclonal antibody 3F4 was previously 
described (Lehmann and Harris, 1995). cDNAs encoding 3F4-tagged 
D177N/Met128, D177NA/al128 and M l28V cloned in pCDNA3 were kindly 
donated by David Harris, Washington University, St. Louis, Missouri, USA. Pst I 
and Not I restriction sites were inserted respectively upstream the 5' and 
downstream the 3' ends of the PrP open reading frame by polymerase chain 
reaction. The products of amplification were cloned into the Pst 1/ Not I 
restriction sites of the Bidirectional Tet Vector pBI-G (BD Clontech, Palo Alto, 
California), containing the Tetracycline-Response-Element (TRE) (Figure 2.1).
For the PCR, two oligonucleotides were synthesized. The following 
criteria were followed to design the primers: 1) the length of the region 
annealing to either the 5’ or 3' end of the PrP cDNA were chosen to have a 
melting temperature (Tm) of approximately 60°C ; 2) the consensus sequences 
for the restriction enzymes were inserted at the 5’ end of each primer and were 
followed by a GC-rich sequence which favours the annealing of the primers 
after the first PCR cycle, and constitute a spacer at the 5’ end of the restriction 
site to facilitate binding of the restriction enzyme; 3) Tm of the full length primer 
o f ap p rox ima te l y  65°C.  The sense pr imer  was:  5' -
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GACCAGCTGCAGATGGCGAACCTTGGCTACTGGCTG-3': the antisense 
primer was: 5'-GACCAGGCGGCCGCTCATCCCACGATCAGGAAGATGAG-3'. 
” j Starting from 5’, each primers is composed by the CG rich sequence GACCAG,
by the restriction site Pst I or Not I and by the PrP sequence (aminoacids 1-8 or 
248-254 plus stop cordon). The PCR was performed in a thermal cycler (PTC- 
200; Mj RESEARCH, Inc., Waltham, Massachusetts) for 20 cycles at 94°C for 
30 s, 55°C for 45 s, and 72°C for 45 s. 10 ng of template DNA was added to 50 
pi of reaction mixture containing 10 mM KCI, 20 mM Tris-HCI pH 8.8, 10 mM 
(NH4 )2S0 4 , 2 mM MgS0 4 , 0.1% Triton X-100, 0.2mM dNTPs (Fisher Scientific 
UK Ltd, Leicestershire, Loughborough, England), 0.5 pM primers and 2 U of 
Vent polymerase (New England BioLabs, Inc., Beverly, Massachusetts), which 
possess 3’ exonuclease proof-reading activity. The calculated length of the 
amplified fragments was 791-bp band for the WT, Ml28V, D177N and 1008 bp 
for the PG14 construct (12 nucleotides of the sense primer + 762 or 979, which 
is the length of the entire cDNA sequence (762 for the WT, M128V and D177N 
PrP, and 979 for PG14 PrP) + 17 nucleotides of the antisense primer) (Figure
2.1 A).
The PCR products were digested with 2 U/pg of Not I (Roche 
Diagnostics, Mannheim, Germany) for 2 h at 37°C and subsequently digested 
with 2 U/pg of Pst I (Roche Diagnostics, Mannheim, Germany) for 2 h at 37°C 
(Figure 2.1 A). Digested samples were separated onto a 0.5% low-melting 
agarose gel and purified by ELUTIP minicolums (Schleicher & Schuell 
Bioscience Inc., Keene, Nevada). 10 pg of pBI-G were digested with 20 U of 
Not I and Pst I for 2 h at 37°C and dephosphorilated by further 1 h incubation 
with 2 U of alkaline phosphatase (Roche Diagnostics, Mannheim, Germany)
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D (Figure 2.1 B). Linearized-dephosphorilated vector was isolated from low-melting112
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agarose gel with ELUTIPS minicolums. For the reaction of ligation, 500 ng of 
insert DNA and 100 ng of linearized, desphophorilated pBI-G were incubated
r  with 1 U of bacteriophage T4 DNA ligase (Roche Diagnostics, Mannheim,
Germany) for 18 h at 16°C (Figure 2.1C). As a negative control 100 ng of 
linearized pBI-G were incubated with 1 U of ligase in the absence of insert DNA.
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Figure 2.1: Strategy for PrP cDNA cloning.
(A) PrP cDNAs containing Pst I and Not I restriction sites were generated by 
PCR. The PCR product was subsequently digested with Pst I and Not I. PrP 
cDNA is shown in red/blue. Primers are shown in green. Letters in green 
represent the sequence recognized by the restriction enzymes. Letters in dark 
represent the nucleotides that do not anneal to the PrP sequence. (B) Multiple 
cloning site (MCS) of pBI-G vector contains Pst I and Not I restriction sites. 
Vector was linearized by enzymatic digestion and dephosphorilated. (C) PrP 
cDNA was subsequently ligated into linearized pBI-G. Dark arrows represent 
the two minimal CMV promoter driving expression of PrP and lacZ. 
Tetracycline-Response-Element (TRE) is shown in maroon.
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Half ligation mixture was used to transform 50 |il of Max efficiency DH5a 
competent cells (Invitrogen Inc., Carlsband, CA), which have a transfection 
efficiency of 10 .^ The transformation mixture was spread on YT agar plates with 
100 pg/ml of ampicillin (Roche Diagnostics, Mannheim, Germany) and grown at 
37°C for 18 h. 10 colonies selected for ampicillin resistance were isolated from 
Q the plate using a sterile pipette tip and used to inoculate 5 ml of YT with 100
p. |ig/ml of ampicillin. After 10 h, bacteria from 2 ml of culture were harvested by
centrifugation at 10,000 x g for 5 min in a microcentrifuge (Biofuge, Heraeus, 
Hanau, Germany). After pouring off the supernatant, plasmid DNA was isolated 
"I from cell pellet using the Wizard Plus SV Minipreps DNA Purification System
(Promega Corporation, Madison, Wisconsin). Half of the total DNA sample (25
n
Lj pil) was digested with 0.5 \ i \ of Pst I and 0.5 \ i \ of Not I in a final volume of 30 \x\
D
D for 2 h at 37°C to release insert DNA from the plasmid. To screen for the 
presence of the insert 10 fxl of digestion product were loaded on 1% agarose.
J Two colonies for each construct were chosen based on the presence of
” j the insert and the absence of abnormal products of digestion. 2 ml of the
corresponding starting liquid culture was used to inoculate 250 ml of fresh 
selective YT medium and grown at 37°C with vigorous shaking (300 rpm). After 
^  18 h, 0.85 ml of bacterial culture was added to a labelled tube containing 0.15
ml of sterile glycerol, vortexed and transferred to -70°C for long-term storage. 
Plasmid DNA was purified using a QIAfilter Plasmid Maxi kit (Qiagen Inc., 
^  Valencia, California) from 200 ml of bacterial culture. To check the plasmid
preparation 1 pg of purified DNA was digested with 2 U of Pst I and 2 U of Not I 
in a final volume of 30 pi for 2 h at 37°C. 0.5 pg of digested plasmid was loaded 
on 1% agarose gel.
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cDNAs were sequenced with the ABI Prism Dye Terminator Cycle ready 
reaction Kit (Perkin Elmer Inc., Wallesley, Massachusetts). The sequencing 
Q reaction mix contained 500 ng of plasmid and 6.4 pmol of primer. Primers were
designed following two criteria: 1) percentage of CG between 40 and 60%; 2) 
length between 17 and 25 nucleotides; 3) Tm between 39° and 45°C. Primers 
were: 5'-TTAGTGAACCGTCAGATC-3' and 5’-ACTGCATTCTAGTTGTGG-3’ 
spanning respectively nucleotides 85-105 and 7745-7762 of the pBI-G vector, 
oligonucleotide 5’-TGCCAAAATGGATCATGG-3’spanning residues 407-424 of 
J  wild-type PrP cDNA.
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2.2 Cell culture
2.2.1 PC12 Tet-on culture
P C I2 Tet-on cells, expressing the rtTA were kindly donated by Dr 
J  Jornvall, Karolinska Institute, Sweden. Cells were grown in Dulbecco’s modified
1  Eagle’s medium (see appendix) at 37°C, in a 5% CO2 atmosphere, on dishes
(BD Falcon, Franklin Lakes, NJ) coated with poly-L-lysine (Sigma Aldrich Co., 
St. Louis, Missouri). They were routinely split by trypsinization to reduce the 
J  formation of cell clumps. To split cells, medium was removed from confluent
dishes. After washing with phosphate buffer saline (PBS, Invitrogen, Inc., 
Carlsband, California), to remove any trace of serum (that inhibits trypsin), cell 
Q were incubated with a minimal volume of trypsin/EDTA solution (500 \ i \  in 60-
mm dishes, 1 ml in 100-mm dishes or 75 cm^ flasks) for 3 min at 37°C. Trypsin 
was inhibited by adding 5-10 ml of fresh medium and cells were seeded in the 
appropriate dishes. When necessary, after having inhibited trypsin, cells were
counted in a Burker chamber. To this aim, 10 pi of cell suspension were
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pipetted in the chamber and counted; the average was calculated on the count 
of three independent squares.
2.2.2 Cell freezing and thawing
Cells were seeded on 100-mm poly-L-lysine coated plates and left grown 
until confluence was reached. Cells were subsequently washed, trypsinized (as 
described above) and resuspended in 10 ml of regular medium. Cell suspension 
was transferred in a 15-ml sterile tube and centrifuged at 1,000 x g for 5 min in 
a 5804R centrifuge (Eppendorf AG, Hamburg, Germany), equipped with a A-4- 
81 rotor. Pellet was resuspended in 5 ml of cold medium containing 10% 
dimethyl sulfoxide (DMSO) (see appendix), divided in 5 criovials (Nalge 
Company, Rochester, New York) and left on ice for 30 min. Vials were 
^  subsequently transferred to a criobox (Nalge Company, Rochester, New York)
P  and pre-frozen at -80°C for 8 h before stocking in liquid nitrogen.
To thaw cells, the frozen vial was incubated at 37°C for 1 min. The cell 
"] suspension was immediately transferred to a 15-ml tube containing 10 ml of
regular medium without selective agents and centrifuged at 1,000 x g for 5 min 
in a 5804 centrifuge (Eppendorf AG, Hamburg, Germany). Cell pellet was
resuspended in 5 ml of medium and cells transferred on a 60-mm dish coated 
with poly-L-lysine. When necessary, selective agents were added after 18 h.
D 
D
1  2.2.3 Test sera for Doxycycline contamination
J  Three lots of horse serum (HS) were tested for doxycycline (Dox, Sigma
Aldrich Co., St. Louis, MO) contamination using the CH0-AA8-Luc control Cell 
Line (kindly donated by Dr Jornvall, Karolinska Institute, Sweden), expressing
118
uD
n
D
D
D
D
D
D
D
n
the tTA. CHO were grown in alpha-minimal essential medium (MEM-a) (see 
appendix) on 60-mm dishes without coating. They were trypsinized, frozen and 
thawed as described for PC12 cells. To test each lot, 6 aliquots of 0.5 x 10  ^
CHO-AAS-Luc Tet-off cells were plated into 2 ml of complete alpha-minimal 
essential medium supplemented with 10% HS of the lot to be tested in 6-well 
culture plates. The inducer (Dox) was added to a final concentration of 10"^ , 10* 
10'\ 10 and 10^ ng/ml and the cells were grown for 48 h. Each sample was 
assayed for luciferase activity using the Luciferase Reporter assay Kit (BD 
Clontech, Palo Alto, California). None of the lots of HS tested showed Dox 
contamination.
2.2.4 Transfection
2.2.4.1 Transient transfection
PC12 Tet-on cells, stably expressing the reverse controlled 
transactivator, were plated on a 6-well plate (BD Falcon, Franklin Lakes, NJ) 
and transfected with lipofectAM IN E Plus reagent (Invitrogen Inc., Carlsband, 
California) when cells reached 80% confluence. 0.4 pg of pBI-G and 4 pg of
"I pTeT-tTS, or 4 pg of pBI-G alone were diluted in a vial containing 200 pi of
O ptiMEM (Invitrogen Inc., Carlsband, California ) (vial n°1 and 2, solution A). A
third vial contained O ptiMEM, without DNA (vial n°3, solution A). At the same 
time, three mixtures of solution B were made, by mixing 200 pi of O ptiMEM with 
20 pi of l ip o f e c tAM IN E. Solutions A and B were combined, mixed and 
^  incubated at room temperature for 15 minutes to allow DNA-liposome
^  complexes to form. During incubation time, regular medium was removed from
P cells, by rinsing with PBS. At the end of the incubation time 1.6 ml of O ptiMEMJ 119
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was added to the tube containing the complexes and overlaid onto the rinsed 
cells. In particular, each mixture was equally divided in two wells (1 ml/well). 
Cell were incubated for 6 h at 37°C before adding 1 ml of regular medium 
containing twice the normal concentration of sera. This medium was replaced 
with fresh complete medium after 18 h. X-gal staining was performed 48 h after 
transfection.
2.2.4.2 Stable transfection
PC12 Tet-on cells, stably expressing the reverse controlled 
transactivator, were plated on seven 100-mm dishes and transfected with 
lipofectA M IN E  Plus reagent when cells reached 80% confluence. Five vials 
J  contained 0.8 pg of pBI-G/PrP (WT or M128V or D177N/Met128 or
1  D177NA/al128 or PG14), 8 pg of pTeT-tTS (encoding for tTS) and 0.1 pg of
pTK-Flyg (encoding for hygromycin resistance) in 100 pi of O ptiMEM  (solution 
A) (Figure 2.2). One vial differed for the presence of 0.8 pg of the empty pBI-G
n
J  (without the insert) and another for the absence of pTK-Hyg plasmid. Seven
vials were subsequently prepared, each containing 100 p i of lipofectA M IN E  
diluted in 100 pi of O ptiMEM (solution B). Solution A and B were combined.
mixed gently and incubated at room temperature for 15 min before adding 6.7 
ml of O ptiMEM. This final solution was dropped on rinsed cells and incubated at 
37°C for 6 h in a CO2 incubator. Following incubation, 7 ml of growth medium 
containing twice the normal concentration of serum were added. Transfection 
J  medium, which did not contain antibiotics nor selective agents, was replaced
with fresh regular medium after 18 h. Cells were grown for 4 weeks in the 
presence of 80 pg/ml hygromycine (Sigma Aldrich Co., St. Louis, Missouri)
120
uadded to the culture medium 72 h post transfection. Every two days half of the 
■J medium was removed and fresh medium was gently added to the cells.
^  Individual clones were picked up by pipetting and seeded in a microtiter
plate (BD Falcon, Franklin Lakes, New Jersey) coated with poly-L-lysine. At 
confluence, each clone was split in two wells of a 48-well plate (BD Falcon, 
Franklin Lakes, New Jersey) (1/3 of the cells in one well and 2/3 in the other). 
The more concentrated well, which reached the confluence quickly, was 
induced for 24 h with 1 pg/ml of Dox and screened for PrP expression by
D
nJ  Western blot with anti-PrP antibody 3F4. Clones expressing PrP were
1  progressively expanded in wells with a bigger diameter, while the non­
expressing clones were discarded. Each positive clone, grown in a 100 mm dish 
J  was frozen. Finally, in order to exclude background expression in the absence
J  of the inducer and to compare the expression level after induction, each clone
was treated with 0-1 pg/ml of Dox and analysed by Western blot. To screen celln
LI transfected with the empty pBI-G, p-galactosidase activity was revealed by X-
D
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gal staining (see below) after Dox induction.
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Figure 2.2: Scheme of transfection.
PC12 Tet-on, expressing rtTA, were transfected with pBI-G/PrP, pTK-Hyg, 
pTet-tTS as described in chapter 2. After selection with 80 ng/ml hygromycine 
clones were amplified and screened for PrP expression.
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^ 2.2.5 Neuronal differentiation
nJ To induce neuronal differentiation, 5,000 PC12 cells/well were seeded on
96-well plate coated with rat tail collagen. The day following plating, the medium 
was replaced by low serum medium (see appendix) containing 100 ng/ml Nerve 
Growth Factor (NGF, Harlan Inc., Indianapolis, Indiana) and 200 fxM 8-(4- 
chlorophenylthio)adenosine3’:5’-cyclic monophosphate sodium salt (CPT- 
cAMP, Roche Diagnostics, Mannheim, Germany). Cells were used after 7 days
nu  of NGF treatment, when 80% of cells were differentiated, as judged by neurite
D
D
D
^  outgrowth.
' 2.2.6 Microglia and PC12 co-culture
nJ  Microglia cultures were prepared by dissociating cerebral cortices of newborn
"j rats. Brains from post-natal day 0-5 rats pups were dissected from the skull and
meninges removed. Tissue was transferred in a 15-ml tube containing 3 ml of
LI PBS and centrifuged at 1,000 x g for 5 min in a 5804R centrifuge (Eppendorf
1 AG, Hamburg, Germany), equipped with a A-4-81 rotor. PBS was subsequently
removed and 2 ml of medium was added. Tissue was disrupted by pipetting andn
J  resuspended cells were seeded on poly-L-lysine coated 75-cm^ flasks. Cultures
were maintained at 37°C with 5% CO2 for 2 weeks until glia cultures were 
confluent.
4 x 10® PC I2 cells were plated on 100-mm dishes coated with rat-tail 
collagen (150 jxg/ml in 30% ethanol) and differentiated as described in section
P  2.2.5. After 7 days cells were washed with PBS, trypsinized and counted.
30,000 cells were diluted in 100 \x\ of DMEM containing 10% FBS, 2 mM
nJ 123
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uglutamine, 5 mM penicillin/streptomycin and 100 ng/mi NGF and seeded on the 
D coliagenated 96-well dish. The day after plating P C I2 microglial cells were
isolated from 75-cm^ flasks by shaking cultures at 260 rpm for 18 h. Microglia 
dislodged into the medium was further purified and counted. 50,000 cells were 
diluted in DMEM containing 10% FBS, 2 mM glutamine, 5 mM 
penicillin/streptomycin and 100 ng/ml NGF, and added to PC I2 cell cultures.
The day after PC12 alone or co-cultured were incubated with 0-1 pg/ml of 
Dox for 48 h before proceeding with MTT assay.
D
2.2.7 Cell viability
Cells were plated in 96-well plate (20,000 c/w) and treated for 24-96 h
1  '
^  with 0-3 (ig/ml Dox before testing cell viability. Medium was replaced every two
| j  days and fresh Dox was added. To test cell viability of NGF-treated P C I2 Tet-
p. on cells, 4x10® PC I2 cells were plated into 100-mm dishes coated with rat-tail
collagen (150 p,g/ml in 30% ethanol) and differentiated as described in section 
2.2.5. After 7 days cells were washed with PBS, trypsinized and counted.
20.000 cells were plated in 96-well plate and treated for 48-96 h with Dox. In 
order to test the effect of PrP expression under stress conditions, cells were 
also cultured in the absence of serum or in the presence of hydrogen peroxide 
(H2O2) or tunicamycin (Sigma Aldrich Co., St. Louis, Missouri). In the first case
20.000 cells/well were plated in regular medium, treated with 0-1 pg/ml Dox for 
24 h before removing serum. Viability was measured after overnight serum 
deprivation. Alternatively, cells were plated and induced for 24 h with 0-1 pg/ml 
Dox before treating with 0-75 pM H2O2 or 0-5 pg/ml tunicamycin for 18 h. In 
each experiments, one well for each condition was lysed in 30 \ i \  of Laemli
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buffer 1X and PrP induction was tested by Western Blotting. Cell viability was 
measured by determining the reduction of 3-(4,5-dimethylthiazole-2yl)-2,5- 
diphenyltetrazolium bromide (MTT, Sigma Aldrich Co., St. Louis, Missouri) or by 
staining DNA with crystal violet (Sigma Aldrich Co., St. Louis, MO). 15 pil of MTT 
were added to each well containing 150 \ i \ of medium followed by incubation for 
2 h at 37°C in a humidified incubator. 200 \x\ of acidic propanol was added to 
dissolve the blue formazan crystals. The absorbance of the solution was read at 
540 nm wavelength using a Labsystem Multiskan (Dasit S.p.A, Cornaredo, 
Italy). For crystal violet staining cells were washed with PBS and 100 \ i \  of 
crystal violet solution was added to each well for 2 minutes. Plates were 
abundantly washed with H2O and air-dried. 100 pil of citrate solution was added 
to dissolve the crystals. The absorbance of the solution was read at 540 nm 
wavelength using a Labsystem Multiskan. Viability was expressed as a mean 
percentage of absorbance of control cells ± s.d.
2.3 Biochemical analyses
2.3.1 Screening of clones
To assay PrP expression, each clone was seeded in 2 wells of a 48-well 
dish (BD Falcon, Franklin Lakes, New Jersey), and incubated with or without 1 
[ig/ml Dox for 24 h. Each well was washed with PBS and 60 \ i \ of Laemli sample 
buffer IX  were added. Samples were heated for 5 min at 95°C, and 25 \x\ were 
analysed by Western blot using antibody 3F4 (1:5,000, see below).
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2.3.2 Protein quantification
Protein extracted from cellular lysates were quantified using the BCA 
Protein assay Reagent Kit (Pierce Inc., Rockford, Illinois). This is a colorimetric 
method based on the biuretic reaction, i.e. the reduction of Cu^ "^  to Cu^^ by 
proteins. 25 \x\ of cellular lysate diluted 1:5 and 1:10 in H2O were pipetted into 
one microplate well. A fresh set of protein standard was prepared by serially 
diluting bovine serum albumine (BSA) stock solution (2 mg/ml). 200 \ i \  of 
reaction mix, prepared by mixing 50 parts of BCA reagent A with 1 part of BCA 
reagent B, was subsequently added to each well and incubated for 30 min at 
37“C. The absorbance of the solution was read at 570 nm wavelength using a 
Labsystem Multiskan (Dasit).
2.3.3 Detergent insolubility and Proteinase-K (PK) resistance assays
To assay detergent insolubility and PK resistance of PrP, cells were 
seeded in a 25-cm^ flask (BD Falcon, Franklin Lakes, NJ) and treated with 1 
J  pg/ml Dox when cells reached 90% confluence. After 24 h induction cells were
lysed in 1.5 ml of lysis buffer at 4° C for 20 min. Lysates were centrifuged at
14,000 X g in a 5804R Eppendorf centrifuge (Eppendorf AG, Hamburg, 
Germany) equipped with a F-45-30-11 rotor for 5 min at 4°C and protein 
concentration of the supernatant was measured with the BCA protein assay, as 
described. 100 ^g were subsequently centrifuged for 40 min at 186,000 x g in 
OPTIMA MAX-E ultracentrifuge (Beckman Coulter Inc., Fullerton, California) 
with a TLA-55 rotor to separate the soluble (S) from the insoluble (P) fraction. 
Soluble proteins were precipitated with 4 volumes of methanol for 2 h at -20°C,
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followed by 30 min at 14,000 x g with a T-60-11 rotor. In this rotor samples are 
J  centrifuged horizontally, allowing concentration of the pellet on the bottom of the
Q tube instead of tube wall, thus facilitating recovery of the precipitated proteins. S
and P fractions were finally resuspended in 25 |il of Laemli sample buffer IX  
and analyzed by Western blot (see below) using the mouse monoclonal anti- 
PrP antibody 3F4.
To assay PK resistance 300 p,g of protein extracts were digested with 
0.25-0.5 pg/ml of PK for 30 min at 37°C. Digestion was terminated by addition 
of phenylmethanesulfonyl fluoride (PMSF, Roche Diagnostics, Mannheim, 
Germany) to a final concentration of 5 mM. Proteins were methanol-precipitated 
and resuspehded in 25 \jl\ of Laemli sample buffer IX  before Western blot 
analysis.
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2.3.4 Western blot analysis
Proteins were denatured by heating for 5 min at 95°C in Laemli sample 
buffer IX, briefly spun in a 5415D microcentrifuge (Eppendorf AG, Hamburg, 
Germany) and loaded on 12% SDS-PAGE (sodium dodecyl suiphate- 
polyacrylamide gels). Gels were run for 2 h at 100 V in a Mini-PROTEAN® 
electrophoresis cell (Biorad Laboratories Inc., Hercules, California). Separated 
proteins were transfered to a polyvinylidene fluoride membrane (PVDF, 
Millipore Corporation, Bedford, Massachusetts) applying a constant current of 
350 mA to a Mini Trans-blot® (Biorad Laboratories Inc., Hercules, California) 
apparatus for 1 h. Membranes were blocked with 5% non-fat-dry milk (NFDM) in 
TTBS (see appendix) before incubation with primary antibody. Primary 
antibodies were diluted in blocking solution and incubated for 1 h at room
127
utemperature or over-night at 4°C. Membranes were washed 3 x 1 0  min in TTBSn
U to remove unbound antibody, followed by incubation for 1 h at room
temperature with IgG peroxidase-conjugated secondary antibodies. Membranes 
were washed 3 x 1 0  min in TTBS before detection with Enhancedn^ Chemiluminescence (ECL, Amersham Biosciences UK Ltd, Little Chalfont,
1  Buckinghamshire, England). This system uses horseradish peroxidase (HRP)-
conjugated secondary antibodies for luminol-based detection. The oxidation of 
luminol by the HRP is detected by exposure to autoradiography films.D
n
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2.4 RNA analysis
Cells were plated on 60-mm dishes, treated for 24 or 96 h with 0-1 [xg/ml 
of Dox. At the same time, in order to test PrP expression cell were seeded in a 
]  48-well plate, treated with 0-Vg/m l Dox for 24 or 96 h and lysed in 60 \x\ of
0
0
Laemli sample buffer IX. 30 \x\ were loaded on 12% SDS-gel and blotted with 
antibody 3F4.
To isolate RNA, cells were chilled on ice and rinsed with cold PBS before
1  adding 1 ml of RNAwiz (Ambion Inc., Austin, Texas). Cell lysates was
transferred to a sterile tube and incubated at room temperature for 5 min. After 
J  adding 200 \ i \ (0.2 X starting volume) of chloroform, following 10 min incubation,
J  samples were centrifuged at 14,000 x g for 15 min at 4°C in a 5804R Eppendorf
centrifuge (Eppendorf AG, Hamburg, Germany ) equipped with a F-45-30-11 
rotor. The mixtures separated into three phases, the upper containing RNA, the 
semi-solid interphase containing DNA, and the lower corresponding to the 
organic phase, containing proteins and lipids. The upper phase was carefully 
transferred to a clean, sterile tube and diluted with 500 pil (0.5 X startingD
D
n
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volume) of of RNase-free water before adding 1 ml (1 X starting volume) of 
isopropanol. Samples were incubated at room temperature for 10 min and 
finally centrifuged at 14,000 x g  for 15 min at 4°C in a with a T-60-11 rotor to 
pellet RNA directly on the bottom of the tube. RNA was washed with 1 ml ofnL-i 75% ethanol, vortexed and centrifuged at 14,000 x g for 5 min. Supernatant was
"J discarded and RNA was air dried and resuspended in 30 p,l of RNase-free
water.n To isolate RNA from tissue, half a brain of the entire cerebellum were
n
J  homogenized respectively in 2.5 ml or 1 ml of RNAwiz using a glass/Teflon
D
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homogenizer; 1 ml of sample was processed as described for cultured cells.
2.4.1 Northern blot
2.4.1.1 Probe labelling
nJ  Mouse PrP cDNAs (3F4 tagged), hamster CHOP cDNA, mouse BiP
cDNA and mouse GAD PH (glyceraldehyde-3 phosphate-dehydrogenase) were 
used as a template for preparation of the probes. Probes were labelled by the 
Gene Images Random-Prime Labelling module (Amersham Biosciences UK 
n  Ltd, Little Chalfont, Buckinghamshire, England). 10 pg of pCDNA3/moPrPWT
and pTZ/moCHOP were digested with specific restriction enzymes to release
n
J  cDNAs. In particular, pBC12/moPrPWT was digested with 20 U of Hind III and
Bam HI (Roche Diagnostics, Mannheim, Germany) and pTZ/moCHOP was 
digested with 20 U of Xba I and Bam HI. Fragments were separated by 
electrophoresis on 0.5% agarose low-melting gel and purified with ELUTIP
J  minicolums. BiP and GADPH cDNAs were kindly provided by Professor Sitia
(San Raffaele Scientific Institute, Dibit, Milan). 50 ng of denatured DNA were
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incubated for 1 h at 37°C with 10 p,! of nucleotide mix (dATP, dTTP, fluorescein- 
dUTP, dCTP and dGTP), 5 \x\ of primers and 5 U of Kienow DNA polymerase in 
a final volume of 50 1^ (all the reagents were provided by the kit). Reaction was 
terminated by adding 20 mM ethylenediaminetetraacetic acid (EDTA). In this 
reaction fluorescein-11-dUTP partially replaces dTTP so that fluorescein- 
labelled probe is generated. Detection relies on anti-fluorescein antibody 
conjugated with alkaline phosphatase, thus avoiding the use of radioactive 
labelling. The enzyme catalyses breakdown of the CDP star substrate 
(disodium 2-ch loro -5-(4 -m ethoxysp iro {1 ,2-d ioxe tane-3 ,2 '-(5 '-ch lo ro ) 
tricyclodecan}-4-yl)-1-phenyl phosphate) producing a chemiluminiscent signal. 
Detection reagents were provided by Gene Image Detection System 
(Amersham Biosciences UK Ltd, Little Chalfont, Buckinghamshire, England).
2.4.1.2 Electrophoresis and Blotting
20 \ ig  of total RNA was heated for 15 min at 65°C in denaturing buffer, 
and chilled on ice. Loading buffer was added to the samples before loading on 
1.25 % agarose gel containing 6% formaldehyde. Gel was run submerged in 
running buffer at 4 V/cm. After viewing by ultraviolet illumination to check RNA 
quality (Ethidium Bromide, which binds nucleic acids is excited by UV light), 
RNA was transfered on a nylon membrane (Hybond-N+, Amersham 
Biosciences UK Ltd, Little Chalfont, Buckinghamshire, England) by capillary 
elution for 18 h and subsequently immobilized by baking the membrane for 2 h 
^  at 80°C. After transfer, the blot was rinsed in SSC 2X (sodium chloride sodium
citric acid), pre-hybridised for 2 h at 60°C in hybridisation buffer and hybridised 
for 18 h at 60°C with the fluorescein-labelled probe (1:1,000 in hybridisation
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ubuffer). Probe was removed by washing once with SSC 2X, 0.1% SDS for 15 
J min at room temperature, once with SSC IX, 0.1% SDS for 15 min at 65°C, and
^  once with SSC 0.5X, 0.1% SDS for 15 min at 65°C. Membrane was pre­
incubated with 5% NFDM in buffer A (blocking buffer) for 2 h at room 
temperature before incubating with alkaline phosphatase-conjugated anti­
fluorescein antibody (1:5,000 in blocking buffer) for 1 h at room temperature. 
Unbound antibody was removed by rinsing 4 times with buffer A containing 
0.3% Tween-20 and once with buffer A without Tween-20. Membrane was 
1  finally incubated for 5 min with 3 ml of CDP star and exposed to Hyperfilm-MP
film (Amersham Biosciences UK Ltd, Little Chalfont, Buckinghamshire, 
England).
n
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2.4.2 Reverse transcriptase-polymerase chain reaction (RT-PCR)
200-500 ng of RNA was primed by incubating at 65®C for 5 min with 300 
ng oligo(dT) (Promega Corporation, Madison, Wisconsin). First strand cDNA 
J  synthesis was carried out for 1 h at 42°C using 4 pi of 5X reverse transcriptase
p  buffer, 0.6 mM dNTP, 10 U of Avian Myeloblastosis Virus (AMV) Reverse
Transcriptase and 20 U of Rnasin Ribonuclease inhibitor (Promega 
1  Corporation, Madison, Wisconsin) in a final volume of 20 pi. 5 pi of the reaction
mixture was subjected to PCR in a reaction mixture (50 pi) composed of 2.5 
units Tag polymerase (Promega Corporation, Madison, Wisconsin), 5 pi buffer 
10X (500 mM KCI, 100 mM Tris-HCI pH 9, 1% Triton X-100) 0.25 mM dNTP, 
^  1.5 mM MgCb, and 300 ng each primer. The primer pairs used for PCR reaction
J
were MXBP1-534: 5’-CCTTGTGGTTGAGAACCAGG-3’ (forward) plus MXBP1- 
804: 5’-CTAGAGGCTTGGTGTATAC-3’ (reverse). 30 thermal cycles comprised
D
□
D
D 131
uD
]
D
n
D
D
J
]
94°C for 30 s, 55°C for 30 s and 72°C for 2 min. 10 pi of the PCR products were 
subjected to electrophoresis on 2% agarose gel.
2.5 Cell imaging
2.5.1 Immunofluorescence
J  PC I2 cells were seeded on poly-L-lysine-coated glass coverslips in 24-
well plates at 50% confluence and induced to express PrP by treating them for 
24 h with 1 pg/ml of Dox. Alternatively, cells were differentiated as described in 
section 2.2.5 before proceeding with immunofluorescence. For surface staining 
of PrP, living cells were incubated with anti-PrP 3F4 antibody (1:500 in
i i-
OPTIMEM) for 1 h at 4°C, washed with ice-cold PBS and fixed in 4% 
paraformaldehyde (PFA) for 1 h at 4°C. After washing with PBS, cells were 
incubated in blocking buffer for 30 min at room temperature and subsequently 
with Alexa 488(green)-conjugated goat anti-mouse IgG (Molecular probes Inc., 
Eugene, Oregon) (1:500 in blocking buffer). After 1 h incubation at room 
temperature cells were rinsed and mounted in FluorSave (Calbiochem 
Corporation, San Diego, California). To visualise intracellular PrP and other
D  intracellular antigens, cells were washed with PBS and fixed in 4% PFA for 1 h
"[ at 4°C. Cells were then rinsed, permeabilized with 0.1% Triton X-100 for 2 min
and blocked for 1 h at room temperature with blocking buffer. Primary antibody1 ■
^  (in blocking solution) was then incubated for 1 h at room temperature. Cells
were rinsed in 0.1% Tween-20/PBS and incubated with Alexa 488(green)- or 
546(red)-conjugated secondary antibody before mounting. To perform co­
localisation experiments, anti-PrP antibody was first incubated, followed by the
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corresponding secondary antibody, before proceeding with organelle markers 
staining. Cells were viewed on BX61 Olympus Fluorescence microscope 
1  equipped with Olympus Fluorview laser confocal scanning system. Digital
images were processed using Adobe Photoshop (Adobe Systems, San Jose, 
California).D
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2.5.2 Apoptosis Detection
To investigate if mutant PrP expression induced apoptosis, cells were 
seeded on poly-L-lysine-coated glass coverslips in 24-well plates at 30-40% 
confluence and induced to express PrP by treating them with 0-1 pg/ml Dox. 
After 24-96 h propidium iodide staining or tdT-mediated dUTP-X nick end 
labelling (TUNEL staining) were performed.
2.5.2.1 Staining with propidium iodide (PI)
Propidium iodide (Pi) is a fluorescent stain for nucleic acid, that allow 
detection of apoptotic cells by morphological analysis of nuclei that appear 
fragmented and pyknotic.
After PrP induction, cells were washed with PBS and fixed in methanol/ 
acetic acid (3:1) for 5 min at 4°C. Cells were subsequently rinsed and a mixture 
1  containing PI was added for 30 min and rinsed again. After mounting, slides
were viewed on BX61 Olympus Fluorescence microscope equipped with 
Olympus Fluorview laser confocal scanning system.
PI staining was also coupled with PrP immunostaining. In this case cells
"j were fixed in methanol/acetic acid (3:1) for 5 min at 4°C, washed and
J
subsequently incubated with antibody 3F4 without previous treatment with
133
uTriton X-100 (this fixation procedure permeabiiises cell membranes). Cells weren
u  subsequently treated as previously described (see section 2.5.1).
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2.S.2.2 TUNEL staining
Because in apoptotic cells DNA is nicked, terminal deoxynucleotidyl 
transferase (tdT) was used to catalyse the addition of deoxyuridinetriphosphate 
(dUTP) conjugated with biotin to the 3’-0H terminus of DNA molecules. 
Apoptotic nuclei were subsequently detected using fluorocrome-labelled avidin. 
]  After PrP induction cells were washed briefly with PBS and fixed in 4%
J  PFA for 1 h at 4°C. Cells were then rinsed and incubated for 30 min in 300 pi of
saponin solution. Cells were washed 5 times in PBS (2 min each wash) and 
^  incubated in tdT reaction mixture for 1 h in a moist chamber at 37°C. After
J  rinsing 3 times in PBS, cells were blocked in blocking buffer and subsequently
incubated with avidin-488 (Molecular probes Inc., Eugene, Oregon) (1:500 in 
staining buffer) respectively for 30 min and 1 h at room temperature. Cells were 
J  washed, mounted and viewed on BX61 Olympus Fluorescence microscope
^  equipped with Olympus Fluorview laser confocal scanning system.
TUNEL staining was also coupled with 3F4 staining. In this case, internal
"I
J  staining for PrP was performed as described in section 2.5.1. After viewing PrP
staining, cells were directly incubated with tdT reaction mixture, without 
previous saponin treatment. The experiment was subsequently performed as
nJ  described above.
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2.5.3 p-galactosidase activity assay
Expression of p-galactosidase is indirectly evaluated by testing its 
enzymatic activity. If p-galactosidase is expressed, in the presence of the 
chromogenic substrate 5-bromo-4chloro-3indolyl-p-d-galactoside (X-gal) blue 
cells are detectable.
Cells were seeded in 24-well plates and induced with 1 pg/ml Dox for 24 
J h. Cells were subsequently fixed in 2% paraformaldehyde, 0.2% glutaraldehyde
1  for 5 min at room temperature and rinsed with PBS before adding 500 pi of X-
gal mixture. Samples were viewed after 2-8 h of incubation at 37°C.
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Chapter 3: Results
1.1 Development of PC12-Tet on cells expressing WT and
mutant PrPs
n
J  3.1.1 Generation of constructs encoding PrP from the Tet-on promoter
In order to facilitate the detection of transfected protein, the 3F4 epitope 
n tag was introduced in mouse PrP sequence. The substitutions L108M and
V111M corresponding to the 3F4 epitope had been previously introduced into
1J  wild-type niouse cDNA or appropriate mouse constructs carrying pathogenic
n  mutations in the laboratory of Dr David Harris, Washington University School of
Medicine, St. Louis Missouri. cDNAs encoding 3F4-tagged mouse wild-type PrP 
(M128, WT), M128V PrP, as well mouse PrP homologues of the human D178N 
(D177N/M128 and D177NA/128) and nine-octapeptide (PG14) mutations had 
been cloned into Hind III and Bam HI restriction sites of pCDNA3 vector. In 
order to sub-clone these cDNAs into pBI-G vector, harbouring the tetracycline- 
responsive element, Pst I and Not I restriction sites were inserted respectively 
to the 5’ and 3’ of the PrP ORF by PCR. Five different PCR reactions were run, 
using as a template one of each of the different cDNAs cloned in pCDNA3. 
When 2 ^1 of PCR product were run on a 1% agarose gel, a band of 
approximately 800 bp was detected for the WT construct and the constructs 
carrying the point mutations, and of 1000 bp for the PG14 construct (Figure 
3.1). These corresponded to the expected lengths, suggesting a correct 
amplification of the bands.
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Figure 3.1: Insertion of Pst I and Not I restriction sites respectively to 5’ 
and 3' of PrP cDNAs.
5 different PCR reactions were performed using M128, M128V, D177N/M128, 
D177NA/128 or PG14 cDNAs cloned in pCDNA3 as a template and primers 
containing the Pst I and Not I restriction sites. 2 iil of PCR products were run on 
1% agarose gel (lanes 1-5). DNA molecular weight markers (HyperLadder, 
Bioline) are given in bp (lane 6).
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PCR products were digested with Pst I and Not 1; pBl-G vector was 
digested with the same enzymes and the 5’ phosphates were removed from
J  both termini by alkaline phosphatase to minimize the possibility that the plasmid
recircularized during the ligation reaction.
Ligation of the cDNA insert to the plasmid involves the formation of new 
bonds between phosphate residues at the 5’ termini of double-stranded DNA 
and adjacent 3'-hydroxyl moieties. For each construct a different ligation 
reactions was prepared: reaction 1 contained cDNA plus plasmid pBI-G 
digested and dephosphoylated; reaction 2 contained pBI-G digested and 
p. dephosphoylated alone; reaction 3 contained 100 pg of circular pBI-G; and
reaction 4 contained no DNA. E s c h e r ic h ia  C o l i competent cells (DH5a strain)
n
J  were subsequently transformed with each reaction mixtufes, incubated at 37°C
n  in liquid medium to allow expression of ampicillin resistance and subsequently
plated on ampicillin (100 pg/ml)-containing agar plates. Plates were examined 
after overnight incubation at 37°C: 20-30 colonies were recovered in plate 1,
n containing cells transformed with both insert DNA and plasmid; 1-2 colonies
J
grew on plate 2 containing cells transform ed with restriction 
digested/dephosphorilated pBI-G; 400-500 colonies grew on plate 3, containing 
cells transformed with circular pBI-G and no colonies grew on plate 4. Table III.I 
summarises the transformation experiment performed for each construct and 
the results obtained.
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Table lll.l: Schematic representation of ligation and transformation experiment
Transformed DNA
500 ng insert DNA, 100 ng pBl-G 
100 ng digested/dephosphorilated. 
pBI-G 
100 pg circular pBI-G
N° of colonies recovered
20-30
1-2
400-500
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uThese results demonstrated that both ligation and transformation 
^  experiments had been achieved. The result of plate 2 indicated that a small
U  percentage of the vector was able to recirculate, suggesting that a few of the
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colonies recovered from plate 1 could contain pBI-G without the insert.
To identify bacterial colonies containing recombinant plasmid, 10 
colonies were picked up from plate 1 and grown in 5 ml of YT liquid medium 
containing ampicillin. Plasmid DNA was extracted from bacteria grown in the 
liquid cultures, digested with Not I and Pst I and subsequently analysed on 1% 
agarose gel. On average, in approximately 6/10 colonies, 2 bands were 
detected, running at -10,000 bp and 800 bp (or 1000 bp for PG14), 
corresponding, respectively, to the linearized vector and the excided cDNA 
insert. In 2/10 colonies only the 10,000 bp band was detected, indicating the 
absence of the insert, and in 2/10 colonies no plasmid DNA at all was detected. 
Figure 3.2 shows an example of colony screening. In this case the insert 
(running at -800 bp) was detected in 4/8 colonies, while the rest of the colonies 
(4/8) were transformed with the empty pBI-G. For each construct, 2 colonies 
containing the recombinant plasmid were frozen at -80°C in 15% glycerol.
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Figure 3.2: Screening of bacterial clones.
In order to screen bacterial cells for the presence of the insert, plasmid DNA 
was extracted from different clones (clones A-H, lanes 2-9) and digested with 
Pst I and Not I. A band running at -800 bp states the presence of the insert 
(lanes 3, 6, 8, 9). DNA molecular weight markers ( HyperLadder, Bioline) are 
given in bp (lane 1).
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uTo exclude the presence of mismatched nucleotides and ensure correct 
-G orientation of PrP cDNAs inside the vector, the inserts and the flanking regions
2  of the plasmid extracted from the selected colonies were sequenced. From
sequence analysis of the wild-type construct, an insertion of -300 bp was 
discovered upstream to the Pst I restriction site, in both the colonies analysed. 
In particular, downstream from the promoter and upstream of the Pst I
n
p  restriction site, the first 300 nucleotides of mouse cDNA were erratically
 ^ inserted. In contrast, the M128V, D177/M128 and D177NA/128 and PG14
^  constructs were correctly inserted. In order to amplify in pBI-G/WT not only the
-n PrP cDNAs but even the flanking regions of the plasmid, PCR reactions were
performed, using primers p(85-105) and p(7745-7762), spanning respectively 
_ nucleotides 85-105 and 7745-7762 of the pBI-G vector. The same reaction was
"j run using pBI-G/M128V and pBI-G/D177N as controls. The PCR product
amplified from the WT construct revealed the presence of a band running -300
{
J  nucleotide higher than expected (see comparison with the band of the other
constructs in Figure 3.3), confirming that an additional fragment of the PrP 
cDNA sequence was inserted in the final construct.
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Figure 3.3: Screening of clones by PCR.
Three clones transformed with pBI-GAA/T PrP were analyzed for the presence 
of the 300 bp insertion. Construct purified from each clone was amplified by 
PCR using primers spanning the vector regions in the 5’ and 3’ of the cDNA 
insert (clones A, B, C, lanes 2-4). pBI-G/M128V PrP, previously checked by 
sequencing, was amplified as a control (5). DNA molecular weight markers 
(HyperLadder, Bioline) are given in bp (lane 1).
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uother colonies were picked up from plate 1 and analysed for the 
presence of the correct cDNA insert. None of the colonies analysed presented 
insert DNA with the expected molecular weight. For this reason, ligation of the 
wild-type PrP cDNA in pBI-G vector and transformation of bacterial cells were 
repeated as previously described. 5 colonies were picked up from the 
1  transformation plate and grown in 5 ml of YT/ampicillin medium. Plasmid DNA
was extracted from liquid culture and the presence of the insert was analysed 
by PCR using primers p(85-105) and p(7745-7762). In all the colonies the 
amplification gave rise to a band of -800 bp corresponding to the expected 
molecular weight. Finally, the absence of mismatched nucleotides and the 
correct orientation of the cDNA insert were verified by DNA sequencing.
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3.1.2 Generation of PC12 Tet-on cells expressing PrP
p. A major aim of this study was to establish inducible PC12 cell lines using
J
the Tet-on expression system. For this reason we used the bidirectional pBI-G 
1  vector which allows coexpression of the gene of interest, PrP, and (3-
^  galactosidase. In order to prevent unregulated expression of PrP in the absence
of the inducer (Dox), we co-transfected the cells with pTet-tTS, encoding the tet- 
J controlled transcriptional silencer.
Preliminary experiments were conducted before performing the stable 
transfection. First, susceptibility of P C I2 Tet-on cells to the selecting agent 
hygromycin was tested by incubating the cells with increasing concentration of 
the antibiotic (0, 10, 20, 25, 50, 80, 100, 150, 200 pg/ml) for 15 days. Cell 
treated with 150 and 200 fig/ml hygromycin died after 24 h, while cells treated 
with 50-100 pg/ml of hygromycin died after 2-3 days. A dose level of 10-25
144
u
0
]
D
D
D
0
D
]
0
D
|ig/ml was not sufficient to kill cells. Because the optimal concentration should 
not kill cells immediately, allowing cells that have been transfected to recover 
from LIPOFECTAMINE toxicity and to express the resistance to the antibiotic, 
an optimal concentration of 80 p.g/ml was chosen for subsequent work.
Transient transfections were then performed in order to test the 
inducibility of the system. PC12 Tet-on cells were plated in a 6 wells-dish; two 
wells were transfected with pBI-G and pTet-tTS, two wells with pBI-G alone and 
two wells were mock transfected. At 24 h post transfection, one well for each 
treatment condition was treated with 1 |ig/ml Dox. Cells were then stained for (3- 
galactosidase activity after 24h of induction. Table III.II summarises this 
transfection experiment and the results obtained. As expected, (3-galactosidase 
activity was not found in wells (5 and 6) that were subjected to the transfection 
procedure in the absence of DNA. In cells transfected with pBI-G and pTet-tTS 
(wells 1, 2) and pBI-G alone (wells 3, 4) the presence of the inducer Dox (wells 
2, 4) activated (3-gal transcription and subsequent protein translation. In some 
cells transfected with pBI-G alone, a faint blue staining was detected even in the 
absence of the inducer (well 3), probably due to low, spontaneous expression of 
|3-galactosidase. Conversely, in the absence of Dox, no signal was detected in 
cell transfected with both pBI-G and pTet-tTS (well 1), indicating that expression 
of the tet-controlled transcriptional silencer effectively turned off expression in 
the absence of inducer. Of note, after induction, staining of cells transfected 
with pBI-G alone was higher than the one of cells transfected with both
plasmids. In particular, not only was the percentage of cells expressing the
J
enzyme higher but also the intensity of the blue signal was greater, indicating
J that a higher induction efficiency was achieved in the absence of the tet-
"] controlled transcriptional silencer. As the goal was to achieve tightly regulated
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expression of PrP and absence of leakage, rather than having high, 
supraphysiological expression levels, we chose to use the pTet-tTS in 
combination with pBI-G.
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Table 111.11: Schematic representation of transient transfection
(-). (+), (++) or (+++) in the fourth column represent the strength of |3-gal activity, as indicated by the 
intensity of the colour in blue cells. (-)= no enzymatic activity, (+)=low activity, (++)= good activity, 
(+++)=high activity.
Dox Percentage of cells p-gal
expressing |3-gal (strength)
activity
pBl-G, pTet-tTS 
pBl-G, pTet-tTS 
pBl-G 
pBl-G
++
+
+++
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Stable transfection was subsequently performed. pBI-G or pBI-G/PrP 
J plasmids were cotransfected with pTet-tTS and pTK-Hyg as described in the
1  Materials and Methods section. Table III.Ill summarises the experiment and the
results obtained.
Cells in plate 7 died after 1 week of hygromycine selection. Conversely, 4 
Q weeks after transfection, about 100 clones were clearly detectable in plates 1-6.
90 clones of each were picked, expanded and subsequently exposed to 1 pig/ml 
Dox for 24 h to induce PrP and |3-galactosidase expression. As revealed by 
Western blot analysis using anti-PrP antibody 3F4, which recognizes 
transgenically-encoded mouse PrP but not endogenous rat PrP, PrP specific 
signals were detected after induction in -5%  of clones (Figure 3.4 shows an 
examf)le of clone screening). Three bands of PrP were detected, corresponding 
to the un-glycosylated, mono-glycosylated and di-glycosylated forms in all the 
clones analysed (see also Figure 3.5), indicating that PrP expressed in PC12- 
Tet-on cells was correctly processed. Few clones showed leakage of PrP
D
n
J
D
n  expression, as manifested by low PrP expression in the absence of the inducer.
J
Clones that displayed no PrP expression in the absence of Dox, and that had
n
J  the highest and comparable PrP and |3-galactosidase expression level after 24
D
D
]
h of induction were chosen for subsequent experiments. Clones transfected 
with the empty vector, to be used as a control, were selected based on staining 
for (3-galactosidase activity.
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Table III.Ill: Schematic representation of stable transfection
1 Empty vector Yes Yes -100 90 4 0
2 WT PrP Yes Yes -100 90 7 1
3 128V PrP Yes Yes -100 90 6 0
4 D177N(128M) PrP Yes Yes -100 90 5 1
5 D177N(128V) PrP Yes Yes -100 90 5 0
6 PG14 PrP Yes Yes -100 90 4 0
7 Empty vector Yes No 0 - . -
149
I
I
I
I
I
I
I
D
0
D
D
D
D
D
I
I
R Tg(WT) A B C D E F G H  I L M N  O
0 
I  
I
Q 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
45-
30-
0##
Figure 3.4: Screening of clones selected for hygromycine resistance by 
Western blot.
Each clone was seeded in one well of a 48-well plate and induced for 24 h with 
Dox when reached confluency. After lysis samples were analyzed by Western 
blotting (clones A-0, lanes 3-15). PrP expression was detected only in two 
clones, E and L (respectively lanes 7 and 12), while the other clones did not 
respond to Dox treatment. 20 ug of brain lysate of Tg(WT), expressing 3F4- 
tagged WT, were loaded as a positive control (lane 1). These mice express 4 
fold the endogenous PrP level. Molecular weights are given in kilodaltons, as 
indicated by Rainbow Markers RNP756(Amersham Biosciences UK Ltd, Little 
Chalfont, Buckinghamshire, England) loaded in lane 2.
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3.1.3 Characterization of PrP expression by PC12 Tet-on cells
The dose-dependency and the kinetics of PrP induction were then 
analysed by monitoring PrP expression after exposure of cells to increasing 
concentrations and times of inducer. Cell transfected with wild-type, M128V, 
D177N/M128, D177NA/128 or PG14 PrP were treated for 24 h with a range of 
concentrations of Dox (0-2 (ig/ml) before lysis and Western blot analysis. As 
shown in Figure 3.5A, PrP expression was tightly regulated: it was undetectable 
in the absence of the inducer, and increased progressively in a dose-dependent 
manner within 0.1-0.5 pig/ml, reaching a maximum at 1 p.g/ml Dox. The 
expression level of transfected PrP at 1 pig/ml Dox was comparable to that of
i
endogenous PrP gene expression, as revealed by Northern blot and by 
Western blot with an antibody that recognizes rat and mouse PrP (Figure 3.5B).
j  To examine the time-course of PrP expression, cells were harvested at
different times after induction with 0.25 jig/mi Dox (Figure 3.50). PrP expression
was detected after 8 h, reached maximum levels at 24-48 h and lasted for at
1  least 96 h. The reversibility of the inducible system was tested by
removing/adding Dox (Figure 3.5D). Cells expressing WT PrP were induced for 
J  18 h with 1 |ig/ml of Dox (lanes 1-4) and chased in Dox-free medium for 0 h
(lane 1), 24 h (lane 2), or 36 h (lanes 3-4) before lysis. After 36 h of chase, cells 
were re-exposed to Dox for 18 h (lane 4). Cells in lane 5 and 6 were induced 
respectively for 18 or 72 h. The protein became undetectable after 24-36 of Dox 
J  withdrawal and could be reinduced in a second round of treatment with Dox.
P Taken together, these results demonstrate that Tet system allowed a tightly
regulated PrP expression.
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Figure 3.5: Regulation of PrP expression in PC12 Tet-on.
(A) Dose response: cells transfected with WT PrP or carrying the PG14 
mutation were induced for 24 h with the indicated doses of Dox and 
subsequently lysed. 50 \xg of proteins were analysed by Western Blot using the 
r  3F4 antibody. In lane 1, 50 ^g of protein extract of cells constitutively
^  expressing WT PrP (upper panel) or PG14 (lower panel) were loaded as a
control.
1  - (B, left) Cells transfected with WT PrP (lanes 1-2) or carrying the PG14
mutation (3-4) were induced for 24 h with 1 |ig /ml of Dox and subsequently 
lysed in RNA Wiz. 20 p,g of total RNA was analysed by Northern blot using a 
PrP-specific probe. Both endogenous rat PrP (E) and transfected mouse PrP 
(T) are detected.
(B, right) Cells transfected with the empty vector (lanes 1-2) or with WT PrP (3- 
4) were induced with 1 [xg/ml Dox for 24 h ( 2, 4) or non induced (1, 3). 25 ^g of 
protein lysates were analysed by Western blotting using 3F4 or 98A3 
antibodies.
(C) Time course. Cells expressing WT or PG14 PrP were induced with 0.25 
}xg/ml of Dox for the indicated times, lysed and analysed as described in panel 
A.
(D) Reversibility of the system. Cells transfected with WT PrP were seeded in 
48 multi-well plates and induced for 18 h with Ipig/ml of Dox (lanes 1-4) and
, chased in Dox-free medium for 0 h (lane 1), 24 h (lane 2), or 36 h (lanes 3, 4) 
before lysis. After 36 h of chase, cells were re-exposed to Dox for 18 h (lane 4). 
Cells in lanes 5 and 6 were induced respectively for 18 of 72 h. PrP expression 
was analysed by Western Blot using antibody 3F4.
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3.2 Characterization of mutant PrP properties
3.2.1 Biochemical properties of PrP molecules
D
Next, it was tested whether mutant PrPs synthesized in PC12 Tet-on ceils 
]  acquired the distinctive biochemical properties documented for mutant PrPs
n constitutively expressed in cultured cells. These properties, which are
reminiscent of PrP^^, include detergent insolubility and proteinase-K resistance.
To test detergent insolubility, cells expressing WT, M128V, D177N/M128, 
D177NA/128 or PG14 PrP were treated for 24 h with 1 |ig/ml Dox. Lysates were 
subjected to ultracentrifugation at 186,000 x g  for 40 min, a protocol that 
sediments PrP^^, but not PrP^ (Caughey et ai., 1991a). Supernatant and pellet 
fractions were subjected to Western blot with antibody 3F4 (Figure 3.6A). While 
WT PrP was entirely soluble, being recovered exclusively in the supernatant 
fraction, D177N and PG14 PrPs were partially detergent-insoluble. The two 
1 variants of the D177N mutation displayed a similar rate of insolubility, which
was lower than for PG14 (D177N/M128: 43±5%; D177NA/128: 45±5%; PG14: 
^  72±8%; mean±sd, n=6; p<0.05 (PG14 vs D177N/M128 and D177NA/128) by
j  Student’s t-test). Similarly to WT PrP, PrP carrying the Met>Val substitution at
codon 128 was entirely soluble.
To assess the protease resistance of PrP, lysates were digested with 0.25 or
nJ  0.5 pg/ml proteinase-K for 30 min at 37°C. As shown in Figure 3.6B, PG14 and
D177N moPrPs were cleaved by the protease to yield fragments that migrated 
between 27 and 30 kDa, the same size as the protease-resistant core of 
authentic PrP^^ In contrast, WT moPrP, as well as M l28V PrP (not shown in
this figure), were completely degraded under these conditions. No substantial
155
udifferences were noticed in the degree of protease resistance (evaluated by 
J  digestion with different concentration of enzymes) among the.different mutants.
Finally, the amount of PK-resistant PrP (PK-resistant PrP/total PrP) was difficult 
to estimate precisely due to the variability of the assay.
These results therefore demonstrated that a portion of mutant PrPs 
1^  synthesized by the Tet-on system acquires PrP^^-like properties.
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Figure 3.6: Mutant PrP acquires abnormal biochemical properties, typical 
of PrP®".
(A) Cells transfected with PrP. wild-type (lanes 1-2) or carrying the substitution 
D177N/M128 (3-4), PG14 (5-6), M128V(7-8) or D177NA/128 (9-10), were 
induced with Dox and subsequently lysed as described in the materials and 
methods. 100 pg of protein extract were centrifugated for 40 min at 186,000 x g  
to separate the soluble (S) and insoluble (P) fractions. Fractions were analyzed 
by Western Blot using the antibody 3F4.
(B) Cells transfected with WT PrP (lanes 1-3) or mutant PrPs(4-12) were 
induced for 24 h with 1 pg/ml Dox and lysed. 300 pg of protein extract were 
digested with 0, 0.25 or 0.5 pg/ml PK and analysed by Western Blot.
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3.2.2 Subcellular localisation of PrP molecules
r-j PrP^ is a cell-surface protein that is attached to the plasma membrane by
a glycosyiphosphatidylinositol (GPI) anchor at the C-terminus. We first checked
nJ  the correct localisation of WT PrP in PC12 Tet-on cells. Cells transfected with
m the empty pBI-G vector or with the pBI-G/moPrP WT plasmid were induced with
Dox and stained for PrP with antibody 3F4. To ensure for correct induction, cells 
were stained for (3-gaIactosidase enzymatic activity, before being 
immunostained with anti-PrP antibody. As shown in Figure 3.7, p-galactosidase 
was expressed by both pBI-G and pBI-GAVT PrP cells, while 3F4 staining was 
detected only in cells transfected with pBI-G/WT PrP.
Several studies have suggested that mutant PrP molecules are 
inefficiently transported to the cell surface (Capellari et al., 2000; Gu et al., 
2003b; Ivanova et al., 2001; Jin et al., 2000; Negro et al., 2001; Petersen et al., 
1  1996; Zanusso et al., 1999). To further investigate these abnormalities the
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localisation of mutant PrPs in P C I2 Tet-on cells was investigated, using 
confocal microscopy.
To visualize PrP on the cell surface, living cells were stained with anti- 
PrP antibody 3F4 without permeabilisation (Figure 3.8A, left panels). Despite 
equivalent levels of PrP induction revealed by Western Blot analysis (Figure 
3.8C), cells synthesizing mutant PrP showed much weaker surface staining 
than those expressing WT PrP. There were noticeable differences among the 
mutants in the extent of this effect, with PG14 PrP showing less surface staining 
than D177N/M128 and D177NA/128. No significant differences were noticed 
between the two variants of the D177N mutation. To visualize intracellular PrP, 
fixed cells were permeabilised with Triton X-100 prior to application of primary
158
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and secondary antibodies (Figure 3.8A, right panels and Figure 3.8B). It was 
J found that in all cells expressing WT PrP, staining was restricted to the cell
p  surface. In contrast, cells expressing mutant PrPs showed an intense
perinuclear staining. Moreover, in 5-10% of these cells, a more widespreadnLJ intracellular pattern was detectable.
1  The altered intracellular distribution of PG14 and D177N PrPs in a subset
of cells suggested that the transit of the mutant proteins along the secretory1
pathway was abnormal. To explore the possibility that mutant PrPs were 
j  retained in the ER, we double labelled cells with PrP and with calnexin, an ER
marker. P C I2 Tet-on cells transfected with WT, D177N, or PG14 PrP were 
induced by treatment with Dox for 24 h. Cells were subsequently fixed, 
permeabilized and stained with monoclonal antibody 3F4 and rabbit anti- 
- j calnexin antibodies followed by Alexa 488 (green)-conjugated anti-mouse and
Alexa 546(red)-conjugated anti-rabbit secondary antibodies respectively (Figure
nJ 3.9). This double labelling showed no colocalization between WT PrP and
D
D calnexin, with the merged image showing no yellow colour. In contrast, mutant 
PrPs colocalized partially with calnexin, producing a yellow colour. These
nJ  results indicate that a portion of the mutant PrP resided in the ER. Anti-giantin
"I antibody was then used to label the Golgi apparatus. Cells transfected with
J
D177N and PG14 PrPs were induced with Dox, fixed, permeabilised and
0
D
D
D
n
stained with rabbit anti-PrP 45-66 and mouse monoclonal anti-giantin antibody 
followed by Alexa 546(red)-conjugated anti-rabbit and Alexa 488(green)- 
conjugated anti-mouse secondary antibodies respectively (Figure 3.10). 
Although some mutant PrP colocalised with giantin, much of the PrP labelling 
did not. These results suggested that in a subset of cells, PG14 and D177N
159
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PrPs are impaired in their transport to the cell surface and partially retained in 
]  the ER.
1  The distribution of these mutants was also analysed in cerebellar granule
neurons (CGN) from Tg mice (Fioriti et al., 2005). In CGN from Tg(WT) micenU PrP was mainly found on the cell membrane where it appeared in a patchy
^  distribution along the neurites, consistent with association of the protein with
membranal “rafts”. In CGN from Tg(PG14) mice, PrP was barely detectable on
1
the cell membrane and along neurites, and was mainly found in intense
-1
j  perinuclear patches, colocalizing with ER and Golgi markers. Low expression
— on the cell surface and intense intracellular immunofluorescence colocalizing in1
part with giantin and trap, were observed also in CGN expressing the 
D177N/M128 and D177NA/128 mutants, although the number of cells 
displaying this altered intracellular PrP distribution was reduced compared to 
PG14 neurons.]
n
J  These data indicate that, similarly to that observed in transfected cells
"I also in primary neurons the pathogenic mutations alter the trafficking of PrP
-J
molecules and cause a portion of them to reside abnormally in intracellular
n
D
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n
compartments.
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Figure 3.7: The bi-directional promoter allows co-expression of PrP and p- 
galactosidase.
Cells transfected with the empty pBI-G vector (A, B), or with pBi-GAA/T PrP(C 
and D) were treated for 24 h with 1 pg/ml of Dox and immunostained for PrP (8, 
D), or for p-galactosidase activity (A, C). As shown in panel D, PrP is correctly 
expressed on the surface of cells transfected with pBI-G/WT PrP. Scale Bar, 
applicable to all panels, is 20 pm.
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Figure 3.8: Mutant PrPs are less present on cell surface.
(A) Cells expressing WT PrP (A, E), PG14 PrP (B, F), D177N(M128) PrP (C, G) 
or D177N(V128) PrP (D, H) were incubated with 3F4 antibody without 
permeabilization to detect PrP on the cell surface (panels A, B, C, D) or fixed 
and permeabilised before incubation with 3F4 to allow antibody entrance. Scale 
Bar, applicable to all panels, is 10 pm.
(B) Low magnification of cells stained for PrP after permeabilisation. Cells 
expressing WT PrP (A), D177N/M128 PrP (B) or PG14 PrP (C) are shown. 
Scale Bar is 20 pm.
(C) Equivalent PrP induction was checked by Western blotting. Cells 
transfected with WT (lane 1), D177N/M128 (2), D177NA/128 (3) and PG14 PrP 
(4) were seeded in one well of a 96-well plate and treated with Dox 
(simultaneously with cells plated for immunofluorescence) before lysis in 25 pi 
of laemli sample buffer and separation onto SDS PAGE.
163
u
0
D
D
D
D
D
D
D
a
D
D
D
D
0
D
D
0
g
g
D
PrP Calnexin Merge
WT
PG14
D177N
zNN
B Figure 3.9: Mutant PrPs coiocalize with an ER marker.
Tf PC12 Tet-on cells transfected with WT, PG14, D177N/M128
. ^  5  FrPs were differentiated with NGF (100 ng/ml), and PrP
>  ^  ^  expression was induced by treatment with 1 pg/ml Dox for 24 h.
45- (A) Cells were fixed, permeabilized and stained with mouse anti-
PrP antibody 3F4 (A, D and G) and rabbit anti-calnexin antibody 
g  (B, E and H) followed by Alexa 488(green)-conjugated anti-
30- mouse and Alexa 546(red)-conjugated anti- rabbit secondary
antibodies. Merged green and red images are shown in C, F and 
I. Scale Bar, applicable to all panels, is 10 pm. The mutant 
D177N/V128 did not behave differently from the D177N/M128 
and was not included in this figure. (B) Before performing
immunofluorescence PrP expression level was checked by
Western blotting using 3F4 antibody, as described in Figure 3.8.
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Figure 3.10: Mutant PrPs partially localize with the Golgi marker Giantin.
PC12 Tet-on transfected with pBI-G/PG14 PrP or pBI-G/D177N/M128 PrP 
were differentiated with NGF (100 ng/ml), and PrP expression was induced by 
treatment with 1 pg/ml of Dox for 24 h. Cells were fixed, permeabilized and 
stained with rabbit anti-PrP antibody P45-66 (A and D) and mouse anti-giantin 
antibody (B and E) followed by Alexa 546(red)-conjugated anti-rabbit and 
Alexa 488(green)-conjugated anti-mouse secondary antibodies. Merged green 
and red images are shown in C and F. Scale Bar, applicable to all panels, is 
10 pm. The mutant D177N/V128 did not behave differently from the 
D177N/M128 and was not included in this figure.
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3.3 Effect of mutant PrP expression
3.3.1 Cell viability after PrP induction
The Tet-on system allowed investigation of the potential cytophatic effect 
of mutant PrP expression. Transfected cells were maintained in Dox-free 
medium until the time of each experiment. To quantitatively measure cell 
viability after PrP expression, cells were seeded in microtiter plates and 
exposed to different concentration of Dox (0-2 pg/ml) for 24, 48, 72 or 96 h. In 
each experiment, to ensure the same rate of induction, PrP expression level 
was checked by Western blotting, using the antibody 3F4. Cell viability was 
tested by the MTT assay and by counting nuclei after staining with propidium 
iodide or TUNEL. No differences were found between different clones after 24- 
72 h of induction (see Figure 3.11 at 48 h). However, a decrease in the number 
of cells expressing D177N and PG14 PrPs was observed after 96 h of Dox
"j exposure (Figure 3.12 and 3.13A). Propidium iodide staining of these cells
revealed the presence of fragmented and pyknotic nuclei (Figure 3.12, lower
panel D), suggesting that the decrease in viable cell number was due to 
apoptosis. However, even though the decrease in cell survival was always 
associated with mutant PrPs and was statistically significant within the same 
experiments, much variability was noticed between independent experiments 
J  with reduction of cell viability detected in only 3 of 10 experiments conducted.
Figure 3.13 shows the effect of mutant PrP expression on cell viability; in one 
case a reduction in cell viability was detected (A), while in the other was not (B).
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Figure 3.11 : Cell viability does not vary after 48 h of Dox exposure.
Cells transfected with the empty vector, WT PrP, D177N/M128, D177NA/128 
and PG14 were exposed to different concentration of Dox (0-1 [ig/ml) for 48 h.
(A) Cell viability was assessed by MTT. Values are the meants.d. of 5-8 wells 
and are expressed as a percentage of control cells (0 Dox).
(B) To check PrP induction, cells transfected with the empty vector (lanes 1-4), 
with WT PrP (5, 8, 11, 14), D177N/M128 PrP(6, 9, 12, 15), D177NA/128 (7, 
10, 13, 16) or PG14 PrP (17-20), treated as indicated by the labelling, were 
analysed by Western blotting. Cells were seeded in one well of a 96-well plate, 
treated with Dox and lysed in 25 \ i \ of laemli sample buffer before separating 
on a 12% SDS gel.
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Figure 3.12: Expression of mutant PrP is associated with apoptosis.
(Upper panels) PC12 Tet-on cells transfected with the empty vector (A, F), WT 
PrP (B, G), PG14 (C, H), D177N(Met128) (D, I) or D177N(Val128) (E. L) were 
exposed to 0 (A-E) or 1 mg/ml Dox (F-L) for 96 h and examined by phase 
contrast microscopy. Pictures were performed with a magnification of 40X on a 
Nikon F-601M camera. PrP expression level after 96 h of induction was 
checked by Western blotting and was equivalent for all the clones (not shown 
in ths figure).
(Lower panels, left) Cells were subsequently stained with propidium iodide, 
mounted and analyzed by confocal microscopy. In this panel, only WT PrP (A, 
C) and PG14 PrP (B, D) are shown before (A, B) and after (C, D) Dox 
treatment. Pyknotic and fragmented cells expressing PG14 PrP(D) are 
indicated by arrowheads. Scale Bar is 10 i^M.
(Bar graph, right): Quantitative evaluation of the apoptotic cells after induction 
of PrP expression. The values are expressed as a percentage of the total 
number of cells; each bar represents the mean±SEM. of 10-12 100 X fields 
from two independent experiments. *p<0.05 and **p<0.01 v e r s u s  cells 
expressing WT in Student’s t-test.
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Figure 3.13: The cytotoxic effect of mutant PrP expression is highly 
variable.
Cells transfected with WT PrP, D177N/M128 PrP, D177NA/128 PrP or PG14 
PrP were treated for 96 h with 0, 0.5 or 1 \ i g / m \  Dox. Viability was 
subsequently assessed by MTT assay, as described in the Materials and 
Methods. Each value is the mean±s.d. of 5-8 wells expressed as a percentage 
of the survival of control cells (0 pg/ml Dox). *p<0.05 and **p<0.01 versus the 
correspondent dose of cells expressing WT in Student’s t-test. While 
differences in cell viability are statistically significant in A, no differences 
among the different clones were found in an independent experiment (B). To 
ensure an equivalent induction in all the clones, PrP expression was analysed 
by Western blotting. Panel C shows PrP expression level achieved in the 
experiment A (left) and B (right) for WT (lanes 1-3), D177N/M128 (4-6), 
D177N/V128 (7-9) and PG14 PrP(10-12). The concentrations of Dox used are 
indicated above (0, 0.5 or 1 pg/ml).
169
uD
D
D
D 
D 
D 
D
It was then investigated whether cells undergoing apoptosis were the 
same cells as those showing an altered intracellular distribution of mutant PrP. 
To answer this question, cells expressing WT and mutant PrPs were exposed to 
Dox for 72 h, fixed, permeabilized and immunostained with anti-PrP antibody 
3F4 followed by an Alexa 488(green)-conjugated anti-mouse secondary 
antibody. After immunofluorescence staining, cells were viewed to confirm that 
PrP was expressed before proceeding with propidium iodide staining. This 
experiment showed that cells with an altered intracellular PrP distribution 
displayed a normal nuclear morphology (Figure 3.14) and that none of the 
apoptotic cells showed retention of transfected PrP in the Golgi/ER.
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Figure 3.14: Cells with altered intracellular PrP distribution show normal 
nuclear morphology.
Cells transfected with pBI-G/PG14 PrP were differentiated with NGF and 
subsequently treated with 1 pg/ml Dox for 72 h before fixing in methanol/acetic 
acid. Cells were stained with anti-PrP antibody 3F4, followed by Alexa 
488(green)-conjugated anti-mouse antibody before performing staining with 
propidium iodide. PrP staining is shown in green, nuclei are red. Scale Bar is 10 
pm.
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3.3.1.1 Cell viability after neuronal differentiation
PC12 cells are rat adrenal pheochromocytoma cells that can be 
differentiated into noradrenergic neurons by treatment with NGF (Greene and 
Tischler, 1976). Because much variability was noticed in the extent of mutant 
PrP toxicity (see above), it was investigated whether acquisition of neuronal 
phenotype resulted in increased susceptibility to mutant PrP expression. Clones 
transfected with WT, D177N, PG14 PrP or with the empty vector were 
differentiated with NGF before inducing expression of the PrP protein. After 3-5 
days of exposure to NGF, cells started to develop neuron-like processes. The 
number and length of such processes continued to increase over the next 7-10 
days of treatment, until -80% of the cells in the cultures had ceased dividing 
and had developed neurites. No differences in the time course or extent of 
neurite extension was noticed among the different clones. Moreover, the 
response of these clones to NGF was comparable to the response of parental 
PC I2 Tet-on cells (Figure 3.ISA). For all the clones, an equivalent expression 
level of transgenic PrP after Dox treatment was checked by Western blotting, 
using the 3F4 antibody (Figure 3.15B). No changes in transgenic PrP
n
J  expression were detected after NGF treatment (not shown); conversely,
changes in the expression level of endogenous PrP due to NGF treatment were 
not evaluated.
1  The extent of cell death associated with mutant PrP expression was not
pj significantly altered by differentiation with NGF (when compared with
undifferentiated cells transfected with the same PrP construct), demonstrating
J that acquisition of the neuronal phenotype did not render PC 12 cells more
D susceptible to mutant PrP toxicity (Figure 3.15C).172
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Figure 3.15: Acquisition of neuronal phenotype does not determine a 
dramatic decrement in cell viability of cells expressing mutant PrP.
(A) Parental PC I2 Tet-on cells or cells transfected with the empty vector pBI-G, 
with WT, D177N/M128, D177NA/128 or PG14 PrP were differentiated as 
described in chapter 2 and examined by phase contrast microscopy. Pictures 
were performed on a Nikon F-601M camera.
(B-C) Differentiated PC I2 Tet-on cells transfected with the different constructs 
were seeded on 96-well plates and treated with or without Dox for 96 h.
(B) PrP expression level after Dox induction was checked by lysing one well of 
cells transfected with the empty vector (lane 1), with WT (2), D177/M128 (3), 
D177NA/128 (4) or PG14 PrP (5) in laemli buffer followed by Western Blotting.
(C) MTT assay was performed on cells treated with of without Dox. Each value 
is the mean±s.d. of 5-8 wells expressed as a percentage of the survival of 
control cells.
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3.3.2 Expression of mutant PrP does not activate microglial response
Previous studies have demonstrated that addition of microglia to neurons 
significantly increased the neurotoxicity induced by PrP^^-like peptides (Bate et
IJ 
]
D 
D 
n
U al., 2002; Brown et al., 1996; Giese et al., 1998), suggesting that microglia
J  contribute to the elimination of neurones sublethally damaged by PrP^^ On the
basis of these observations we tested whether PC12 cells expressing mutant 
PrP molecules with scrapie-like properties were recognized as abnormal and 
killed by microglia. Clones transfected with WT, D177N or PG14 PrPs or with 
the empty vector, and then differentiated with NGF, were seeded in a 96 wells- 
plates. After 24 h purified primary rat microglia was added to the PC I2 cultures. 
PC I2 cells alone or PC I2 cells co-cultured with microglia were treated for 48 h 
- j  with 0-1 j^g/ml Dox before assaying cell viability. No difference in cell survival
J
was found between pure PCI2 cell cultures and cells co-cultured with microglia, 
indicating that the presence of microglia did not alter viability of differentiated 
n  PC12 cells transfected with mutant PrPs (Figure 3.16A). Transgenic PrP
expression was checked by Western blotting in all the clones (Figure 3.16B).
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Figure 3.16: Microglia does not kill cells expressing 
mutant PrP.
(A) Cells transfected with the empty vector, with pBI- 
G/WT PrP, pBI-G/D177N/M128 PrP, D177NA/128 or 
pBI-G/PG14 PrP were differentiated and seeded in a 
microtiter plate in the presence (+) or absence (-) of 
microglia. Cells were incubated with 1 \ ig / r r \ \ Dox for 48 
h before performing MTT assay. Each value is the 
mean±s.d. of 5-8 wells expressed as a percentage of 
the survival of the control cells, (no Dox, with or without 
microglia).
(B) One well seeded with PC12 cells expressing WT 
PrP (lane 1 and 2) or expressing D177N/M128 PrP (3), 
D177NA/128 PrP (4) or PG14 PrP (5) were lysed in 
laemli sample buffer and moPrP was analysed by
Western blotting. PC12 cells analysed in lane 2 were co-cultured in the 
presence of microglia to check for the influence of microglia on moPrP 
expression.
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3.3.3 PrP expression does not alter response to cellular stress
It has been reported that PrP can protect neurones from apoptosis 
induced by serum deprivation (Kim et al., 2004; Kuwahara et al., 1999) and 
^  from oxidative stress (Brown et al., 1997b; White et al., 1999). To evaluate the
protective role of WT PrP in our cell model and the possibility that mutant PrP 
could exacerbate the effect of stress inducers, cell viability was evaluated in 
cells cultured after serum deprivation or in the presence of 0-75 H2O2 . Cells
transfected with the empty vector, with pBI-GAA/T PrP, pBI-G/D177N PrP in the 
two forms or with pBI-G/PG14 PrP were cultured in the absence of serum 
before and after treatment with Dox. Cell viability was compared to the viability 
of cells cultured in regular medium (Figure 3.17A). Alternatively, cells 
transfected with pBI-G/WT PrP, pBI-G/PG14 PrP or with pBI-G/D177N PrP in 
the two forms were treated with 0-75 fxM H2O2 for 24 h before and after 
induction with Dox (Figure 3.17B). As shown in Figure 3.17 A and B, the viability
J  of cells grown in the presence of Dox did not differ significantly from that of cells
grown in the absence of Dox. These results indicated that neither WT or mutant 
J  PrP expression affected the cellular response to the two stressors tested. In
1  some cases, there was a slight increase in survival of Dox-treated cells (Figure
3.17A); however this effect was not ascribable to PrP expression, as it was 
present even in the case of cells transfected with the empty pBI-G vector. As 
described above, expression level of transgenic PrP was checked by Western 
blotting (Figure 3.17C and 3.17D).
176
u
I
f l
I
I
I
I
I
I
I
I
I
I
I
I
I
D
D
I
I
D
100
n 80>
E 603(0 40
âS
20
0
I I -  DOX 
+ DOX
pBI-G WT D177N D177N
(Met128) (Val128)
Serum deprivation
PG14
B
140 
«120 
1 100
140 
« 120 
I  100
40
20
0
PG14WT
- Dox 
+ Dox
Dox
-m-+ Dox
40
7525075250
HgOg (piM) HgOg (i^M)
D177N (Val128)D177N (Met 128) 140 
«120 
1 100
140 
« 120 
I  100
- Dox 
+ Dox- Dox 
+ Dox
60
4040
7525 750 0 25
HgOg (m^M) HgOg (|iM)
177
DD
D
0
D
B
B
n
i >
D
Q  Q_ Q  CL
4 5 t
30- 30-
1 2 3 4 1 2 3 4
U
B 
fl 
II 
B  
II 
D
D Figure 3.17: PrP expression does not alter viability of cells grown after
serum deprivation or in the presence of H2O2 .
0 (A) Cells transfected with pBI-G, pBI-G/WT PrP, pB!-G/PG14 PrP, pBI- G/D177N(Met128) PrP or pBI-G/D177N(Val128) PrP were treated with 0 or 1 jig/ml Dox. After 24 h the regular medium was replaced with serum-free 
n  medium and cell viability assessed by MTT after 18 h. Each value is the
mean±s.d of 5-8 wells expressed as a percentage of the survival of control cells
■ grown in regular medium and in the absence of Dox.(B) Cells transfected with pBI-G/WT PrP, pBI-G/PG14 PrP, pBI- G/D177N(Met128) PrP or pBI-G/D177N(Val128) PrP were treated with 0, or 1 
H p,g/ml Dox. After 24 h of Dox induction, cells were treated with 0, 25 or 75 \xM
y  H2O2 for 18 h before assaying cell viability by MTT. Each value is the mean±s.d
of 5-8 wells expressed as a percentage of the survival of control cells (no Dox, 
no H2O2).
(C-D) PrP expression level achieved after Dox induction was checked by 
Western blotting. Cells transfected with WT PrP (lane 1), D177N/M128 PrP (2),
D D177NA/128 PrP (3) or PG14 PrP (4) and treated for 24 h wih 1 pg/mi Dox were lysed in laemli sample buffer before loading on SDS gel. Panel C shows PrP expression level of cells before serum deprivation, panel D shows PrP 
expression level of cells before H2O2 treatment.
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n The drug tunicamycin inhibits protein glycosylation, causing protein
accumulation in the ER and activation of ER stress response (Dorner et al., 
J 1990; Leavitt et al., 1977). Based on the assumption that misfolded PrP
accum ulate in the ER, it was hypothesized that ER stress (induced by 
tunicamycin) could affect PrP distribution and/or cell viability. Moreover, 
because PrP is normally glycosylated, this drug acts directly on PrP. 
Immunofluorescence experiments were performed on cells treated with Dox and 
tunicamycin. This analysis showed no differences in PrP distribution after 
tunicamycin treatment (Figure 3.18A), although the drug efficiently inhibited the 
1  glycosylation of the protein (Figure 3.18B and 3.19B). The viability of cells in the
presence of tunicamycin was then tested. Cells transfected with WT, 
D177N/M128, D177N/V128 or PG14 PrPs were treated with tunicamycin (2.5 or 
5 |ig/ml), with Dox alone, or were co-treated with tunicamycin and Dox. The 
presence of tunicamycin caused a marked reduction in cell viability in all clones 
analysed (probably due to the toxicity of the drug itself) which was independent 
of the presence of absence of Dox (Figure 3.19A). MoPrP expression level was
D
D
D
n  equivalent in all the clones used in this experiment (Figure 3.19B).
J
Altogether these results indicate that neither deprivation of trophic
0
D
D
D
D
n
factors, nor oxidative stress by H2O2 or induction of ER-stress by tunicamycin 
affected the extent of cell death after mutant PrP expression.
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Figure 3.18: Treatment with tunicamycin does not alter the intracellular 
distribution of PrP.
Cells transfected with pBI-G/WT PrP or pBI-G/D177NA/128 PrP where treated 
with 1 |ig/ml Dox or co-treated with 1 fig/ml Dox and 1 pg/ml tunicamycin for 24 
h.
(A) Cells expressing WT PrP and D177A/128 PrP were fixed, permeabilized 
and stained with 3F4. Scale Bar is 20 |im.
(B) Cells expressing WT PrP and treated with or without tunicamycin were lysed 
in Laemli buffer and analyzed by Western blot using anti-PrP antibody 3F4. 
After treatment with tunicamycin a single band, running at 27 kDa and 
corresponding to the unglycosylated form of PrP, was detected.
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Figure 3.19: WT or mutant PrP expression does not alter susceptibility to 
tunicamycin.
Cells transfected with WT PrP, D177N/M128, D177NA/128 or PG14 were 
treated with 0 or 1 jxg/ml Dox. After 24 h cells were incubated with 0, 2.5 or 5 
pg/ml tunicamycin for 18 h before performing MTT assay (A) of lysis (B).
(A) The bar graph shows the result of MTT assay. Each bar represents the 
meanis.d. of 5-7 replicates.
(B) After 24 h of induction cells expressing WT (lanes 1-3), D177N/M128 (4-6), 
D177NA/128 (7-9) or PG14 PrP (10-12) and treated with the indicated 
concentrations of tunicamycin (0, 2.5 or 5 |ig/ml) were analysed by Western 
blotting.
181
u]
D
D
D
3.4 Does mutant PrP trigger ER stress?
3.4.1 Analysis of ER stress markers in PC I2 Tet-on cells
To explore the possibility that expression of D177N or PG14 PrPs
triggered toxic response pathways in the ER, the mRNA level of the molecular 
n
J chaperon BiP (GRP78) and transcriptional factor CHOP-10 (GADDI53) were
p  measured. mRNA levels of BiP and CHOP were analysed in cells transfected
with WT, Ml28V, D177N or PG14 PrP after 24 h of induction with 1 [xg/ml Dox.
D
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n
As shown in Figure 3.20A, PrP expression did not alter the amount of BiP or 
CHOP transcripts. IREIa-dependent splicing of XBP1 mRNA, which constitutes 
one of the first events in ER-stress (Kaufman, 1999; Lee et al., 2002), was then 
assessed. RT-PCR analysis was performed on mRNA isolated from 
tunicamycin- or Dox-treated cells (Figure 3.20B). While the spliced form of 
XBP1 was readily detected after tunicamycin treatment, no changes were 
detected in cells exposed to Dox in any of the clones analysed. Again, the 
induction of PrP achieved in these experiments was equivalent, as revealed by 
Western blot analysis (Figure 3.200). Because the highest changes in cell 
viability had been detected after 96 h of mutant PrP induction, the same 
experiments were performed on mRNA extracted from cells induced with 1 
p.g/ml Dox for 96 h. Again, no increase of the ER-stress markers analysed was 
detected.
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Figure 3.20: Mutant PrP expression does not trigger ER stress response.
(A) Two clones transfected with pBI-G/WT PrP (lanes 1-4), two clones 
transfected with pBI-G/D177N/M128 PrP (5-8) and two clones transfected with 
pBI-G/PG14 PrP were induced for 24 h with 0 or 1 pg/ml Dox. 20 pg of total 
RNA extracted were analysed by Northern Blot, using anti-BiP (upper panel) 
or anti-CHOP (middle panel) specific probes. CHOP and BiP expression level 
was normalised on the level of expression of GADPH (lower panel). The 
mutant D177NA/128 did not behave differently from the other constructs and 
was not included in this figure.
(B) Alternatively, cells expressing WT or D177N/M128 PrP were treated for 24 h 
with 1 pg/ml Dox (lanes 3, 4, 7, 8), in the presence (lanes 4, 8) or absence of 
tunicamycin (lanes 3, 7) or treated with tunicamycin in the absence of Dox (2, 
6). Total RNA was extracted and the presence of XBP1 alternative splicing was 
analyzed by RT PCR. Each product of amplification was separated on 1% 
agarose gel. Spliced forms (s) were detected only in samples treated with 
tunicamycin. RT-PCR analysis of clones transfected with PG14 or D177NA/128 
PrP gave the same result and was not included in this picture.
(C) Each clone transfected with WT PrP (lanes 1-4), D177N/M128 PrP (5-8) or 
PG14 PrP (9-12) was analysed for PrP expression before (1-2, 5-6, 9-10) and 
after Dox induction (3-4, 7-8, 11-12) by Western blotting.
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D Since only 5% of cells expressing mutant PrPs display an altered 
intracellular distribution of PrP and only between 2 and 5% of these cells 
J underwent apoptosis, it was possible that only a limited number of cells
1  accumulated sufficient amount of mutant PrP in the ER to activate ER-stress
response leading to apoptosis. If this were the case, then analysis of total RNA 
D  extracted from whole cultures could contain low, undetectable levels of BiP,
CHOP and XBP1 transcripts. To directly test if UPR markers were activated in 
the cells accumulating PrP, immunofluorescence experiments were performed
1 using anti-PrP and anti-CHOP antibodies. Cells expressing WT or mutant PrP 
^  were treated for 48 h with Dox or for 18 h with tunicamycin and subsequently
^  immunostained with the two antibodies. As expected, 5% of cells expressing
PG14 PrP displayed an abnormal ER distribution of PrP; however, no cells 
" j showed increased levels of CHOP. Cells treated with tunicamycin showed an
intense nuclear staining indicative of CHOP induction (Figure 3.21).D
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Figure 3.21: CHOP is not activated in cells that accumulate mutant PrP in 
the ER.
Cells transfected with pBI-G/PG14 were induced for 48 with 1 |ig/ml Dox 
(panels A, B, C) or for 18 h with 1 p,g/ml tunicamycin (panel D). Cells were 
subsequently fixed, permeabilized and stained with anti-PrP antibody (A) and 
with anti-CHOP (B) followed by Alexa 488 (green)-conjugated anti-mouse and 
Alexa 546 (red)-conjugated anti-rabbit. Merged image between the two 
antibodies is shown in panel C. Cells treated with tunicamycin were stained with 
anti-CHOP antibody as a positive control for CHOP induction (D). Scale Bar, is 
10 x^m. . ^
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3.4.2 Analysis of ER stress markers in transgenic mice
The activation of the UPR was also analysed in transgenic mice expressing
n
J  WT (Tg(WT)) or PG14 (Tg(PG14)) PrPs, or mice in which the PrP gene had
been ablated (PrP°^°). Accumulation of PG14 PrP in the brains of the Tg(PG14) 
mice causes a progressive neurological disorder characterized by apoptosis of 
cerebellar granule neurons (Chiesa et al., 2000; Chiesa et al., 1998). RNA was
" j isolated from the cerebellum or from the whole brain of Tg(PG14) mice at
'  -i
different ages, corresponding to different stages of the disease, as well as from 
]  age-matched Tg(WT) and PrP°^° mice. The expression level of BiP mRNA in
Tg(PG14) was comparable to that of Tg(WT) and PrP°^° mice (Figure 3.22A) 
and did not change significantly with aging (Figure 3.22A and 3.228). CHOP 
mRNA was not clearly detectable in the CNS of these mice, probably because it 
J  is expressed at low level in normal brain (Anguelova et al., 2000; Dimcheff et
al., 2003; Reifenberger et al., 1994); however the analysis of the cerebellum of 
Tg(PG14) rhice did not revealed variation in CHOP expression level during 
^  aging (Figure 3.22B).
Taken together, these analyses did not reveal evidence for an involvement 
of the ER stress response as a neurotoxic pathway triggered by mutant PrP 
accumulation.
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Figure 3.22: Accumulation of mutant PrP in the central nervous system 
(CNS) of transgenic mice does not induce the expression of BiP or CHOP.
(A) Age-matched PrP°^° mice (lanes 1-2, 9-10), Tg(WT) (expressing 4 times the 
endogenous level of PrP )(lanes 3-5, 11-13), Tg(PG14-C) (lanes 6-7, 14-15) 
(expressing 0.3 times the endogenous level of PrP) or Tg(PG14-A3) 
(expressing 1 time the endogenous level of PrP)(lanes 8, 16-18) were sacrificed 
at the indicated ages. Total RNA was extracted from the cerebellum (1-8) or 
from total brain (9-18) and 20 [xg were analysed by Northern blot using PrP and 
BiP-specific probes.
(B) Tg(PG14-A3) were sacrificed at the indicated ages. Total RNA was 
extracted from the cerebellum and 20 ixg were analysed by Northern blot using 
PrP, CHOP, BiP or GADPH-specific probes.
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Chapter 4: Discussion
In this thesis, a cellular model of familial prion diseases has been 
generated in which PrP expression can be switched on by adding doxycycline. 
Mutant PrPs expressed acquired PrP^^-like properties, were retained inside the 
cell and were sometimes associated with the induction of apoptosis. Since it is
nJ  known that retention of misfolded protein can lead to stress in the ER and
P] consequently to cell death (Aridor and Balch, 1999), the activation of markers
typical of ER stress was investigated. The results presented here suggest that 
neuronal cell death in familial prion diseases is not linked to ER stress.
4.1 Generation of PC12 Tet-on expressing W T and m utant PrPs
Mouse PrP molecules modified to carry the epitope for the 3F4 antibody 
(Kascsak et al., 1987) were expressed in PC12 Tet-on cells. The presence of 
this epitope does not affect the properties of the protein (Scott et al., 1993b) and 
makes it possible to distinguish transfected PrP from endogenous rat PrP. 
Moreover, the 3F4 antibody presents several advantages; first, has a very high 
affinity for PrP; secondly its epitope (aminoacids 109-112) is inside the protease 
resistant core of the protein, and thus the 3F4 antibody recognizes not only the 
full length protein but also the proteolytic fragment resulting from digestion of 
the protein with proteinase-K (Kascsak et al., 1987); and third, the 3F4 epitope 
is buried in native PrP^ "^ , thus allowing selective recognition of PrP^^ from PrP^ 
by immunoprécipitation or by ELISA in non-denaturing conditions (Chiesa et al.,
2003; Peretz et al., 1997; Safar et al., 1998).
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1  3F4-tagged mouse PrPs were cloned into the Pst 1/ Not I restriction sites
of pBI-G. The sequencing of the constructs revealed an insertion of 300 bp 
J  upstream from the Pst I restriction site of pBi-GAA/T PrP. This insertion was
probably due to a rare, non-specific event of recombination between molecules 
of pBl-G/WT PrP or between pBI-G and non ligated insert and was not 
observed when the experiment was repeated a second time.
The capability of Dox to modulate expression was first checked by 
assaying p-galactosidase activity after transient transfection of the empty pBI-G 
alone or in combination with pTet-tTS. In the first case, the comparison between 
non induced cells and cells induced with 1 [xg/rni Dox demonstrated that the 
-j expression was not completely silenced in the absence of the inducer. To avoid
leakage, it was decided to introduce the transcriptional silencer pTet-tTS, even 
J if the number of expressing cells and the absolute expression level was
reduced. The addition of tTS reduces backgroung expression in mammalian cell 
lines (Forster et al., 1999; Freundlieb et al., 1999; Rossi et al., 1998) and in 
transgenic animals (Perez et al., 2002; Zhu et al., 2001) even if sometimes 
n  affects the maximal expression level (Knott et al., 2002). The introduction of tTS
allowed the selection of clones with no basal activity, but was not possible to
1
J  achieve high level of expression. However, this expression level, that was
1  comparable to PrP expression in P C I2 cells, allowed studies of toxicity in a
physiologic context.
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4.2 Stable transfection of pBI-G/PrP and analysis of protein 
expression
In stable transfections, the percentage of cells expressing PrP was 
clearly lower than the number of cells with (3-gal activity after transient 
transfection. This difference was not due to a different transfection efficiency 
between the two methods (see table III.II and III.Ill) but probably reflected the 
fact that protein expression was analysed at different times after transfection 
(48 h after transient transfection, more than 4 weeks after stable transfection). 
In fact, it is known that the expression of a transgene is maximum 24-48 h post­
transfection (Colbere-Garapin and Garapin, 1983), and decreases afterwards. 
During the first 24-48 h, all the cells in which plasmid has entered activate 
transcription and translation of the gene of interest. However, in the majority of 
the cases, the plasmid is not integrated into the cellular genome and is lost or 
degraded. In contrast in the few cells in which the plasmid has been integrated 
the expression of the gene of interest will persist. To select cells that have been 
transfected with the plasmid and avoid loss of the plasmid, cells are 
j j  continuously grown in medium containing the selective agent (Colbere-Garapin
and Garapin, 1983).
PrP expression level was well modulated by different doses of the 
J  inducer, and increased with increasing concentration of Dox, reaching a
maximum at 1 [xg/ml. Northern Blot experiments performed on induced cells, 
using a probe recognizing both mouse and rat PrPs, revealed that at 1 pg/ml, 
the amount of transcript was equivalent to the endogenous rat mRNA level. The 
distinction between the two mRNA forms was possible because of the
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difference in molecular weight. No further increased expression level was 
detected using higher concentration of the inducer (2-5 jxg/ml). Moreover, after 
72-96 h of induction with 5 ^ig/ml, deleterious effects on cells were clearly 
observed: this effect was not related to PrP expression but was due to toxicity of 
Dox itself, as demonstrated by comparing the viability of cells expressing PrP 
versus cells transfected with the empty pBl-G.
The time course of PrP expression demonstrated that the induction was 
rapid and lasted at least 72-96 h, while after this period the expression level 
started to decrease in all clones analyzed. The explanation for this finding is not
nJ clear, although this phenomenon in PC12 Tet-on cells expressing Bcl-2 has
"j been previously described (Schwarz et al., 2002).
In previous studies mouse PrP was expressed in N2a cells using either
nJ  the Tet-on or the Tet-off system (WindI et al., 1999). In that model, treatment
with Dox revealed a leakage of inducibility in N2a Tet-off, while a good 
expression level was achieved in N2a Tet-on cells. The quantitative regulation
D
D
D
of PrP expression in N2a Tet-on cells was examined by inducing expression for
48 h with various concentration of Dox. PrP expression was detected at 5 ng/ml
and the signal reached saturation at Dox concentrations around 500/1000
ng/ml. The maximum expression level achieved was much higher than that in
normal mouse brain and that in cells expressing PrP under the control of a
constitutive viral promoter. The time-course revealed induction of PrP after 3-5
h, with a maximal expression level after 20 h. The effect of longer treatments
was not shown. Wild-type PrP was also expressed in RK13 Tet-on (Rachidi et
al., 2003). PrP induction was Dox-dependent, being detectable at 10 ng/ml and
reaching a maximum at 500 ng/ml of Dox. Kinetics of induction with 500 ng/ml
showed that expression was detected after 8 h, reaching a maximum after 24h.
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Again the effect of longer treatments was not shown. Therefore, in N2a Tet-on 
(WindI et al., 1999), in RK13 Tet-on (Rachidi et al., 2003) and in PC12 Tet-on, 
PrP has a similar dose-dependence and kinetic of induction.
J  Finally, in the system developed in this thesis it was possible to activate
and inactivate transcription by repeatedly adding and removing Dox, thereby 
demonstrating that the inducibility of the system was not lost after the first cycle 
of induction.
D
These pilot experiments therefore demonstrated that the system
J
developed did operate and allowed determination of the best experimental 
1 conditions for use in subsequent studies.
[  4.3 Mutant PrPs expressed in PC12 Tet-on acquire abnormal
^ biochemical properties and are less represented on the cell
n surface compared to WT PrP
J  Several cellular models of familial prion diseases have been previously
P, established in which mutant PrPs were constitutively expressed from viral
promoters. In those systems, mutant PrP acquired abnormal properties
reminiscent of PrP^ *^ , such as detergent insolubility and PK resistance (Chiesa 
and Harris, 2000; Daude et al., 1997; Lehmann and Harris, 1996a; Lehmann 
and Harris, 1996b; Negro et al., 2001; Priola and Chesebro, 1998). In this 
thesis, an inducible model was developed in which expression of transfected 
PrP was not constitutive but was induced by doxycycline added to the culture 
medium. For all the different PrPs expressed (WT or mutant), the mostnJ  abundant form was the di-glycosylated form, with the un-glycosylated least
1  present. This result demonstrate that transgenic PrP is recognized by the
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cellular machinery and suggests that the presence of a mutation in the PrP 
molecule does not intrinsically alter the ratio among the glycoforms. Previous 
studies have shown that the presence of the mutation at codon 178 of human 
PrP (or 177 of murine PrP) increase (Lehmann and Harris, 1996a) or decrease 
(Petersen et al., 1996) the amount of the un-glycosylayed form in respect of WT 
PrP. These apparent discrepancies probably reflect differences in cell lines 
J  used and in PrP primary sequence: in fact, while Lehmann et al. (1996) used
mouse PrP (without the 3F4 tag) transfected into CHO cells, Petersen et al. 
(1996) used human PrP transfected into M-17 human neuroblastomal cells.
Consistent with the results obtained in constitutive expression models 
(Chiesa and Harris, 2000; Daude et al., 1997; Lehmann and Harris, 1996a; 
Lehmann and Harris, 1996b; Negro et al., 2001; Priola and Chesebro, 1998) the 
J mutant PrPs, carrying either the D177N mutation in the two forms (linked to
M128 or Ml28V) or the 9 octapeptide insertion (PG14) in the present (inducible) 
system became detergent insoluble and all developed resistance to protease. 
The glycoform ratios of insoluble and PK-resistant PrP were similar, suggesting 
that the three glycoforms have the same propensity to misfold.
The ability of mutant PrP to acquire abnormal biochemical properties in a
n
J  Tet-on model has recently also been demonstrated in murine neuroblastoma
D
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D
(N2a) cells expressing a murine PrP in which all the alanine residues of the 
sequence AGAAAAGA (spanning aminoacids 109-112) were replaced by 
glycine residues (Wegner et al., 2002). This “artificial” mutant protein became 
J  resistant to PK digestion 20 h after synthesis. The data presented in this thesis
demonstrate that pathogenic mutants linked to familial prion diseases also 
acquire abnormal biochemical properties when expressed using a Tet-on 
1  system.
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uD in PC12 Tet-on cells (as well as in N2a Tet-on) acquisition of PrP^^-like 
properties is not impaired by long-term treatment with doxycycline, a drug that 
J  has been reported to have anti scrapie properties (Forloni et al., 2002). In fact it
was shown that incubation with doxycycline at concentration ranging from 10 
[xM to 1 mM resulted in a dose dependent decrease in protease resistance of 
^  PrpSc purified from infected hamster brains. These concentrations, effective in
those studies, however, are 1000 fold higher than concentration of Dox used to 
J  activate transcription in the Tet-on system. Moreover, before transfecting PC I2
Tet-on cells, the effect of doxycycline on the PrP^^ properties of mutant PrP 
Q expressed in stable transfected PC12 cells was tested. No differences in
detergent insolubility or PK resistance of mutant PrP was found between cells 
treated with Dox compared to nori treated cells at the levels of Dox used in the 
Tet-on system.D
^  Several studies have demonstrated that the presence of a mutation in the
PrP sequence intrinsically favours the conformational change towards a (3- 
J sheet-rich state. First, recombinant PrP carrying pathogenic mutations
"1 aggregated into inclusion bodies when expressed in E s c h e r ic h ia  co//. (Liemann
and Glockshuber, 1999; Swietnicki et al., 1998). Second, synthetic peptides
n
U spanning human PrP residues 169-185 carrying the D178N showed increased
^  aggregation compared to WT sequence (Forloni et al., 1999). Third, mutant PrP
expressed in cultured cells acquired abnormal biochemical properties 
reminiscent of PrP^^ (Chiesa and Flarris, 2000; Daude et al., 1997; Lehmann 
J  and Harris, 1996a; Lehmann and Harris, 1996b; Negro et al., 2001; Priola and
Chesebro, 1998).
Pulse chase experiments performed on transfected cells expressing
1  mutant PrPs demonstrated that PrP^^-like properties were acquired in a
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stepwise fashion by new synthetized PrP molecules (Daude et al., 1997;
u
Lehmann and Harris, 1996b). The earliest biochemical change that was 
J  detected within minutes of pulse-labelling cells was resistance to PIPLC. This
1  observation suggested that an initial alteration in the mutant PrP (that probably
]
reflected an intrinsic hydrophobicity of the molecules) occurred in the ER or very 
soon after translation of the polypeptide chain. The second change was 
^  acquisition of detergent insolubility, which was not maximal until 1 h of chase,
occurred in a post-Golgi location and presumably reflected aggregation of PrP. 
Finally, mutant PrP acquired protease resistance, several hours after labelling, 
j  demonstrating that acquisition of detergent insolubility and PK resistance were
]
D
n
D
0
D
D
temporally distinct states. These results argued that the generation of PrP^^
involves intrinsic structural features of the mutant PrP molecule itself and that 
the efficiency of the process is promoted by organelle-specific factors. The data 
presented in this thesis suggest that the presence of the mutation confers to the
new synthesized protein the propensity to misfold and are therefore in
J  agreement with the pulse-chase experiments carried out in constitutive models
(Daude et al., 1997; Lehmann and Harris, 1996b). In particular it was noted that 
the amount of detergent insoluble PrP increased progressively after induction,nJ  reaching a maximum after 48-72 h of Dox treatment.
Quantification of mutant PrP insolubility revealed a greater propensity of
PG14 molecules to distribute in the pellet fraction compared to D177N
mutations (D177N/M128: 45±7.5%; D177NA/128: 46±9%; PG14: 60±14%;
n=3). These data are in agreement with previous analysis of the effect of
different mutations (either point substitution or insertional) on detergent
insolubility of PrP expressed (Ivanova et al., 2001 ; Lehmann and Harris,
1996b). In these studies the insertional mutation PG14 was more efficient in
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inducing insolubility compared with the point mutations P101L, D177N or 
E199K. Moreover, previous work demonstrated that in cells transfected with PrP 
carrying different insertional mutation, the longer the insertion, the more PrP 
^  was found in the pellet fraction (Priola and Chesebro, 1998). These data
suggest that alterations in the octapeptide region, which lies within the 
unstructured N-terminus of PrP, confer a greater propensity to form insoluble 
J  aggregates than point mutations in the C-terminal region.
^  The percentage of insoluble PrP was similar for the D177N/M128 and for
I
 ^ the D177NA/128, suggesting that the polymorphism at codon 128 did not
J influence the conformation determined by the mutation D>N at codon 177.
-, According with these data, studies on the thermodynamic stabilities of human
PrP(121-231) showed that the exchange of Asp178 by Asn destabilises the 
variants D178N/M129 and D178NA/129 by a similar value (Liemann and 
n  Glockshuber, 1999).
Also, in this thesis, immunofluorescence experiments showed that while
J WT PrP was expressed on the cell surface, mutant proteins were less
"I represented, with the PG14 construct showing the least extent of surface
staining. This phenomenon was not caused by different affinities of the different
J PrP molecules to antibodies but reflected a different subcellular distribution of
1  the protein. Indeed, PG14 PrP and D177N PrPs were predominantly detected
inside the cell, and colocalized with Golgi markers in the majority of cases; in
J  5% of the cells mutant PrP showed a widespread distribution and colocalized
with ER markers, suggesting retention in the endoplasmic reticulum. The
reason for this difference in the intracellular distribution among different
^  individual cells from the same clone is unclear but could be due to different
J  expression levels of mutant PrP or to differences in the capability of the cell to
197
u
D
D
metabolise mutant PrP. In either case, the excess of PrP could accumulate in 
the endoplasmic reticulum, with consequent damage to the cell. Similar results 
have also been obtained in other cell lines (Ivanova et al., 2001; Priola and 
Chesebro, 1998) and in cultures of primary neurons obtained from Tg mice 
expressing PG14 or D177N PrPs. (Fioriti et al., 2005). In the present studies 
^  such PrP was retained in the ER and there was no evidence for the presence of
mutant PrP in the cytosol, as was described by Ma and Linguist (Ma and 
Lindquist, 2001) in their studies of PrP carrying the D177N mutation transfected 
^  in COS cells.
^  Recently it has been shown that the different subcellular localisation of
PI mutant PrPs is due to a retarded transit towards the cell surface, when
compared with WT PrP, rather than delivery impairment (Drisaldi et al., 2003).
On the basis of these results it was assumed that the presence of the mutation 
favoured the misfolding of the protein and that this slowed its delivery to cell 
surface. One could therefore hypothesise that the propensity of each mutant 
protein to aggregate would influence the kinetics of its transit towards the cell 
surface, and thus that mutations that confer to PrP a great propensity to
aggregate (like PG14) would cause a marked reduction of cell surface
distribution of the protein. The finding that PG14 PrP was more detergent 
insoluble than the other mutant proteins studied here and showed greater 
retention in the ER than D177N PrP corroborates this hypothesis.
It has been previously demonstrated that treatment with tunicamycin did 
not impair transport of WT PrP to the cell surface (Lehmann and Harris, 1997; 
Petersen et al., 1996) but favoured degradation of unglycosylated PrP carrying 
the D178N mutation (Petersen et al., 1996). In the PC12 Tet-on model 
developed in this thesis tunicamycin treatment did not influence subcellular
D
D
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localisation either of WT PrP, in agreement with previous data, or that of mutant 
PrPs. These data suggest that PrP biosynthetic trafficking is not altered by the 
absence of sugar residues, or following ER stress induced by tunicamycin.
Taken together the data described suggest that the presence of the 
mutation favours the misfolding of PrP expressed in PC12 Tet-on cells. The 
conformation change favours the retention in the endoplasmic reticulum and 
induces the aggregated state of the protein but does not alter its post- 
translational modifications.
n 4.4 Effects of mutant PrP expression
4.4.1 Prolonged expression of mutant PrP causes the appearance of 
p. apoptotic cells
The inducible model allowed us to test if mutant PrP expression could 
induce cytotoxicity and, conversely, if WT PrP expression could “rescue” cells
nU from death, induced by various stimuli, as described previously (Brown et al.,
1  1997b; Kuwahara et al., 1999; White et al., 1999). The toxicity of PrP^^ has
been recapitulated in vitro, by applying PrP^^ purified from infected brains to
neurons in culture (Giese et al., 1998; Muller et al., 1993; Post et al., 2000). In
1  particular, more recently, it has been demonstrated that neurons expressing
ovine PrP exposed to infected sheep brain underwent apoptosis (Gronier et al.,
J  2004). An alternative strategy has been to analyse the effect on cultured
J  neurons of synthetic peptides derived from the PrP sequence. The peptide
^  spanning residues 106-126 has been found to form protease-resistant, p-
sheets-rich aggregates reminiscent of PrP^^ (De Gioia et al., 1994; Jobling et
al., 1999; Selvaggini et al., 1993) and caused apoptotic death of cultured
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D”  neurons (Brown et al., 1994; Brown et al., 1996; Fioriti et al., 2004; Forloni et
al., 1993; Forloni et al., 1994). Conversely, a clear cytotoxic effect of PrP 
carrying pathogenic mutations had not been previously demonstrated in 
1  transfected cells (Chiesa and Harris, 2000; Daude et al., 1997; Lehmann and
Harris, 1996a; Lehmann and Harris, 1996b; Negro et al., 2001; Priola and 
Chesebro, 1998). However, because the expression of mutant PrP was not 
inducible but constitutive in all those models, it was possible that clones 
resistant to mutant PrP toxicity had survived after transfection and clonal 
selection (i.e. the use of selecting agents could have masked the potential 
toxicity of mutant PrP). The advantage of the model used in the present studies 
over constitutive models related to the possibility of switching on protein 
expression only at the time of the experiment, thus avoiding any unwanted 
selection of clones intrinsically resistant to PrP toxicity. Cells were kept in a 
Dox-free medium until the time of the experiment; moreover, because 
doxycycline is often administrated to animals, only bovine and horse sera tested 
for the absence of this antibiotic were used in this study. The results obtained 
"1 suggested that the prolonged expression of mutant PrP is associated with a
decrease in cell viability and with the appearance of apoptotic cells. In this
nu context it was of interest to note that PG14 PrP has been shown to be a potent
Q trigger of neuronal death in  v iv o , as transgenic mice expressing this protein
develop a neurodegenerative illness characterized by apoptosis of cerebellar
J  granule neurons (Chiesa et al., 2000; Chiesa et al., 1998).
1  The observed phenomenon of increased neural apoptosis in the present
study was specific to the mutant PrPs, as it was not detected in cells transfected
with WT PrP or with the empty pBI-G, but was not easily reproducible. The
explanation of this inconsistency could relate to the variability in the induction
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level observed after Dox treatment. In an attempt to correlate PrP expression or 
its subcellular distribution with apoptosis, TUNEL staining or staining with 
propidium iodide was performed on cells immunostained for PrP. However, cells 
n  with an ER-distribution or showing an high expression level of PrP were not
those undergoing apoptosis. Conversely, no PrP signal was detectable in 
J  apoptotic cells, probably due to the reduced protein synthesis in cells
1  undergoing apoptosis (Sheikh and Fornace, 1999). However it cannot be
excluded that although cells displaying high level of intracellular PrP were not 
undergoing apoptosis at the time of staining they might not do so as a later 
, event.
It is worth to consider that endogenous, wild-type PrP expression, that is 
quite similar to the maximum expression level of the transfected PrP, could 
account for the inconstancy of the toxicity. Even if the mutation in one single 
allele is sufficient for the development of genetic forms, one could speculate 
that in this model D177N and PG14 can not act as dominant mutations, due to 
the species barrier between mouse and rat PrP.
P  Brain and spinal cord are the sites of primary pathology in prion
diseases, raising the hypothesis that neurons are more sensitive to PrP^^ 
J  accumulation than other cell types. To test the potential cytopathic effect of
"] mutant PrP expression on neuronal phenotype, PC I2 cells were differentiated
with NGF before inducing PrP expression. However, it was not possible to 
detect differences in terms of cell viability between undifferentiated and
D
D
" j differentiated cells, demonstrating that P C I2 cells that acquire a neuronal
J
phenotype are not more susceptible to mutant PrP expression. In agreement
D
n
with this finding, previous data showed that in stably transfected P C I2 cells, 
neither the biochemical properties of WT and PG14 PrP nor cell viability
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"1 changed after NGF differentiation (Chiesa and Harris, 2000). In this thesis the
potential increment of endogenous PrP expression due to NGF treatment (as 
]  previously reported by two different groups (Mobley et al., 1988; Wion et al,
"I 1988)) was not investigated. However, the increased expression level of
J
endogenous, wild-type PrP could have masked the toxicity of mutant PrP 
J  expressed, that did not vary after differentiation.
1  Microglial activation proceeds the detection of apoptotic neuronal cell
death in scrapie-infected hamster brains (Giese et al., 1998). Moreover, it has
been reported that microglia increased cell death induced by PrP^^ purified from
infected brain and by neurotoxic PrP peptides in cultured neuronal cells (Bate et
al., 2002; Brown et al., 1996; Giese et al., 1998). These data suggest that
microglial activation is involved in the neurotoxicity of PrP^^ in  v i t r o  and i n  v iv o .
J  To investigate if microglia could influence cell viability of P C I2 Tet-on cells
expressing mutant PrPs, we co-cultured differentiated PC I2 Tet-on cells with
rat microglia. However, our results demonstrated that the addition of rat
microglia did not result in increased susceptibility of neurons to the toxic effects
p. ç F  mutant PrP expression. Possible explanations for this negative result are that
unlike other systems, microglia is not able to trigger death signalling in neuronal
1  PC I2 cells. Second, microglia does not trigger death signalling because it does
not express mutant PrP. Finally, change induced on neurones by the mutant
PrP are not efficient to activate the microglia.
To test the effect of various toxic stimuli on cells expressing mutant PrP
compared to cells expressing WT PrP, different clones were treated with H2O2 ,
tunicamycin or were grown in the absence of serum before and after PrP
induction. Cell viability assays of the same clone exposed to these stimuli in the
1 induced or non-induced state revealed that expression of mutant PrP did not
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render cells more susceptible to the insults. Conversely, in some cases, a mild, 
non statistically significant increase in the number of cells was noticed after Dox 
treatment. This increase was not due to a protective effect of the PrP construct, 
being present even in the absence of the insult and in cells transfected with the 
empty vector. One explanation of this finding could be due to a slight trophic 
LJ effect of Dox. Doxycycline has been shown to stimulate proliferation of T-cells
(Batinac et al., 2003) and of periodontal ligament cells (Zhao et al., 2003). 
Moreover, it has been shown that doxycycline protects neurons against 
apoptosis induced by ionising radiation (Tikka et al., 2001). Finally, these 
experiments revealed that the over-expression of WT PrP did not rescue cells 
from death induced by H2O2 , tunicamycin or serum deprivation. This last finding 
does not exclude the possibility that WT PrP has a neuroprotective role (as 
J  previously demonstrated (Brown et al., 1997b; Kuwahara et al., 1999;
q  McLennan et al., 2004; White et al., 1999) but suggests that additional
expression of WT protein to PC 12 cells, which normally express endogenous 
PrP, does not make differences in protecting from toxic stimuli. Finally, the 
expression of endogenous, wild-type PrP, could explain the lack of increased 
susceptibility of cells expressing mutant PrP expression towards the toxic 
stimuli.
D
D
^  In summary, data presented in this thesis show that mutant PrP
J
expression was rarely associated to decrease in the cellular viability. Moren
J  consistent results could be achieved neither by differentiating cells with NGF
D nor by co-culturing them with microglia. Finally, mutant PrP expression did not
increase susceptibility to various toxic stimuli. To explain the inconstancy ofnU these data it can hypothesized that toxicity was related to the absolute
1  expression of mutant PrP achieved in each single experiments or to an
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"j undefined experimental condition which favoured death of cell expressing
mutant PrPs.
J Finally it is possible to speculate that the primary and consistent
1  consequence of mutant prion expression is an alteration in cell signalling that
can or cannot lead to cell death (see below).
-J It is worth to consider that endogenous PrP expression could have
J  interfered in the evaluation of the toxicity triggered by mutant PrP expression. In
D
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order to rule out this hypothesis, evaluation of the toxicity of mutant PrP could 
be performed in cells in which the endogenous PrP has been shut down.
J 4.4.2 Expression of mutant PrP does not trigger ER stress
nU Secretory and membrane proteins that are retained in the ER may be
J  subjected to a quality control process in which they are retrotranslocated into
the cytoplasm and degraded by the proteasome (Bonifacino and Weissman,
1998; Tsai et al., 2002). This mechanism is meant to ensure that abnormally
folded proteins, do not reach the plasma membrane. Two PrP mutants,
Y145stop and Q160stop appear to be degraded primarily by the
retrotranslocation/proteasome pathway (Lorenz et al., 2002; Zanusso et al.,
1  1999). Conversely, it has been shown that although PG14 and D177N PrPs are
delayed in their exit from the ER, they are not subjected to retrograde transport
into the cytoplasm to be degraded by the proteasome (Drisaldi et al., 2003).
Blockage of proteasome activity in PC12 Tet-on cells did not cause
accumulation of PrP, confirming that PG14 and D177N are not degraded by the
proteasome in this system. In some other diseases, such us hereditary
enphysema (PiZ variant), the retained protein accumulates in the ER and
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"I triggers ER stress response pathways without being retrotranslocated into the
cytosol (Aridor and Balch, 1999). Up-regulation of ER-stress chaperone proteins 
have been documented in N2a challenged with PrP^^ and in brains of humans 
affected with sporadic and variant CJD (Hetz et al., 2003).To test if retention of 
PG14 and D177N PrP could stimulate ER stress, the expression of markers 
typical of ER stress was examined. The data demonstrated that neither early 
” 1 UPR markers, such as a XBP1 splicing event, nor BiP or CHOP are induced
following expression of PG14 or D177N PrPs. The absence of induction of UPRnU markers was confirmed in  v iv o , through the analysis of transgenic mice
j expressing PG14 PrP. The possibility that UPR was a rare event, involving only
a few cells, was explored by performing CHOP immunostaining on induced 
]  PC I2 Tet-on cells, and on cultured neurons from Tg mice. These experiments
^  showed that CHOP was not activated in cells expressing mutant PrPs. Taken
together, these data suggest that accumulation of PG14 or D177N PrPs does 
not trigger ER stress and consequently that ER stress is not the cause of cell 
death seen in the cell models studied here nor in the brains of Tg(PG14) mice.
^  D177N or PG14 mutations have not been shown to clearly favour
formation of PrP forms partially localized in the cytosol, as ^^^PrP (Stewart and
nJ  Harris, 2001), or totally cytosolic (Drisaldi et al., 2003)(Fioriti et al., 2005).
Moreover, toxicity of ^^ "^ PrP (Hegde et al., 1999 ; Stewart and Harris, 2003) and
J
cytosolic PrP (Drisaldi et al., 2003; Ma et al., 2002; Roucou et al., 2003; Wang 
J et al., 2004) is still controversial. For these reasons the presence of cytosolic
forms of PrP and the relevance in the pathogenicity of the D177N and PG14 
mutations were not investigated accurately in this thesis.nJ  Alternatively it is possible to speculate that mutant PrP molecules that
Q are responsible for neurodegeneration are not the ones that are retained
205
lj
n
J
J
D
n
uintracellularly, but those that reach the cell surface, by altering the normal 
physiologic role or by a gain of function of the protein. In this case PrP might 
damage cells by altering membrane properties, or interacting abnormally with 
other proteins (Figure 4.1). Recently Tg(PG14) mice were crossed to Bax'^‘ 
mice, in which the pro-apoptotic gene Bax had been ablated to obtain 
Tg(PG14)/Bax'^' offspring (Chiesa et al., 2004). Clinical and neuropathological 
"I evaluation of these double Tg mice revealed that deleting Bax was enough to
rescue cerebellar granule cells from apoptosis but did not affect thenJ  development of clinical symptoms nor synaptic loss and shrinkage in the
D
D molecular layer of the cerebellum. These results indicate that synaptic 
abnormalities induced by accumulation of PG14 PrP contribute significantly to 
the neurological syndrome seen in Tg(PG14) mice and therefore support the 
hypothesis that PrP present on cell surface is indeed responsible for occurrence 
of the disease. Injury to synapses may lead secondarily to death of granule 
neuron, via Bax activation. Synaptic damage has been documented in models 
J  of murine scrapie (Jeffrey et al., 2000a) and in sporadic and inherited CJD
(Jeffrey et al., 2001; Kitamoto et al., 1992), suggesting a common role in prion 
disease.
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Figure 4.1: Possible pathway for cellular damage that could be initiated by 
PrP carrying D177N and PG14 mutations.
Mutant PrP retained in the ER could trigger ER stress response and lead to 
apoptosis. However, results presented in this thesis strongly argue against the 
involvement of ER stress. Alternatively it is possible to speculate that 
neurotoxicity is triggered by molecules that reach the cell surface. Mutant PrPs 
could interact abnormally with other proteins, thus leading to synaptic 
dysfunction documented for Tg(PG14). Synaptic dysfunction could 
consequently induce neuronal death.
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1  A support for the hypothesis that altered forms of PrP may cause
synaptic dysfunction comes from studies of differentiated PC12 infected with 
J  scrapie prions (Rubenstein et al., 1991). In fact, when compared to controls,
J  these cells have shown a decreased activity of choline acetyltransferase and
acetylcholinesterase, accompanied by an increment of choline. On the basis of 
these results the model developed in this thesis will be used to investigate the 
effect of mutant PrP expression on the activity of some cholinergic pathway- 
Pj related enzymes.
Finally, to exclude the involvement of ER stress Tg(PG14) mice could be 
crossed to transgenic mice expressing an ER stress indicator, constructed by 
PI fusing XBP1 and venus, a variant of green fluorescent protein (GFP) (Iwawaki
et al., 2004). During stress, the spliced indicator mRNA is translated into an 
XBP1-venus fusion protein, which can be detected by its fluorescence, 
n  Tg(PG14) mice could also be crossed to mice transgenic for a GFP carrying an
active degradation signal for the proteasome (Lindsten et al., 2003).
n
J  Administration of proteasome inhibitors to these mice resulted in accumulation
of GFP in multiple tissues. Analysing the crossed mice, changes in the amount 
of GFP are expected if expression of PG14 PrP activate the UPR pathway
D
D
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Chapter 5: Appendix
]
p, 5.1 Solutions
1 5.1.1 Bacterial media
1 L YT: 1 g Tryptone, 5 g Yeast Extract, 5 g NaCI (for plates 15 g of 
-J Bacto-agar was added).
5.1.2 Cell culture
Coating:
Poiv-L-iysine coating: Plates were incubated for 2 h at 37°C or overnight 
at room temperature with an appropriate volume of poly-L-lysine solution 
(Sigma Aldrich Co., St. Louis, Missouri) (0.1 mg/ml diluted in sterile 
water). After removing poly-L-lysine, plates were washed three times with 
PBS and air-dried.
Collagen coating: 150 pg/ml of rat-tail collagen (Cohesion Inc., Palo Alto, 
California) were diluted in 30% ethanol. 25 pi of this solution were added 
J  to each well of a microtitre plate and air-dried. Alternatively, 3.5 ml were
added to a 100-mm plate.
Media:
PC12 Tet-on: DMEM (Biochrom AG, Berlin, Germany), supplemented
D
D
D
D
D
"I with 5% inactivated foetal bovine serum (PBS, Gibco, Life Technologies,
Paisley, Scotland), 10% inactivated horse serum (HS, Sigma Aldrich Co:,
J St. Louis. Missouri), 5 mM penicillin/streptomycin (Invitrogen, life
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technologies, Carlsband, California), 2 mM L-glutamine (Gibco, Life 
Technologies, Paisley, Scotland), 200 pg/ml G418 (Gibco, Life 
Technologies, Paisley, Scotland).
1  CHO: MEM-a (Gibco, Life Technologies, Paisley, Scotland),
supplemented with 10% PBS (Gibco, Life Technologies, Paisley, 
Scotland), 5 mM penicillin/streptomycin, 2 mM L-glutamine, 200 pg/ml 
1  G418. Por testing sera, PBS was replaced by HS.
M icrog lia : DMEM conta in ing 2 mM glutam ine, 5 mM
penicillin/streptomycin and 10% PBS.
Cells freezing medium: DMEM (or MEM-a), supplemented with 2 mM 
glutamine, 20% PBS and 10% dimethyl sulfoxide (DMSO, Sigma Aldrich 
Co., St. Louis, Missouri).
Neuronal differentiation: DMEM supplemented with 1% HS, 5 mM 
penicillin/streptomycin, 2 mM L-glutamine, 200 pg/ml G418, 80 pg/ml 
hygromycine.
Serum inactivation: PBS or HS were incubated for 20 min at 56°C to
0
D
D
inactivate complement, which can mediate cell lysis.
Splitting cells:
Trvpsin/EDTA solution: Trypsin/EDTA stock solution (0.5% Trypsin, 5.3 
mM EDTA, Gibco, Life Technologies, Paisley, Scotland) was diluted 10 
fold in sterile PBS.
Viability assay:
J  MTT 10X: 4 mg/mL MTT (Sigma Aldrich Co., St. Louis, Missouri ) in
Phospate Buffered Saline (PBS, Gibco, Life Technologies, Paisley, 
Scotland).
Acidic propanol: 40 mM HCI in propanol.
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Crystal violet solution: 0.5% crystal violet (Sigma Aldrich Co., St. Louis, 
Missouri ) in H20/methanol solution (4 :1).
Citrate solution: 0.05M Sodium citrate in 47.5% ethanol.
Lysis/loading buffers:
Laemli sample buffer 2X: 100 mM Tris-HCI pH 6.8, 4% (w/v) SDS, Sigma 
Aldrich Co., St. Louis, Missouri), 20% (v/v) Glycerol, 0.2% (w/v) 
bromophenol blue, 100 mM dithiothreitol (DTT, Sigma Aldrich Co., St. 
Louis, Missouri).
Lysis buffer: 10 mM Tris pH 7.4, 100 mM NaCI, 0.5% Igepal Ca-640 
(Sigma Aldrich Co., St. Louis, Missouri) and 0.5% Deoxycholic acid 
(DOC, Sigma Aldrich Co., St. Louis, Missouri).
5.1.3 Western blotting
1  Laemli Running Buffer 10X: 240 mM Tris, 14% g Glycine (Sigma Aldrich
Co., St. Louis, Missouri), 1% SDS.n^
 CAPS Transfer Buffer 10X: 2.4% CAPS (3-(cyclohesylamino-)1-
propanesulfonic acid. Sigma Aldrich Co., St. Louis, Missouri), pH 11.
Tris buffer saline (TBS) 10X: lOOmM Tris-HCI, pH 7.4, 1.5M NaCI.
TTBS: 0.1% Tween-20 (Sigma Aldrich Co., St. Louis, Missouri) in TBS
5.1.4 Agarose gel electroforesis
TAE Running buffer 50X: 0.2M Tris Base, 5.7% Acetic acid, 0.05 M 
EDTA.
211
uD
D
5.1.5 RNA analysis
RNase-free water: 500 \ i\ of Diethyl pyrocarbonate (DEPC, Sigma Aldrich 
Co., St. Louis, Missouri) in 500 ml water. Autoclaved for 30 min.
Northern blotting:
Denaturing buffer: 0.6% 3-(N-Morpholino) propanesulfonic acid (MOPS, 
Sigma Aldrich Co., St. Louis, Missouri) containing 32.5% deionized 
formamide (Sigma Aldrich Co., St. Louis, Missouri), 7% formaldehyde 
(Sigma Aldrich Co., St. Louis, MO) and 0.0026 [xg/ml Ethidium Bromide 
"j (Sigma Aldrich Co., St. Louis, Missouri).
Loading buffer 10X: 0.4% (w/v) bromophenol blue, 50% (v/v) glycerol and 
J ImMEDTA.
1  SSC 20X (for capillary elution): 0.3M sodium citrate, 3 M NaCI.
MOPS Running Buffer 10X: 0.2M MOPS, 50 mM sodium acetate, 1 mM 
J  EDTA.
J  Hybridisation buffer: SSC 5X, 5% Dextran Sulfate (Sigma Aldrich Co., St.
Louis, Missouri), 0.1% SDS, denatured salmon sperm DNA 100 pg/ml, 
0.05% liquid block (provided by the kit), 
r  Buffer A: 0.1 M Tris-HCI, pH 9.5. 0.3M NaCI.
RT-PCR:
Reverse transcriptase buffer 5X (Promega Corporation, Madison, 
Q Wisconsin)!: 250 mM Tris-HCI pH 8.3, 250 mM KCI, 50 mM MgCL, 2.5
mM spermidine, 50 mM DTT.
D
D
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5.1.6 Cell imaging 
Imunostaining:
PFA: 16% stock solution was purchased by Electron Microscopy 
Sciences, Washington, Pennsylvania. 4% solutions were made fresh in 
each experiments.
Blocking buffer: 5% NFDM, 2% PBS in PBS 
Propidium iodide staining:
Propidium Iodide mix: 10 pg/ml propidium iodide (Sigma Aldrich Co., St. 
Louis, Missouri), 500 fxg/ml RNase A (Sigma Aldrich Co., St. Louis, 
Missouri ), in PBS.
TUNEL staining:
Saponin solution: 0.1% (w/v) saponin (Sigma Aldrich Co., St. Louis, 
Missouri), 0.005% (v/v) Tween-20 (Sigma Aldrich Co., St. Louis, 
Missouri), ImM EDTA in PBS.
tdT reaction mixture: 5X reaction buffer, 2.5 mM CoCL, 20U TdT, 2 nM 
biotin-16-dUTP.
Blocking buffer: SSC 4X, 0.05 NFDM.
Staining buffer: SSC 4X, 0.001 Triton X-100, 0.05 NFDM.
X-gal staining:
X-gal mixture: 1 mg/ml X-gal (Sigma Aldrich Co., St. Louis, Missouri), 2 
mM MgCL, 5 mM K3Fe(CN)e and 5 mM l<4 Fe(CN)6 in PBS.
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5.2 Antibodies
3F4 monoclonal antibody (epitope 109-112 of human PrP) was a gift 
from Richard Kascsak and was diluted 1:5,000 and 1:500 for Western blot and 
J  immunoflorescence, respectively; P45-66 rabbit polyclonal antibody (raised
against residues 45-66 of moPrP) was a gift from David A. Harris (Washington
nJ  University, St. Louis, Missouri) and was used 1:1,000 or 1:250 for Western blot
D
D
D
D
and immunoflorescence, respectively. Mouse monoclonal antibody 98A3, kindly 
provided by Jan P.M. Langeveld (CIDC-Lelystad), was diluted 1:5000 for 
Western blot. Anti-actin monoclonal antibody (MAB1501R, Chemicon 
International, Temecula, California) was diluited 1:10,000 for Western blot. Anti- 
CHOP antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, California) was 
used 1:200 or 1:50 for Western blot and immunoflorescence, respectively. Anti- 
^  giantin monoclonal antibody and anti-calnexin rabbit polyclonal antibody were a
gift from Professor Roberto Sitia (San Raffaele Scientific Institute, Dibit, Milan) 
and were used 1:1,000 and 1:100, respectively for immunoflourescence. Anti­
mouse and anti-rabbit IgG peroxidase-coniugated secondary antibody (Santa 
Cruz Biotechnology, Inc, Santa Cruz, California) were diluted 1:5,000. Alexa 
488(green)-goat anti-mouse IgG and Alexa546(red)-goat anti-rabbit IgG 
"} (Molecular probes Inc., Eugene, Oregon) were diluted 1:500.
D
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nu 5.3 Transgenic mice
D
D
Transgenic mice expressing wild-type and PG14 mouse PrPs tagged 
with an epitope for the monoclonal antibody 3F4 were previously generated 
(Chiesa et al., 1998). In this study transgenic mice of the Tg(WT-EI) line that 
express 4 times the endogenous PrP level, referred throughout the text as
n
J  Tg(WT), as well as Tg(PG14-A3) mice expressing PG14 PrP at the endogenous
n  level, and Tg(PG14-C) mice expressing 0.3 times the endogenous level, were
J
used. These transgenic mice were originally generated on a C57BL/6J X CBA/J 
hybrid and were subsequently bred with the Zürich I line of PrP°^° mice 
(C57BL/6J X 129 background) (Bueler et al., 1992), resulting in animals that 
express Tg PrP but not endogenous mouse PrP. PrP°^° mice were non- 
transgenic littermates of Tg(WT) and Tg(PG14) animals.
D
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